[
    {
        "id": 0,
        "document_id": 0,
        "biomarkers": [
            0
        ],
        "context_id": 0,
        "description": "The European Medicines Agency (EMA) has authorized brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine for the treatment of adult patients with previously untreated CD30+ stage III or IV Hodgkin lymphoma (HL).",
        "evidence": "Approval",
        "implication_id": 0,
        "indication_id": 0,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 1,
        "document_id": 0,
        "biomarkers": [
            0
        ],
        "context_id": 0,
        "description": "The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with CD30+ Hodgkin lymphoma (HL) at increased risk of relapase or progression following autologous stemc ell transplant (ASCT).",
        "evidence": "Approval",
        "implication_id": 1,
        "indication_id": 1,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 2,
        "document_id": 0,
        "biomarkers": [
            0
        ],
        "context_id": 0,
        "description": "The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL) either following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.",
        "evidence": "Approval",
        "implication_id": 1,
        "indication_id": 2,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 3,
        "document_id": 0,
        "biomarkers": [
            0
        ],
        "context_id": 1,
        "description": "The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.",
        "evidence": "Approval",
        "implication_id": 1,
        "indication_id": 3,
        "last_updated": "2024-06-13",
        "deprecated": false
    },
    {
        "id": 4,
        "document_id": 1,
        "biomarkers": [
            1,
            2
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized everolimus in combination with exemestane for the treatment of adult patients with hormone receptor-positive, HER2/neu negative advanced breast cancer in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 2,
        "indication_id": 4,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 5,
        "document_id": 1,
        "biomarkers": [
            3,
            2
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized everolimus in combination with exemestane for the treatment of adult patients with hormone receptor-positive, HER2/neu negative advanced breast cancer in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 2,
        "indication_id": 4,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 6,
        "document_id": 1,
        "biomarkers": [
            1,
            3,
            2
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized everolimus in combination with exemestane for the treatment of adult patients with hormone receptor-positive, HER2/neu negative advanced breast cancer in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 2,
        "indication_id": 4,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 7,
        "document_id": 2,
        "biomarkers": [
            4
        ],
        "context_id": 3,
        "description": "The European Medicines Agency (EMA) has authorized niraparib with abiraterone acetate in combination with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.",
        "evidence": "Approval",
        "implication_id": 3,
        "indication_id": 5,
        "last_updated": "2024-03-05",
        "deprecated": false
    },
    {
        "id": 8,
        "document_id": 2,
        "biomarkers": [
            5
        ],
        "context_id": 3,
        "description": "The European Medicines Agency (EMA) has authorized niraparib with abiraterone acetate in combination with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.",
        "evidence": "Approval",
        "implication_id": 3,
        "indication_id": 5,
        "last_updated": "2024-03-05",
        "deprecated": false
    },
    {
        "id": 9,
        "document_id": 2,
        "biomarkers": [
            6
        ],
        "context_id": 3,
        "description": "The European Medicines Agency (EMA) has authorized niraparib with abiraterone acetate in combination with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.",
        "evidence": "Approval",
        "implication_id": 3,
        "indication_id": 5,
        "last_updated": "2024-03-05",
        "deprecated": false
    },
    {
        "id": 10,
        "document_id": 2,
        "biomarkers": [
            7
        ],
        "context_id": 3,
        "description": "The European Medicines Agency (EMA) has authorized niraparib with abiraterone acetate in combination with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.",
        "evidence": "Approval",
        "implication_id": 3,
        "indication_id": 5,
        "last_updated": "2024-03-05",
        "deprecated": false
    },
    {
        "id": 11,
        "document_id": 3,
        "biomarkers": [
            8
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized alectinib as a monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).",
        "evidence": "Approval",
        "implication_id": 4,
        "indication_id": 6,
        "last_updated": "2024-03-06",
        "deprecated": false
    },
    {
        "id": 12,
        "document_id": 3,
        "biomarkers": [
            8
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized alectinib as a monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.",
        "evidence": "Approval",
        "implication_id": 4,
        "indication_id": 7,
        "last_updated": "2024-03-06",
        "deprecated": false
    },
    {
        "id": 13,
        "document_id": 3,
        "biomarkers": [
            8
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized alectinib as a monotherapy for the adjuvant treatment following complete tumor resection for adult patients with ALK-positive non-small cell lung cancer (NSCLC) at high risk of recurrence.",
        "evidence": "Approval",
        "implication_id": 4,
        "indication_id": 193,
        "last_updated": "2024-03-06",
        "deprecated": false
    },
    {
        "id": 14,
        "document_id": 4,
        "biomarkers": [
            8
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized brigatinib as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who were previously not treated with an ALK inhibitor.",
        "evidence": "Approval",
        "implication_id": 5,
        "indication_id": 8,
        "last_updated": "2024-03-06",
        "deprecated": false
    },
    {
        "id": 15,
        "document_id": 4,
        "biomarkers": [
            8
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized brigatinib as a monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.",
        "evidence": "Approval",
        "implication_id": 5,
        "indication_id": 9,
        "last_updated": "2024-03-06",
        "deprecated": false
    },
    {
        "id": 16,
        "document_id": 5,
        "biomarkers": [
            9
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized bevacizumab in combination with erlotinib for the first-line treatment of adult patients with unresectable advanced, metastatic, or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating variants. This indication is based on JO25567, a randomized, open-label, multi-centre phase 2 study that defined EGFR activating variants as either exon 19 deletions or exon 21 p.L858R.",
        "evidence": "Approval",
        "implication_id": 6,
        "indication_id": 10,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 17,
        "document_id": 5,
        "biomarkers": [
            10
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized bevacizumab in combination with erlotinib for the first-line treatment of adult patients with unresectable advanced, metastatic, or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating variants. This indication is based on JO25567, a randomized, open-label, multi-centre phase 2 study that defined EGFR activating variants as either exon 19 deletions or exon 21 p.L858R.",
        "evidence": "Approval",
        "implication_id": 6,
        "indication_id": 10,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 18,
        "document_id": 6,
        "biomarkers": [
            11
        ],
        "context_id": 5,
        "description": "The European Medicines Agency (EMA) has authorized avapritinib as a monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring the platelet-derived growth factor receptor alpha (PDGFRA) p.D842V variant.",
        "evidence": "Approval",
        "implication_id": 7,
        "indication_id": 11,
        "last_updated": "2024-03-06",
        "deprecated": false
    },
    {
        "id": 19,
        "document_id": 7,
        "biomarkers": [
            12,
            13
        ],
        "context_id": 6,
        "description": "The European Medicines Agency (EMA) has authorized Besponsa (inotuzumab ozogamicin) as a monotherapy for the treatment of adult patients with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukemia (ALL). Adult patients with Philidelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least one tyrosine kinase inhibitor (TKI).",
        "evidence": "Approval",
        "implication_id": 8,
        "indication_id": 12,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 20,
        "document_id": 7,
        "biomarkers": [
            13
        ],
        "context_id": 6,
        "description": "The European Medicines Agency (EMA) has authorized Besponsa (inotuzumab ozogamicin) as a monotherapy for the treatment of adult patients with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukemia (ALL). Adult patients with Philidelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least one tyrosine kinase inhibitor (TKI).",
        "evidence": "Approval",
        "implication_id": 8,
        "indication_id": 12,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 21,
        "document_id": 8,
        "biomarkers": [
            14
        ],
        "context_id": 6,
        "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of adult patients with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.",
        "evidence": "Approval",
        "implication_id": 9,
        "indication_id": 13,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 22,
        "document_id": 8,
        "biomarkers": [
            12,
            14
        ],
        "context_id": 6,
        "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of adult patients with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.",
        "evidence": "Approval",
        "implication_id": 9,
        "indication_id": 13,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 23,
        "document_id": 8,
        "biomarkers": [
            15,
            14
        ],
        "context_id": 6,
        "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of adult patients with Philadelphia chromosome negative CD19 positive B-cell precusor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.",
        "evidence": "Approval",
        "implication_id": 9,
        "indication_id": 14,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 24,
        "document_id": 8,
        "biomarkers": [
            15,
            14
        ],
        "context_id": 6,
        "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of pediatric patients aged 1 year or older with Philidelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL) which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplants.",
        "evidence": "Approval",
        "implication_id": 9,
        "indication_id": 15,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 25,
        "document_id": 8,
        "biomarkers": [
            15,
            14
        ],
        "context_id": 6,
        "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of pediatric patients aged 1 year or older with high-risk first relapsed Philidelphia chromosome negative CD19 positive B-cell precursor ALL as part of the consolidation therapy.",
        "evidence": "Approval",
        "implication_id": 9,
        "indication_id": 16,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 26,
        "document_id": 9,
        "biomarkers": [
            12
        ],
        "context_id": 7,
        "description": "The European Medicines Agency (EMA) has authorized bosutinib as for the treatment of adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).",
        "evidence": "Approval",
        "implication_id": 10,
        "indication_id": 17,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 27,
        "document_id": 9,
        "biomarkers": [
            12
        ],
        "context_id": 7,
        "description": "The European Medicines Agency (EMA) has authorized bosutinib as for the treatment of adult patients with chronic phase, accelerated phase, and blast phase Ph+ CML previously treated with one or more tyrosine kinase inhibitors and for whom imatinib, nilotinib, and dasatinib are no considered appropriate treatment options.",
        "evidence": "Approval",
        "implication_id": 10,
        "indication_id": 18,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 28,
        "document_id": 10,
        "biomarkers": [
            16
        ],
        "context_id": 8,
        "description": "The European Medicines Agency (EMA) has authorized encorafenib in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. The efficacy and safety of encorafenib have been established only in patients with melanoma tumours expressing BRAF V600E and V600K variants or colorectal tumours expressing BRAF V600E.",
        "evidence": "Approval",
        "implication_id": 11,
        "indication_id": 19,
        "last_updated": "2024-03-06",
        "deprecated": false
    },
    {
        "id": 29,
        "document_id": 10,
        "biomarkers": [
            17
        ],
        "context_id": 8,
        "description": "The European Medicines Agency (EMA) has authorized encorafenib in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. The efficacy and safety of encorafenib have been established only in patients with melanoma tumours expressing BRAF V600E and V600K variants or colorectal tumours expressing BRAF V600E.",
        "evidence": "Approval",
        "implication_id": 11,
        "indication_id": 19,
        "last_updated": "2024-03-06",
        "deprecated": false
    },
    {
        "id": 30,
        "document_id": 10,
        "biomarkers": [
            16
        ],
        "context_id": 9,
        "description": "The European Medicines Agency (EMA) has authorized encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF p.V600E variant, who have received prior systemic therapy. The efficacy and safety of encorafenib have been established only in patients with melanoma tumours expressing BRAF V600E and V600K variants or colorectal tumours expressing BRAF V600E.",
        "evidence": "Approval",
        "implication_id": 12,
        "indication_id": 20,
        "last_updated": "2024-03-06",
        "deprecated": false
    },
    {
        "id": 31,
        "document_id": 10,
        "biomarkers": [
            16
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized encorafenib in combination with binimetinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.",
        "evidence": "Approval",
        "implication_id": 13,
        "indication_id": 197,
        "last_updated": "2024-10-20",
        "deprecated": false
    },
    {
        "id": 32,
        "document_id": 11,
        "biomarkers": [
            18
        ],
        "context_id": 10,
        "description": "The European Medicines Agency (EMA) has authorized vandetanib for the treatment of aggressive and symptomatic Rearranged during Transfection (RET) mutant medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Vandetanib is indicated in adults, children, and adolescents aged 5 years and older.",
        "evidence": "Approval",
        "implication_id": 14,
        "indication_id": 21,
        "last_updated": "2024-03-06",
        "deprecated": false
    },
    {
        "id": 33,
        "document_id": 12,
        "biomarkers": [
            16
        ],
        "context_id": 8,
        "description": "The European Medicines Agency (EMA) has authorized cobimetinib in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF p.V600 variant.",
        "evidence": "Approval",
        "implication_id": 15,
        "indication_id": 22,
        "last_updated": "2024-03-06",
        "deprecated": false
    },
    {
        "id": 34,
        "document_id": 12,
        "biomarkers": [
            17
        ],
        "context_id": 8,
        "description": "The European Medicines Agency (EMA) has authorized cobimetinib in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF p.V600 variant.",
        "evidence": "Approval",
        "implication_id": 15,
        "indication_id": 22,
        "last_updated": "2024-03-06",
        "deprecated": false
    },
    {
        "id": 35,
        "document_id": 13,
        "biomarkers": [
            19
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized ramucirumab in combination with erlotinib as a first-line treatment for adult patients with metastatic non-small cell lung cancer with activating EGFR variants.",
        "evidence": "Approval",
        "implication_id": 16,
        "indication_id": 23,
        "last_updated": "2024-03-07",
        "deprecated": false
    },
    {
        "id": 36,
        "document_id": 14,
        "biomarkers": [
            20
        ],
        "context_id": 11,
        "description": "The European Medicines Agency (EMA) has authorized docetaxel in combination with trastuzumab for the treatment of patients with metastatic breast cancer whose tumors over express HER2 and who previously have not received chemotherapy for metastatic disease.",
        "evidence": "Approval",
        "implication_id": 17,
        "indication_id": 24,
        "last_updated": "2024-03-07",
        "deprecated": false
    },
    {
        "id": 37,
        "document_id": 14,
        "biomarkers": [
            21
        ],
        "context_id": 11,
        "description": "The European Medicines Agency (EMA) has authorized docetaxel in combination with trastuzumab for the treatment of patients with metastatic breast cancer whose tumors over express HER2 and who previously have not received chemotherapy for metastatic disease.",
        "evidence": "Inferential",
        "implication_id": 17,
        "indication_id": 24,
        "last_updated": "2024-03-07",
        "deprecated": false
    },
    {
        "id": 38,
        "document_id": 14,
        "biomarkers": [
            20
        ],
        "context_id": 12,
        "description": "The European Medicines Agency (EMA) has authorized docetaxel in combination with trastuzumab for the treatment of patients with metastatic breast cancer whose tumors over express HER2 and who previously have not received chemotherapy for metastatic disease.",
        "evidence": "Approval",
        "implication_id": 17,
        "indication_id": 24,
        "last_updated": "2024-03-07",
        "deprecated": false
    },
    {
        "id": 39,
        "document_id": 14,
        "biomarkers": [
            21
        ],
        "context_id": 12,
        "description": "The European Medicines Agency (EMA) has authorized docetaxel in combination with trastuzumab for the treatment of patients with metastatic breast cancer whose tumors over express HER2 and who previously have not received chemotherapy for metastatic disease.",
        "evidence": "Inferential",
        "implication_id": 17,
        "indication_id": 24,
        "last_updated": "2024-03-07",
        "deprecated": false
    },
    {
        "id": 40,
        "document_id": 15,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimes.",
        "evidence": "Approval",
        "implication_id": 18,
        "indication_id": 25,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 41,
        "document_id": 15,
        "biomarkers": [
            21
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimes.",
        "evidence": "Inferential",
        "implication_id": 18,
        "indication_id": 25,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 42,
        "document_id": 15,
        "biomarkers": [
            22
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. For the purposes of this indication, HER2-low is defined as a score of IHC 1+ or IHC 2+/ISH-, as assessed by a CE-marked IVD medical device or alternative valid test.",
        "evidence": "Approval",
        "implication_id": 18,
        "indication_id": 26,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 43,
        "document_id": 15,
        "biomarkers": [
            21
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan for the treatment of adult patients with advanced non-small cell lung cancer whose tumors have an activating HER2 (ERBB2) variant and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.",
        "evidence": "Approval",
        "implication_id": 18,
        "indication_id": 27,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 44,
        "document_id": 15,
        "biomarkers": [
            23
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan for the treatment of adult patients with advanced non-small cell lung cancer whose tumors have an activating HER2 (ERBB2) variant and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.",
        "evidence": "Approval",
        "implication_id": 18,
        "indication_id": 27,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 45,
        "document_id": 15,
        "biomarkers": [
            20
        ],
        "context_id": 13,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regime.",
        "evidence": "Approval",
        "implication_id": 18,
        "indication_id": 28,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 46,
        "document_id": 15,
        "biomarkers": [
            21
        ],
        "context_id": 13,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regime.",
        "evidence": "Inferential",
        "implication_id": 18,
        "indication_id": 28,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 47,
        "document_id": 16,
        "biomarkers": [
            24,
            25,
            26,
            27
        ],
        "context_id": 9,
        "description": "The European Medicines Agency (EMA) has authorized cetuximab as a single agent for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.",
        "evidence": "Approval",
        "implication_id": 19,
        "indication_id": 29,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 48,
        "document_id": 16,
        "biomarkers": [
            24,
            25,
            26,
            27
        ],
        "context_id": 9,
        "description": "The European Medicines Agency (EMA) has authorized cetuximab in combination with irinotecan-based chemotherapy for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer.",
        "evidence": "Approval",
        "implication_id": 20,
        "indication_id": 30,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 49,
        "document_id": 16,
        "biomarkers": [
            24,
            25,
            26,
            27
        ],
        "context_id": 9,
        "description": "The European Medicines Agency (EMA) has authorized cetuximab in combination with FOLFOX (folinic acid, 5-fluorouracil, and oxaliplatin) for the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer.",
        "evidence": "Approval",
        "implication_id": 21,
        "indication_id": 31,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 50,
        "document_id": 17,
        "biomarkers": [
            1
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized fulvestrant as a monotherapy for the treatment of patients who are postmenopausal women with estrogen receptor positive, locally advanced or metastatic breast cancer. These patients should not have been previously treated with endocrine therapy, or have had disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy.",
        "evidence": "Approval",
        "implication_id": 22,
        "indication_id": 32,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 51,
        "document_id": 17,
        "biomarkers": [
            1
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized fulvestrant as a monotherapy for the treatment of patients who are postmenopausal women with estrogen receptor positive, locally advanced or metastatic breast cancer. These patients should not have been previously treated with endocrine therapy, or have had disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy.",
        "evidence": "Approval",
        "implication_id": 22,
        "indication_id": 32,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 52,
        "document_id": 17,
        "biomarkers": [
            1,
            2
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized fulvestrant in combination with palbociclib for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.",
        "evidence": "Approval",
        "implication_id": 23,
        "indication_id": 33,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 53,
        "document_id": 17,
        "biomarkers": [
            3,
            2
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized fulvestrant in combination with palbociclib for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.",
        "evidence": "Approval",
        "implication_id": 23,
        "indication_id": 33,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 54,
        "document_id": 17,
        "biomarkers": [
            1,
            3,
            2
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized fulvestrant in combination with palbociclib for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.",
        "evidence": "Approval",
        "implication_id": 23,
        "indication_id": 33,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 55,
        "document_id": 17,
        "biomarkers": [
            1,
            2
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized fulvestrant in combination with palbociclib for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.",
        "evidence": "Approval",
        "implication_id": 23,
        "indication_id": 33,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 56,
        "document_id": 17,
        "biomarkers": [
            3,
            2
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized fulvestrant in combination with palbociclib for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.",
        "evidence": "Approval",
        "implication_id": 23,
        "indication_id": 33,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 57,
        "document_id": 17,
        "biomarkers": [
            1,
            3,
            2
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized fulvestrant in combination with palbociclib for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.",
        "evidence": "Approval",
        "implication_id": 23,
        "indication_id": 33,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 58,
        "document_id": 18,
        "biomarkers": [
            18
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized pralsetinib as a monotherapy treatment for adult patients with RET fusion-positive advanced non-small cell lung cancer (NSCLC) who have not previously been treated with a RET inhibitor.",
        "evidence": "Approval",
        "implication_id": 24,
        "indication_id": 34,
        "last_updated": "2024-03-07",
        "deprecated": false
    },
    {
        "id": 59,
        "document_id": 19,
        "biomarkers": [
            19
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized gefitinib as a monotherapy treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating variants of EGFR-TK.",
        "evidence": "Approval",
        "implication_id": 25,
        "indication_id": 35,
        "last_updated": "2024-03-07",
        "deprecated": false
    },
    {
        "id": 60,
        "document_id": 20,
        "biomarkers": [
            19
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized afatinib as a monotherapy indicated for the treatment of EGFR TKI-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR variants.",
        "evidence": "Approval",
        "implication_id": 26,
        "indication_id": 36,
        "last_updated": "2024-03-07",
        "deprecated": false
    },
    {
        "id": 61,
        "document_id": 21,
        "biomarkers": [
            20
        ],
        "context_id": 16,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab as a monotherapy for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have received at least two chemotherapy regimes for their metastatic disease. Prior chemotherapy must have been included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must have also failed hormonal therapy, unless a patient is unsuitable for those treatments. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
        "evidence": "Approval",
        "implication_id": 27,
        "indication_id": 37,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 62,
        "document_id": 21,
        "biomarkers": [
            20
        ],
        "context_id": 17,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab as a monotherapy for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have received at least two chemotherapy regimes for their metastatic disease. Prior chemotherapy must have been included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must have also failed hormonal therapy, unless a patient is unsuitable for those treatments. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
        "evidence": "Approval",
        "implication_id": 27,
        "indication_id": 37,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 63,
        "document_id": 21,
        "biomarkers": [
            20
        ],
        "context_id": 16,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
        "evidence": "Approval",
        "implication_id": 28,
        "indication_id": 38,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 64,
        "document_id": 21,
        "biomarkers": [
            20
        ],
        "context_id": 17,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
        "evidence": "Approval",
        "implication_id": 28,
        "indication_id": 38,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 65,
        "document_id": 21,
        "biomarkers": [
            20
        ],
        "context_id": 16,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with docetaxel for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have not received chemotherapy for their metastatic disease. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
        "evidence": "Approval",
        "implication_id": 29,
        "indication_id": 39,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 66,
        "document_id": 21,
        "biomarkers": [
            20
        ],
        "context_id": 17,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with docetaxel for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have not received chemotherapy for their metastatic disease. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
        "evidence": "Approval",
        "implication_id": 29,
        "indication_id": 39,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 67,
        "document_id": 21,
        "biomarkers": [
            20
        ],
        "context_id": 16,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
        "evidence": "Approval",
        "implication_id": 30,
        "indication_id": 40,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 68,
        "document_id": 21,
        "biomarkers": [
            20
        ],
        "context_id": 17,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
        "evidence": "Approval",
        "implication_id": 30,
        "indication_id": 40,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 69,
        "document_id": 21,
        "biomarkers": [
            20
        ],
        "context_id": 18,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab for the treatment of adult patients with HER2 positive early breast cancer (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant), and radiotherapy (if applicable). The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
        "evidence": "Approval",
        "implication_id": 27,
        "indication_id": 41,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 70,
        "document_id": 21,
        "biomarkers": [
            20
        ],
        "context_id": 18,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel or docetaxel for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
        "evidence": "Approval",
        "implication_id": 31,
        "indication_id": 42,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 71,
        "document_id": 21,
        "biomarkers": [
            20
        ],
        "context_id": 18,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel or docetaxel for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
        "evidence": "Approval",
        "implication_id": 32,
        "indication_id": 42,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 72,
        "document_id": 21,
        "biomarkers": [
            20
        ],
        "context_id": 18,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin for the treatment of adult patients with HER2 positive early breast cancer (EBC). The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
        "evidence": "Approval",
        "implication_id": 33,
        "indication_id": 43,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 73,
        "document_id": 21,
        "biomarkers": [
            20
        ],
        "context_id": 18,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with neoadjuvant chemotherapy followed by adjuvant trastuzumab for the treatment of adult patients with HER2 positive early breast cancer (EBC) whose tumors are locally advanced (including inflammatory) disease or > 2 cm in diameter. This indication is based on the multicenter randomized trial MO16432 which used doxorubicin in combination with paclitaxel for the neoadjuvant chemotherapy. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
        "evidence": "Approval",
        "implication_id": 34,
        "indication_id": 44,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 74,
        "document_id": 21,
        "biomarkers": [
            21
        ],
        "context_id": 16,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab as a monotherapy for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have received at least two chemotherapy regimes for their metastatic disease. Prior chemotherapy must have been included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must have also failed hormonal therapy, unless a patient is unsuitable for those treatments. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
        "evidence": "Inferential",
        "implication_id": 27,
        "indication_id": 37,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 75,
        "document_id": 21,
        "biomarkers": [
            21
        ],
        "context_id": 17,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab as a monotherapy for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have received at least two chemotherapy regimes for their metastatic disease. Prior chemotherapy must have been included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must have also failed hormonal therapy, unless a patient is unsuitable for those treatments. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
        "evidence": "Inferential",
        "implication_id": 27,
        "indication_id": 37,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 76,
        "document_id": 21,
        "biomarkers": [
            21
        ],
        "context_id": 16,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
        "evidence": "Inferential",
        "implication_id": 28,
        "indication_id": 38,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 77,
        "document_id": 21,
        "biomarkers": [
            21
        ],
        "context_id": 17,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
        "evidence": "Inferential",
        "implication_id": 28,
        "indication_id": 38,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 78,
        "document_id": 21,
        "biomarkers": [
            21
        ],
        "context_id": 16,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with docetaxel for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have not received chemotherapy for their metastatic disease. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
        "evidence": "Inferential",
        "implication_id": 29,
        "indication_id": 39,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 79,
        "document_id": 21,
        "biomarkers": [
            21
        ],
        "context_id": 17,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with docetaxel for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have not received chemotherapy for their metastatic disease. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
        "evidence": "Inferential",
        "implication_id": 29,
        "indication_id": 39,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 80,
        "document_id": 21,
        "biomarkers": [
            21
        ],
        "context_id": 16,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
        "evidence": "Inferential",
        "implication_id": 30,
        "indication_id": 40,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 81,
        "document_id": 21,
        "biomarkers": [
            21
        ],
        "context_id": 17,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
        "evidence": "Inferential",
        "implication_id": 30,
        "indication_id": 40,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 82,
        "document_id": 21,
        "biomarkers": [
            21
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab for the treatment of adult patients with HER2 positive early breast cancer (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant), and radiotherapy (if applicable). The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
        "evidence": "Inferential",
        "implication_id": 27,
        "indication_id": 41,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 83,
        "document_id": 21,
        "biomarkers": [
            21
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel or docetaxel for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
        "evidence": "Inferential",
        "implication_id": 31,
        "indication_id": 42,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 84,
        "document_id": 21,
        "biomarkers": [
            21
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel or docetaxel for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
        "evidence": "Inferential",
        "implication_id": 32,
        "indication_id": 42,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 85,
        "document_id": 21,
        "biomarkers": [
            21
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin for the treatment of adult patients with HER2 positive early breast cancer (EBC). The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
        "evidence": "Inferential",
        "implication_id": 33,
        "indication_id": 43,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 86,
        "document_id": 21,
        "biomarkers": [
            21
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with neoadjuvant chemotherapy followed by adjuvant trastuzumab for the treatment of adult patients with HER2 positive early breast cancer (EBC) whose tumors are locally advanced (including inflammatory) disease or > 2 cm in diameter. This indication is based on the multicenter randomized trial MO16432 which used doxorubicin in combination with paclitaxel for the neoadjuvant chemotherapy. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.",
        "evidence": "Inferential",
        "implication_id": 35,
        "indication_id": 44,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 87,
        "document_id": 21,
        "biomarkers": [
            20
        ],
        "context_id": 19,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of adult patients with HER2 positive metastatic adenocracinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. The production information for trastuzumab in this indication further specifies that trastuzumab should only be used in patients with metastatic gastric cancer whose tumors have HER2 overexpressed as defined by IHC 2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result, as measured by an accurate and validated assay.",
        "evidence": "Approval",
        "implication_id": 36,
        "indication_id": 45,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 88,
        "document_id": 21,
        "biomarkers": [
            20
        ],
        "context_id": 19,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of adult patients with HER2 positive metastatic adenocracinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. The production information for trastuzumab in this indication further specifies that trastuzumab should only be used in patients with metastatic gastric cancer whose tumors have HER2 overexpressed as defined by IHC 2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result, as measured by an accurate and validated assay.",
        "evidence": "Approval",
        "implication_id": 37,
        "indication_id": 45,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 89,
        "document_id": 21,
        "biomarkers": [
            21
        ],
        "context_id": 19,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of adult patients with HER2 positive metastatic adenocracinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. The production information for trastuzumab in this indication further specifies that trastuzumab should only be used in patients with metastatic gastric cancer whose tumors have HER2 overexpressed as defined by IHC 2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result, as measured by an accurate and validated assay.",
        "evidence": "Inferential",
        "implication_id": 36,
        "indication_id": 45,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 90,
        "document_id": 21,
        "biomarkers": [
            21
        ],
        "context_id": 19,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of adult patients with HER2 positive metastatic adenocracinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. The production information for trastuzumab in this indication further specifies that trastuzumab should only be used in patients with metastatic gastric cancer whose tumors have HER2 overexpressed as defined by IHC 2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result, as measured by an accurate and validated assay.",
        "evidence": "Inferential",
        "implication_id": 37,
        "indication_id": 45,
        "last_updated": "2024-03-12",
        "deprecated": false
    },
    {
        "id": 91,
        "document_id": 22,
        "biomarkers": [
            2,
            1
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with an aromatase inhibitor for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This indication is based on a randomized phase 3 study, PALOMA-2, that evaluated letrozole in combination with either palbociclib or placebo. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.",
        "evidence": "Approval",
        "implication_id": 38,
        "indication_id": 46,
        "last_updated": "2024-03-13",
        "deprecated": false
    },
    {
        "id": 92,
        "document_id": 22,
        "biomarkers": [
            2,
            3
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with an aromatase inhibitor for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This indication is based on a randomized phase 3 study, PALOMA-2, that evaluated letrozole in combination with either palbociclib or placebo. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.",
        "evidence": "Approval",
        "implication_id": 38,
        "indication_id": 46,
        "last_updated": "2024-03-13",
        "deprecated": false
    },
    {
        "id": 93,
        "document_id": 22,
        "biomarkers": [
            2,
            1,
            3
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with an aromatase inhibitor for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This indication is based on a randomized phase 3 study, PALOMA-2, that evaluated letrozole in combination with either palbociclib or placebo. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.",
        "evidence": "Approval",
        "implication_id": 38,
        "indication_id": 46,
        "last_updated": "2024-03-13",
        "deprecated": false
    },
    {
        "id": 94,
        "document_id": 22,
        "biomarkers": [
            2,
            1
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with an aromatase inhibitor for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This indication is based on a randomized phase 3 study, PALOMA-2, that evaluated letrozole in combination with either palbociclib or placebo. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.",
        "evidence": "Approval",
        "implication_id": 38,
        "indication_id": 46,
        "last_updated": "2024-03-13",
        "deprecated": false
    },
    {
        "id": 95,
        "document_id": 22,
        "biomarkers": [
            2,
            3
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with an aromatase inhibitor for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This indication is based on a randomized phase 3 study, PALOMA-2, that evaluated letrozole in combination with either palbociclib or placebo. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.",
        "evidence": "Approval",
        "implication_id": 38,
        "indication_id": 46,
        "last_updated": "2024-03-13",
        "deprecated": false
    },
    {
        "id": 96,
        "document_id": 22,
        "biomarkers": [
            2,
            1,
            3
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with an aromatase inhibitor for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This indication is based on a randomized phase 3 study, PALOMA-2, that evaluated letrozole in combination with either palbociclib or placebo. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.",
        "evidence": "Approval",
        "implication_id": 38,
        "indication_id": 46,
        "last_updated": "2024-03-13",
        "deprecated": false
    },
    {
        "id": 97,
        "document_id": 22,
        "biomarkers": [
            2,
            1
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with fulvestrant for patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, who have also received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.",
        "evidence": "Approval",
        "implication_id": 39,
        "indication_id": 47,
        "last_updated": "2024-03-13",
        "deprecated": false
    },
    {
        "id": 98,
        "document_id": 22,
        "biomarkers": [
            2,
            3
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with fulvestrant for patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, who have also received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.",
        "evidence": "Approval",
        "implication_id": 39,
        "indication_id": 47,
        "last_updated": "2024-03-13",
        "deprecated": false
    },
    {
        "id": 99,
        "document_id": 22,
        "biomarkers": [
            2,
            1,
            3
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with fulvestrant for patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, who have also received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.",
        "evidence": "Approval",
        "implication_id": 39,
        "indication_id": 47,
        "last_updated": "2024-03-13",
        "deprecated": false
    },
    {
        "id": 100,
        "document_id": 22,
        "biomarkers": [
            2,
            1
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with fulvestrant for patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, who have also received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.",
        "evidence": "Approval",
        "implication_id": 39,
        "indication_id": 47,
        "last_updated": "2024-03-13",
        "deprecated": false
    },
    {
        "id": 101,
        "document_id": 22,
        "biomarkers": [
            2,
            3
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with fulvestrant for patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, who have also received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.",
        "evidence": "Approval",
        "implication_id": 39,
        "indication_id": 47,
        "last_updated": "2024-03-13",
        "deprecated": false
    },
    {
        "id": 102,
        "document_id": 22,
        "biomarkers": [
            2,
            1,
            3
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with fulvestrant for patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, who have also received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.",
        "evidence": "Approval",
        "implication_id": 39,
        "indication_id": 47,
        "last_updated": "2024-03-13",
        "deprecated": false
    },
    {
        "id": 103,
        "document_id": 23,
        "biomarkers": [
            12
        ],
        "context_id": 20,
        "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.",
        "evidence": "Approval",
        "implication_id": 40,
        "indication_id": 48,
        "last_updated": "2024-03-07",
        "deprecated": false
    },
    {
        "id": 104,
        "document_id": 23,
        "biomarkers": [
            12
        ],
        "context_id": 20,
        "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult and pediatric patients with Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukemia (CML) in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.",
        "evidence": "Approval",
        "implication_id": 40,
        "indication_id": 49,
        "last_updated": "2024-03-07",
        "deprecated": false
    },
    {
        "id": 105,
        "document_id": 23,
        "biomarkers": [
            12
        ],
        "context_id": 21,
        "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) integrated with chemotherapy.",
        "evidence": "Approval",
        "implication_id": 40,
        "indication_id": 50,
        "last_updated": "2024-03-07",
        "deprecated": false
    },
    {
        "id": 106,
        "document_id": 23,
        "biomarkers": [
            12
        ],
        "context_id": 21,
        "description": "The European Medicines Agency (EMA) has authorized imatinib as a monotherapy treatment for adult patients with relapased or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).",
        "evidence": "Approval",
        "implication_id": 40,
        "indication_id": 51,
        "last_updated": "2024-03-07",
        "deprecated": false
    },
    {
        "id": 107,
        "document_id": 23,
        "biomarkers": [
            28
        ],
        "context_id": 22,
        "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor (PDGFR) gene rearrangements.",
        "evidence": "Approval",
        "implication_id": 40,
        "indication_id": 52,
        "last_updated": "2024-03-07",
        "deprecated": false
    },
    {
        "id": 108,
        "document_id": 23,
        "biomarkers": [
            29
        ],
        "context_id": 22,
        "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor (PDGFR) gene rearrangements.",
        "evidence": "Approval",
        "implication_id": 40,
        "indication_id": 52,
        "last_updated": "2024-03-07",
        "deprecated": false
    },
    {
        "id": 109,
        "document_id": 23,
        "biomarkers": [
            28
        ],
        "context_id": 23,
        "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor (PDGFR) gene rearrangements.",
        "evidence": "Approval",
        "implication_id": 40,
        "indication_id": 52,
        "last_updated": "2024-03-07",
        "deprecated": false
    },
    {
        "id": 110,
        "document_id": 23,
        "biomarkers": [
            29
        ],
        "context_id": 23,
        "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor (PDGFR) gene rearrangements.",
        "evidence": "Approval",
        "implication_id": 40,
        "indication_id": 52,
        "last_updated": "2024-03-07",
        "deprecated": false
    },
    {
        "id": 111,
        "document_id": 23,
        "biomarkers": [
            30
        ],
        "context_id": 24,
        "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with a FIP1L1::PDGFRA rearrangement.",
        "evidence": "Approval",
        "implication_id": 40,
        "indication_id": 53,
        "last_updated": "2024-03-07",
        "deprecated": false
    },
    {
        "id": 112,
        "document_id": 23,
        "biomarkers": [
            31
        ],
        "context_id": 25,
        "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).",
        "evidence": "Approval",
        "implication_id": 41,
        "indication_id": 54,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 113,
        "document_id": 23,
        "biomarkers": [
            31
        ],
        "context_id": 25,
        "description": "The European Medicines Agency (EMA) has authorized imatinib for the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD 117) positive gastrointestinal stromal tumors (GIST). Patients who have a low or very low risk of recurrence should not received adjuvant treatment.",
        "evidence": "Approval",
        "implication_id": 41,
        "indication_id": 55,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 114,
        "document_id": 24,
        "biomarkers": [
            32
        ],
        "context_id": 20,
        "description": "The European Medicines Agency (EMA) has authorized ponatinib for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the p.T315I variant.",
        "evidence": "Approval",
        "implication_id": 42,
        "indication_id": 56,
        "last_updated": "2024-03-07",
        "deprecated": false
    },
    {
        "id": 115,
        "document_id": 24,
        "biomarkers": [
            12
        ],
        "context_id": 26,
        "description": "The European Medicines Agency (EMA) has authorized ponatinib for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I variant.",
        "evidence": "Approval",
        "implication_id": 42,
        "indication_id": 57,
        "last_updated": "2024-03-07",
        "deprecated": false
    },
    {
        "id": 116,
        "document_id": 24,
        "biomarkers": [
            12,
            32
        ],
        "context_id": 26,
        "description": "The European Medicines Agency (EMA) has authorized ponatinib for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I variant.",
        "evidence": "Approval",
        "implication_id": 42,
        "indication_id": 57,
        "last_updated": "2024-03-07",
        "deprecated": false
    },
    {
        "id": 117,
        "document_id": 25,
        "biomarkers": [
            33
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized durvalumab as a monotherapy for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) whose tumors express PD-L1 on >= 1% of tumor cells and whose disease has not progressed following platinum-based chemoradiation therapy.",
        "evidence": "Approval",
        "implication_id": 43,
        "indication_id": 58,
        "last_updated": "2024-03-13",
        "deprecated": false
    },
    {
        "id": 118,
        "document_id": 25,
        "biomarkers": [
            34,
            35
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized durvalumab in combination with tremelimumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) and no sensitizing EGFR mutations or ALK positive mutations. This indication is POSEIDON (NCT03164616), a randomized, multicenter, active-controlled, and open-label study where the specific chemotherapy regime used was based on the histology of the patient's NSCLC.",
        "evidence": "Approval",
        "implication_id": 44,
        "indication_id": 59,
        "last_updated": "2024-03-13",
        "deprecated": false
    },
    {
        "id": 119,
        "document_id": 25,
        "biomarkers": [
            36
        ],
        "context_id": 27,
        "description": "The European Medicines Agency (EMA) has authorized durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) or durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).",
        "evidence": "Approval",
        "implication_id": 45,
        "indication_id": 145,
        "last_updated": "2024-08-24",
        "deprecated": false
    },
    {
        "id": 120,
        "document_id": 25,
        "biomarkers": [
            37
        ],
        "context_id": 27,
        "description": "The European Medicines Agency (EMA) has authorized durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) or durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).",
        "evidence": "Approval",
        "implication_id": 46,
        "indication_id": 145,
        "last_updated": "2024-08-24",
        "deprecated": false
    },
    {
        "id": 121,
        "document_id": 26,
        "biomarkers": [
            34,
            35
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) and no sensitizing EGFR mutations or ALK positive mutations. This indication is POSEIDON (NCT03164616), a randomized, multicenter, active-controlled, and open-label study where the specific chemotherapy regime used was based on the histology of the patient's NSCLC.",
        "evidence": "Approval",
        "implication_id": 47,
        "indication_id": 60,
        "last_updated": "2024-03-13",
        "deprecated": false
    },
    {
        "id": 122,
        "document_id": 27,
        "biomarkers": [
            38
        ],
        "context_id": 28,
        "description": "The European Medicines Agency (EMA) has authorized dostarlimab in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR) / microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) who are candidates for systemic therapy.",
        "evidence": "Approval",
        "implication_id": 48,
        "indication_id": 61,
        "last_updated": "2024-03-09",
        "deprecated": false
    },
    {
        "id": 123,
        "document_id": 27,
        "biomarkers": [
            36
        ],
        "context_id": 28,
        "description": "The European Medicines Agency (EMA) has authorized dostarlimab in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR) / microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) who are candidates for systemic therapy.",
        "evidence": "Approval",
        "implication_id": 48,
        "indication_id": 61,
        "last_updated": "2024-03-09",
        "deprecated": false
    },
    {
        "id": 124,
        "document_id": 27,
        "biomarkers": [
            38
        ],
        "context_id": 28,
        "description": "The European Medicines Agency (EMA) has authorized dostarlimab as a monotherapy for the treatment of adult patients with mismatch repair deficiency (dMMR) / microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.",
        "evidence": "Approval",
        "implication_id": 49,
        "indication_id": 62,
        "last_updated": "2024-03-09",
        "deprecated": false
    },
    {
        "id": 125,
        "document_id": 27,
        "biomarkers": [
            36
        ],
        "context_id": 28,
        "description": "The European Medicines Agency (EMA) has authorized dostarlimab as a monotherapy for the treatment of adult patients with mismatch repair deficiency (dMMR) / microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.",
        "evidence": "Approval",
        "implication_id": 49,
        "indication_id": 62,
        "last_updated": "2024-03-09",
        "deprecated": false
    },
    {
        "id": 126,
        "document_id": 28,
        "biomarkers": [
            39,
            35,
            34
        ],
        "context_id": 29,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors express PD-L1 with a >= 50% tumor proportion score (TPS) with no EGFR or ALK positive tumor mutations.",
        "evidence": "Approval",
        "implication_id": 50,
        "indication_id": 63,
        "last_updated": "2024-03-10",
        "deprecated": false
    },
    {
        "id": 127,
        "document_id": 28,
        "biomarkers": [
            40,
            35,
            34
        ],
        "context_id": 29,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors express PD-L1 with a >= 50% tumor proportion score (TPS) with no EGFR or ALK positive tumor mutations.",
        "evidence": "Inferential",
        "implication_id": 50,
        "indication_id": 63,
        "last_updated": "2024-03-10",
        "deprecated": false
    },
    {
        "id": 128,
        "document_id": 28,
        "biomarkers": [
            35,
            34
        ],
        "context_id": 29,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors have no EGFR or ALK positive mutations. This indication is based on results from KEYNOTE-024, where patients received pembrolizumab in combination with investigator's choice of platinum-containing chemotherapy, including: pemetrexed with carboplatin, pemetrexed with cisplatin, gemcitabine and cisplatin, gemcitabine and carboplatin, or paclitaxel and carboplatin.",
        "evidence": "Approval",
        "implication_id": 51,
        "indication_id": 64,
        "last_updated": "2024-03-10",
        "deprecated": false
    },
    {
        "id": 129,
        "document_id": 28,
        "biomarkers": [
            35,
            34
        ],
        "context_id": 29,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors have no EGFR or ALK positive mutations. This indication is based on results from KEYNOTE-024, where patients received pembrolizumab in combination with investigator's choice of platinum-containing chemotherapy, including: pemetrexed with carboplatin, pemetrexed with cisplatin, gemcitabine and cisplatin, gemcitabine and carboplatin, or paclitaxel and carboplatin.",
        "evidence": "Approval",
        "implication_id": 52,
        "indication_id": 64,
        "last_updated": "2024-03-10",
        "deprecated": false
    },
    {
        "id": 130,
        "document_id": 28,
        "biomarkers": [
            35,
            34
        ],
        "context_id": 29,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors have no EGFR or ALK positive mutations. This indication is based on results from KEYNOTE-024, where patients received pembrolizumab in combination with investigator's choice of platinum-containing chemotherapy, including: pemetrexed with carboplatin, pemetrexed with cisplatin, gemcitabine and cisplatin, gemcitabine and carboplatin, or paclitaxel and carboplatin.",
        "evidence": "Approval",
        "implication_id": 53,
        "indication_id": 64,
        "last_updated": "2024-03-10",
        "deprecated": false
    },
    {
        "id": 131,
        "document_id": 28,
        "biomarkers": [
            35,
            34
        ],
        "context_id": 29,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors have no EGFR or ALK positive mutations. This indication is based on results from KEYNOTE-024, where patients received pembrolizumab in combination with investigator's choice of platinum-containing chemotherapy, including: pemetrexed with carboplatin, pemetrexed with cisplatin, gemcitabine and cisplatin, gemcitabine and carboplatin, or paclitaxel and carboplatin.",
        "evidence": "Approval",
        "implication_id": 54,
        "indication_id": 64,
        "last_updated": "2024-03-10",
        "deprecated": false
    },
    {
        "id": 132,
        "document_id": 28,
        "biomarkers": [
            35,
            34
        ],
        "context_id": 29,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors have no EGFR or ALK positive mutations. This indication is based on results from KEYNOTE-024, where patients received pembrolizumab in combination with investigator's choice of platinum-containing chemotherapy, including: pemetrexed with carboplatin, pemetrexed with cisplatin, gemcitabine and cisplatin, gemcitabine and carboplatin, or paclitaxel and carboplatin.",
        "evidence": "Approval",
        "implication_id": 55,
        "indication_id": 64,
        "last_updated": "2024-03-10",
        "deprecated": false
    },
    {
        "id": 133,
        "document_id": 28,
        "biomarkers": [
            33
        ],
        "context_id": 29,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung carcinoma whose tumors express PD-L1 with a >= 1% tumor proportion score (TPS) and who have recieved at least one prior chemotherapy regime. Patients with EGFR or ALK positive tumor mutations should also have received targeted therapy before receiving pembrolizumab.",
        "evidence": "Approval",
        "implication_id": 50,
        "indication_id": 65,
        "last_updated": "2024-03-10",
        "deprecated": false
    },
    {
        "id": 134,
        "document_id": 28,
        "biomarkers": [
            41
        ],
        "context_id": 30,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 with a combined positive score (CPS) >= 10.",
        "evidence": "Approval",
        "implication_id": 50,
        "indication_id": 66,
        "last_updated": "2024-03-10",
        "deprecated": false
    },
    {
        "id": 135,
        "document_id": 28,
        "biomarkers": [
            42
        ],
        "context_id": 31,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.",
        "evidence": "Approval",
        "implication_id": 50,
        "indication_id": 67,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 136,
        "document_id": 28,
        "biomarkers": [
            42
        ],
        "context_id": 31,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.",
        "evidence": "Approval",
        "implication_id": 56,
        "indication_id": 67,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 137,
        "document_id": 28,
        "biomarkers": [
            42
        ],
        "context_id": 31,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.",
        "evidence": "Approval",
        "implication_id": 57,
        "indication_id": 67,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 138,
        "document_id": 28,
        "biomarkers": [
            39
        ],
        "context_id": 31,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma whose tumors express PD-L1 with a tumor proportion score >= 50% and who have progressed on or after platinum-containing chemotherapy.",
        "evidence": "Approval",
        "implication_id": 50,
        "indication_id": 68,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 139,
        "document_id": 28,
        "biomarkers": [
            38
        ],
        "context_id": 9,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) colorectal cancer as a first line-treatment for metastatic colorectal cancer or treatment of unresectable or metastatic colorectal cancer after previously fluoropryimidine-based combination therapy.",
        "evidence": "Approval",
        "implication_id": 50,
        "indication_id": 69,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 140,
        "document_id": 28,
        "biomarkers": [
            36
        ],
        "context_id": 9,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) colorectal cancer as a first line-treatment for metastatic colorectal cancer or treatment of unresectable or metastatic colorectal cancer after previously fluoropryimidine-based combination therapy.",
        "evidence": "Approval",
        "implication_id": 50,
        "indication_id": 69,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 141,
        "document_id": 28,
        "biomarkers": [
            38
        ],
        "context_id": 32,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation.",
        "evidence": "Approval",
        "implication_id": 50,
        "indication_id": 70,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 142,
        "document_id": 28,
        "biomarkers": [
            36
        ],
        "context_id": 32,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation.",
        "evidence": "Approval",
        "implication_id": 50,
        "indication_id": 70,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 143,
        "document_id": 28,
        "biomarkers": [
            38
        ],
        "context_id": 33,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.",
        "evidence": "Approval",
        "implication_id": 50,
        "indication_id": 71,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 144,
        "document_id": 28,
        "biomarkers": [
            36
        ],
        "context_id": 33,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.",
        "evidence": "Approval",
        "implication_id": 50,
        "indication_id": 71,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 145,
        "document_id": 28,
        "biomarkers": [
            38
        ],
        "context_id": 34,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.",
        "evidence": "Approval",
        "implication_id": 50,
        "indication_id": 71,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 146,
        "document_id": 28,
        "biomarkers": [
            36
        ],
        "context_id": 34,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.",
        "evidence": "Approval",
        "implication_id": 50,
        "indication_id": 71,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 147,
        "document_id": 28,
        "biomarkers": [
            38
        ],
        "context_id": 35,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.",
        "evidence": "Approval",
        "implication_id": 50,
        "indication_id": 71,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 148,
        "document_id": 28,
        "biomarkers": [
            36
        ],
        "context_id": 35,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.",
        "evidence": "Approval",
        "implication_id": 50,
        "indication_id": 71,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 149,
        "document_id": 28,
        "biomarkers": [
            41
        ],
        "context_id": 36,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy as a first-line treatment for adult patients with locally advanced unresectable or metastatic esophageal carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 10.",
        "evidence": "Approval",
        "implication_id": 58,
        "indication_id": 72,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 150,
        "document_id": 28,
        "biomarkers": [
            41
        ],
        "context_id": 36,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy as a first-line treatment for adult patients with locally advanced unresectable or metastatic esophageal carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 10.",
        "evidence": "Approval",
        "implication_id": 59,
        "indication_id": 72,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 151,
        "document_id": 28,
        "biomarkers": [
            43,
            2,
            44
        ],
        "context_id": 37,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy for the neoadjuvant treatment, and then continued as a monotherapy for the adjuvant treatment after surgery, of adult patients with locally advanced or early-stage triple-negative breast cancer at high risk of recurrence.",
        "evidence": "Approval",
        "implication_id": 50,
        "indication_id": 73,
        "last_updated": "2024-05-16",
        "deprecated": false
    },
    {
        "id": 152,
        "document_id": 28,
        "biomarkers": [
            41,
            43,
            2,
            44
        ],
        "context_id": 37,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 10 and who have not received prior chemotherapy for metastatic disease. This indication is based on KEYNOTE-355, a phase 3, randomizewd, double-blind, multi-center, placebo-controlled study where the efficacy of pembrolizumab in combination with: (i) paclitaxel, (ii) nab-paclitaxel, or (iii) gemcitabine and carboplatin were investigated for the treatment of patients with TNBC who were previously untreated for metastatic disease.",
        "evidence": "Approval",
        "implication_id": 60,
        "indication_id": 74,
        "last_updated": "2024-05-16",
        "deprecated": false
    },
    {
        "id": 153,
        "document_id": 28,
        "biomarkers": [
            41,
            43,
            2,
            44
        ],
        "context_id": 37,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 10 and who have not received prior chemotherapy for metastatic disease. This indication is based on KEYNOTE-355, a phase 3, randomizewd, double-blind, multi-center, placebo-controlled study where the efficacy of pembrolizumab in combination with: (i) paclitaxel, (ii) nab-paclitaxel, or (iii) gemcitabine and carboplatin were investigated for the treatment of patients with TNBC who were previously untreated for metastatic disease.",
        "evidence": "Approval",
        "implication_id": 61,
        "indication_id": 74,
        "last_updated": "2024-05-16",
        "deprecated": false
    },
    {
        "id": 154,
        "document_id": 28,
        "biomarkers": [
            41,
            43,
            2,
            44
        ],
        "context_id": 37,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 10 and who have not received prior chemotherapy for metastatic disease. This indication is based on KEYNOTE-355, a phase 3, randomizewd, double-blind, multi-center, placebo-controlled study where the efficacy of pembrolizumab in combination with: (i) paclitaxel, (ii) nab-paclitaxel, or (iii) gemcitabine and carboplatin were investigated for the treatment of patients with TNBC who were previously untreated for metastatic disease.",
        "evidence": "Approval",
        "implication_id": 62,
        "indication_id": 74,
        "last_updated": "2024-05-16",
        "deprecated": false
    },
    {
        "id": 155,
        "document_id": 28,
        "biomarkers": [
            42
        ],
        "context_id": 38,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy and with or without bevacizumab for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 1. This indication is based on KEYNOTE-826, a multicenter, randomized, double-blind, and placebo-controlled study that studied the efficacy of pembrolizumab in combination with paclitaxel and cisplatin or paclitaxel and carboplatin, with or without bevacizumab in 617 patients meeting this indication's clinical criteria.",
        "evidence": "Approval",
        "implication_id": 63,
        "indication_id": 75,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 156,
        "document_id": 28,
        "biomarkers": [
            42
        ],
        "context_id": 38,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy and with or without bevacizumab for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 1. This indication is based on KEYNOTE-826, a multicenter, randomized, double-blind, and placebo-controlled study that studied the efficacy of pembrolizumab in combination with paclitaxel and cisplatin or paclitaxel and carboplatin, with or without bevacizumab in 617 patients meeting this indication's clinical criteria.",
        "evidence": "Approval",
        "implication_id": 64,
        "indication_id": 75,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 157,
        "document_id": 28,
        "biomarkers": [
            20,
            42
        ],
        "context_id": 39,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastro-esophageal junction adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.",
        "evidence": "Approval",
        "implication_id": 65,
        "indication_id": 76,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 158,
        "document_id": 28,
        "biomarkers": [
            20,
            42
        ],
        "context_id": 39,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastro-esophageal junction adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.",
        "evidence": "Approval",
        "implication_id": 66,
        "indication_id": 76,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 159,
        "document_id": 28,
        "biomarkers": [
            2,
            42
        ],
        "context_id": 39,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.",
        "evidence": "Approval",
        "implication_id": 67,
        "indication_id": 77,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 160,
        "document_id": 28,
        "biomarkers": [
            2,
            42
        ],
        "context_id": 39,
        "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.",
        "evidence": "Approval",
        "implication_id": 68,
        "indication_id": 77,
        "last_updated": "2024-03-11",
        "deprecated": false
    },
    {
        "id": 161,
        "document_id": 29,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab emtansine for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.",
        "evidence": "Approval",
        "implication_id": 69,
        "indication_id": 78,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 162,
        "document_id": 29,
        "biomarkers": [
            21
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab emtansine for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.",
        "evidence": "Inferential",
        "implication_id": 69,
        "indication_id": 78,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 163,
        "document_id": 29,
        "biomarkers": [
            20
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab emtansine for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in cobmination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.",
        "evidence": "Approval",
        "implication_id": 69,
        "indication_id": 79,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 164,
        "document_id": 29,
        "biomarkers": [
            21
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab emtansine for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in cobmination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.",
        "evidence": "Inferential",
        "implication_id": 69,
        "indication_id": 79,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 165,
        "document_id": 29,
        "biomarkers": [
            20
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab emtansine for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in cobmination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.",
        "evidence": "Approval",
        "implication_id": 69,
        "indication_id": 79,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 166,
        "document_id": 29,
        "biomarkers": [
            21
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized trastuzumab emtansine for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in cobmination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.",
        "evidence": "Inferential",
        "implication_id": 69,
        "indication_id": 79,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 167,
        "document_id": 30,
        "biomarkers": [
            1,
            2
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 70,
        "indication_id": 80,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 168,
        "document_id": 30,
        "biomarkers": [
            3,
            2
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 70,
        "indication_id": 80,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 169,
        "document_id": 30,
        "biomarkers": [
            1,
            3,
            2
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 70,
        "indication_id": 80,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 170,
        "document_id": 30,
        "biomarkers": [
            1,
            2
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 70,
        "indication_id": 80,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 171,
        "document_id": 30,
        "biomarkers": [
            3,
            2
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 70,
        "indication_id": 80,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 172,
        "document_id": 30,
        "biomarkers": [
            1,
            3,
            2
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 70,
        "indication_id": 80,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 173,
        "document_id": 30,
        "biomarkers": [
            1,
            2
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 71,
        "indication_id": 80,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 174,
        "document_id": 30,
        "biomarkers": [
            3,
            2
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 71,
        "indication_id": 80,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 175,
        "document_id": 30,
        "biomarkers": [
            1,
            3,
            2
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 71,
        "indication_id": 80,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 176,
        "document_id": 30,
        "biomarkers": [
            1,
            2
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 71,
        "indication_id": 80,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 177,
        "document_id": 30,
        "biomarkers": [
            3,
            2
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 71,
        "indication_id": 80,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 178,
        "document_id": 30,
        "biomarkers": [
            1,
            3,
            2
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 71,
        "indication_id": 80,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 179,
        "document_id": 31,
        "biomarkers": [
            45
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized adagrasib as a monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with the KRAS p.G12C variant and disease progression after at least one prior systemic therapy.",
        "evidence": "Approval",
        "implication_id": 72,
        "indication_id": 81,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 180,
        "document_id": 32,
        "biomarkers": [
            39,
            34,
            35,
            46
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized cemiplimab as a monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in >= 50% of tumor cells), with no EGFR, ALK, or ROS1 aberrations. This indication is specifically for patients who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or patients with metastatic NSCLC.",
        "evidence": "Approval",
        "implication_id": 73,
        "indication_id": 82,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 181,
        "document_id": 32,
        "biomarkers": [
            33,
            34,
            35,
            46
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized cemiplimab in combination with platinum-based chemotherapy for the first-line treatment of adult patients with NSCLC expressing PD-L1 (in >= 1% of tumor cells), with no EGFR, ALK, or ROS1 aberrations. This indication is specifically for patients who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or patients with metastatic NSCLC. This indication is based on Study 16113, a randomized, multi-center, double-blind, active-controlled trial. The chemotherapy used in this study consisted of either carboplatin or cisplatin in combination with paclitaxel or pemetrexed.",
        "evidence": "Approval",
        "implication_id": 74,
        "indication_id": 83,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 182,
        "document_id": 33,
        "biomarkers": [
            8
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized lorlatinib as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.",
        "evidence": "Approval",
        "implication_id": 75,
        "indication_id": 84,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 183,
        "document_id": 33,
        "biomarkers": [
            8
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized lorlatinib as a monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or crizotinib and at least one other ALK TKI.",
        "evidence": "Approval",
        "implication_id": 75,
        "indication_id": 85,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 184,
        "document_id": 34,
        "biomarkers": [
            45
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized sotorasib as a monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with the KRAS p.G12C variant and who have progressed after at least one prior line of systemic therapy.",
        "evidence": "Approval",
        "implication_id": 76,
        "indication_id": 86,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 185,
        "document_id": 35,
        "biomarkers": [
            47
        ],
        "context_id": 40,
        "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 77,
        "indication_id": 87,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 186,
        "document_id": 35,
        "biomarkers": [
            47
        ],
        "context_id": 41,
        "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 77,
        "indication_id": 87,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 187,
        "document_id": 35,
        "biomarkers": [
            47
        ],
        "context_id": 42,
        "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 77,
        "indication_id": 87,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 188,
        "document_id": 35,
        "biomarkers": [
            48
        ],
        "context_id": 40,
        "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 77,
        "indication_id": 87,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 189,
        "document_id": 35,
        "biomarkers": [
            48
        ],
        "context_id": 41,
        "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 77,
        "indication_id": 87,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 190,
        "document_id": 35,
        "biomarkers": [
            48
        ],
        "context_id": 42,
        "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 77,
        "indication_id": 87,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 191,
        "document_id": 35,
        "biomarkers": [
            49
        ],
        "context_id": 40,
        "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 77,
        "indication_id": 87,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 192,
        "document_id": 35,
        "biomarkers": [
            49
        ],
        "context_id": 41,
        "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 77,
        "indication_id": 87,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 193,
        "document_id": 35,
        "biomarkers": [
            49
        ],
        "context_id": 42,
        "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 77,
        "indication_id": 87,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 194,
        "document_id": 35,
        "biomarkers": [
            50
        ],
        "context_id": 40,
        "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 77,
        "indication_id": 87,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 195,
        "document_id": 35,
        "biomarkers": [
            50
        ],
        "context_id": 41,
        "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 77,
        "indication_id": 87,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 196,
        "document_id": 35,
        "biomarkers": [
            50
        ],
        "context_id": 42,
        "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 77,
        "indication_id": 87,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 197,
        "document_id": 35,
        "biomarkers": [
            47
        ],
        "context_id": 40,
        "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 78,
        "indication_id": 89,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 198,
        "document_id": 35,
        "biomarkers": [
            47
        ],
        "context_id": 41,
        "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 79,
        "indication_id": 89,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 199,
        "document_id": 35,
        "biomarkers": [
            47
        ],
        "context_id": 42,
        "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 79,
        "indication_id": 89,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 200,
        "document_id": 35,
        "biomarkers": [
            48
        ],
        "context_id": 40,
        "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 79,
        "indication_id": 89,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 201,
        "document_id": 35,
        "biomarkers": [
            48
        ],
        "context_id": 41,
        "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 79,
        "indication_id": 89,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 202,
        "document_id": 35,
        "biomarkers": [
            48
        ],
        "context_id": 42,
        "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 79,
        "indication_id": 89,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 203,
        "document_id": 35,
        "biomarkers": [
            49
        ],
        "context_id": 40,
        "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 79,
        "indication_id": 89,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 204,
        "document_id": 35,
        "biomarkers": [
            49
        ],
        "context_id": 41,
        "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 79,
        "indication_id": 89,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 205,
        "document_id": 35,
        "biomarkers": [
            49
        ],
        "context_id": 42,
        "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 79,
        "indication_id": 89,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 206,
        "document_id": 35,
        "biomarkers": [
            50
        ],
        "context_id": 40,
        "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 79,
        "indication_id": 89,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 207,
        "document_id": 35,
        "biomarkers": [
            50
        ],
        "context_id": 41,
        "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 79,
        "indication_id": 89,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 208,
        "document_id": 35,
        "biomarkers": [
            50
        ],
        "context_id": 42,
        "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 79,
        "indication_id": 89,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 209,
        "document_id": 35,
        "biomarkers": [
            51
        ],
        "context_id": 40,
        "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 78,
        "indication_id": 89,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 210,
        "document_id": 35,
        "biomarkers": [
            51
        ],
        "context_id": 41,
        "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 79,
        "indication_id": 89,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 211,
        "document_id": 35,
        "biomarkers": [
            51
        ],
        "context_id": 42,
        "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 79,
        "indication_id": 89,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 212,
        "document_id": 35,
        "biomarkers": [
            48,
            2
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered sunsuitable for endocrine therapy.",
        "evidence": "Approval",
        "implication_id": 77,
        "indication_id": 90,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 213,
        "document_id": 35,
        "biomarkers": [
            48,
            2
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered sunsuitable for endocrine therapy.",
        "evidence": "Approval",
        "implication_id": 77,
        "indication_id": 90,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 214,
        "document_id": 35,
        "biomarkers": [
            48,
            2
        ],
        "context_id": 18,
        "description": "The European Medicines Agency (EMA) has authorized olaparib as both a monotherapy and in combination with endocrine for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. Lynparza's product information cites the OlympiA trial, where olaparib was compared against placebo for the treatment of patients with germline BRCA1/2 mutated and HER2-negative high risk early breast cancer.",
        "evidence": "Approval",
        "implication_id": 77,
        "indication_id": 91,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 215,
        "document_id": 35,
        "biomarkers": [
            50,
            2
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered sunsuitable for endocrine therapy.",
        "evidence": "Approval",
        "implication_id": 77,
        "indication_id": 90,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 216,
        "document_id": 35,
        "biomarkers": [
            50,
            2
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered sunsuitable for endocrine therapy.",
        "evidence": "Approval",
        "implication_id": 77,
        "indication_id": 90,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 217,
        "document_id": 35,
        "biomarkers": [
            50,
            2
        ],
        "context_id": 18,
        "description": "The European Medicines Agency (EMA) has authorized olaparib as both a monotherapy and in combination with endocrine for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. Lynparza's product information cites the OlympiA trial, where olaparib was compared against placebo for the treatment of patients with germline BRCA1/2 mutated and HER2-negative high risk early breast cancer.",
        "evidence": "Approval",
        "implication_id": 77,
        "indication_id": 91,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 218,
        "document_id": 35,
        "biomarkers": [
            48
        ],
        "context_id": 43,
        "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.",
        "evidence": "Approval",
        "implication_id": 77,
        "indication_id": 92,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 219,
        "document_id": 35,
        "biomarkers": [
            50
        ],
        "context_id": 43,
        "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.",
        "evidence": "Approval",
        "implication_id": 77,
        "indication_id": 92,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 220,
        "document_id": 35,
        "biomarkers": [
            47
        ],
        "context_id": 44,
        "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.",
        "evidence": "Approval",
        "implication_id": 77,
        "indication_id": 93,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 221,
        "document_id": 35,
        "biomarkers": [
            49
        ],
        "context_id": 44,
        "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.",
        "evidence": "Approval",
        "implication_id": 77,
        "indication_id": 93,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 222,
        "document_id": 35,
        "biomarkers": [
            48
        ],
        "context_id": 44,
        "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.",
        "evidence": "Approval",
        "implication_id": 77,
        "indication_id": 93,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 223,
        "document_id": 35,
        "biomarkers": [
            50
        ],
        "context_id": 44,
        "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.",
        "evidence": "Approval",
        "implication_id": 77,
        "indication_id": 93,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 224,
        "document_id": 35,
        "biomarkers": [
            37
        ],
        "context_id": 27,
        "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with durvalumab for the maintenance treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair proficient (pMMR) whose disease has not progressed on first-line treatment with durvalumab in combination with carboplatin and paclitaxel.",
        "evidence": "Approval",
        "implication_id": 80,
        "indication_id": 88,
        "last_updated": "2024-08-25",
        "deprecated": false
    },
    {
        "id": 225,
        "document_id": 36,
        "biomarkers": [
            52
        ],
        "context_id": 45,
        "description": "The European Medicines Agency (EMA) has given futibatinib conditional market authorization as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement that have progressed after at least one line of prior systemic therapy.",
        "evidence": "Approval",
        "implication_id": 81,
        "indication_id": 94,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 226,
        "document_id": 36,
        "biomarkers": [
            53
        ],
        "context_id": 45,
        "description": "The European Medicines Agency (EMA) has given futibatinib conditional market authorization as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement that have progressed after at least one line of prior systemic therapy.",
        "evidence": "Approval",
        "implication_id": 81,
        "indication_id": 94,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 227,
        "document_id": 37,
        "biomarkers": [
            54
        ],
        "context_id": 46,
        "description": "The European Medicines Agency (EMA) has authorized rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma.",
        "evidence": "Approval",
        "implication_id": 82,
        "indication_id": 95,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 228,
        "document_id": 37,
        "biomarkers": [
            54
        ],
        "context_id": 47,
        "description": "The European Medicines Agency (EMA) has authorized rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma.",
        "evidence": "Approval",
        "implication_id": 82,
        "indication_id": 95,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 229,
        "document_id": 37,
        "biomarkers": [
            54
        ],
        "context_id": 48,
        "description": "The European Medicines Agency (EMA) has authorized rituximab in combination with chemotherapy for the treatment of pediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL) / Burkitt leukemia (mature B-cell acute leukemia) (BAL) or Burkitt-like lymphoma (BLL). This indication is based on a multicenter, open-label, randomized study of Lymphome Malin B (LMB) chemotherapy (corticosteroids, vincristine, cyclophosphamide, high-dose methotrexate, cytarabine, doxorubicin, etoposide and triple drug [methotrexate/cytarabine/ corticosteroid] intrathecal therapy) alone or in combination with rituximab.",
        "evidence": "Approval",
        "implication_id": 83,
        "indication_id": 96,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 230,
        "document_id": 37,
        "biomarkers": [
            54
        ],
        "context_id": 49,
        "description": "The European Medicines Agency (EMA) has authorized rituximab in combination with chemotherapy for the treatment of pediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL) / Burkitt leukemia (mature B-cell acute leukemia) (BAL) or Burkitt-like lymphoma (BLL). This indication is based on a multicenter, open-label, randomized study of Lymphome Malin B (LMB) chemotherapy (corticosteroids, vincristine, cyclophosphamide, high-dose methotrexate, cytarabine, doxorubicin, etoposide and triple drug [methotrexate/cytarabine/ corticosteroid] intrathecal therapy) alone or in combination with rituximab.",
        "evidence": "Approval",
        "implication_id": 83,
        "indication_id": 96,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 231,
        "document_id": 37,
        "biomarkers": [
            54
        ],
        "context_id": 50,
        "description": "The European Medicines Agency (EMA) has authorized rituximab in combination with chemotherapy for the treatment of pediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL) / Burkitt leukemia (mature B-cell acute leukemia) (BAL) or Burkitt-like lymphoma (BLL). This indication is based on a multicenter, open-label, randomized study of Lymphome Malin B (LMB) chemotherapy (corticosteroids, vincristine, cyclophosphamide, high-dose methotrexate, cytarabine, doxorubicin, etoposide and triple drug [methotrexate/cytarabine/ corticosteroid] intrathecal therapy) alone or in combination with rituximab.",
        "evidence": "Approval",
        "implication_id": 83,
        "indication_id": 96,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 232,
        "document_id": 38,
        "biomarkers": [
            16
        ],
        "context_id": 8,
        "description": "The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. Trametinib's product information further states that trametinib as a monotherapy has not demonstrated clinical activity in patients who have progressed on prior BRAF inhibitor therapy.",
        "evidence": "Approval",
        "implication_id": 84,
        "indication_id": 97,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 233,
        "document_id": 38,
        "biomarkers": [
            17
        ],
        "context_id": 8,
        "description": "The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. Trametinib's product information further states that trametinib as a monotherapy has not demonstrated clinical activity in patients who have progressed on prior BRAF inhibitor therapy.",
        "evidence": "Approval",
        "implication_id": 84,
        "indication_id": 97,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 234,
        "document_id": 38,
        "biomarkers": [
            16
        ],
        "context_id": 8,
        "description": "The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. Trametinib's product information further states that trametinib as a monotherapy has not demonstrated clinical activity in patients who have progressed on prior BRAF inhibitor therapy.",
        "evidence": "Approval",
        "implication_id": 85,
        "indication_id": 97,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 235,
        "document_id": 38,
        "biomarkers": [
            16
        ],
        "context_id": 8,
        "description": "The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 variant, following complete resection.",
        "evidence": "Approval",
        "implication_id": 85,
        "indication_id": 98,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 236,
        "document_id": 38,
        "biomarkers": [
            17
        ],
        "context_id": 8,
        "description": "The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. Trametinib's product information further states that trametinib as a monotherapy has not demonstrated clinical activity in patients who have progressed on prior BRAF inhibitor therapy.",
        "evidence": "Approval",
        "implication_id": 85,
        "indication_id": 97,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 237,
        "document_id": 38,
        "biomarkers": [
            17
        ],
        "context_id": 8,
        "description": "The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 variant, following complete resection.",
        "evidence": "Approval",
        "implication_id": 85,
        "indication_id": 98,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 238,
        "document_id": 38,
        "biomarkers": [
            16
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 variant.",
        "evidence": "Approval",
        "implication_id": 85,
        "indication_id": 99,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 239,
        "document_id": 38,
        "biomarkers": [
            17
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 variant.",
        "evidence": "Approval",
        "implication_id": 85,
        "indication_id": 99,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 240,
        "document_id": 39,
        "biomarkers": [
            16
        ],
        "context_id": 8,
        "description": "The European Medicines Agency (EMA) has authorized binimetinib in combination with encorafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",
        "evidence": "Approval",
        "implication_id": 86,
        "indication_id": 100,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 241,
        "document_id": 39,
        "biomarkers": [
            17
        ],
        "context_id": 8,
        "description": "The European Medicines Agency (EMA) has authorized binimetinib in combination with encorafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.",
        "evidence": "Approval",
        "implication_id": 86,
        "indication_id": 100,
        "last_updated": "2024-03-19",
        "deprecated": false
    },
    {
        "id": 242,
        "document_id": 39,
        "biomarkers": [
            16
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized binimetinib in combination with encorafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.",
        "evidence": "Approval",
        "implication_id": 86,
        "indication_id": 196,
        "last_updated": "2024-10-20",
        "deprecated": false
    },
    {
        "id": 243,
        "document_id": 40,
        "biomarkers": [
            55
        ],
        "context_id": 51,
        "description": "The European Medicines Agency (EMA) has authorized gemtuzumab ozogamicin in combination with cytarabine and daunorubicin for the treatment of patients aged 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukaemia (APL).",
        "evidence": "Approval",
        "implication_id": 87,
        "indication_id": 101,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 244,
        "document_id": 41,
        "biomarkers": [
            20,
            1,
            3
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.",
        "evidence": "Approval",
        "implication_id": 88,
        "indication_id": 102,
        "last_updated": "2024-04-20",
        "deprecated": false
    },
    {
        "id": 245,
        "document_id": 41,
        "biomarkers": [
            20,
            1
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.",
        "evidence": "Approval",
        "implication_id": 88,
        "indication_id": 102,
        "last_updated": "2024-04-20",
        "deprecated": false
    },
    {
        "id": 246,
        "document_id": 41,
        "biomarkers": [
            20,
            3
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.",
        "evidence": "Approval",
        "implication_id": 88,
        "indication_id": 102,
        "last_updated": "2024-04-20",
        "deprecated": false
    },
    {
        "id": 247,
        "document_id": 41,
        "biomarkers": [
            21,
            1,
            3
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.",
        "evidence": "Inferential",
        "implication_id": 88,
        "indication_id": 102,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 248,
        "document_id": 41,
        "biomarkers": [
            21,
            1
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.",
        "evidence": "Inferential",
        "implication_id": 88,
        "indication_id": 102,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 249,
        "document_id": 41,
        "biomarkers": [
            21,
            3
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.",
        "evidence": "Inferential",
        "implication_id": 88,
        "indication_id": 102,
        "last_updated": "2024-03-20",
        "deprecated": false
    },
    {
        "id": 250,
        "document_id": 42,
        "biomarkers": [
            35,
            34
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",
        "evidence": "Approval",
        "implication_id": 89,
        "indication_id": 103,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 251,
        "document_id": 42,
        "biomarkers": [
            35,
            34
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",
        "evidence": "Approval",
        "implication_id": 90,
        "indication_id": 103,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 252,
        "document_id": 42,
        "biomarkers": [
            35,
            34
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",
        "evidence": "Approval",
        "implication_id": 91,
        "indication_id": 103,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 253,
        "document_id": 42,
        "biomarkers": [
            33
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors haev PD-L1 expression >= 1%. This indication is based on CA209816, a randomized, open-label, phase 3 study where the selection of platinum-based chemotherapy was investigator's choice of paclitaxel and carboplatin, pemetrexed and cisplatin, or gemcitabine and cisplatin.",
        "evidence": "Approval",
        "implication_id": 92,
        "indication_id": 104,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 254,
        "document_id": 42,
        "biomarkers": [
            33
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors haev PD-L1 expression >= 1%. This indication is based on CA209816, a randomized, open-label, phase 3 study where the selection of platinum-based chemotherapy was investigator's choice of paclitaxel and carboplatin, pemetrexed and cisplatin, or gemcitabine and cisplatin.",
        "evidence": "Approval",
        "implication_id": 93,
        "indication_id": 104,
        "last_updated": "2024-06-19",
        "deprecated": false
    },
    {
        "id": 255,
        "document_id": 42,
        "biomarkers": [
            33
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors haev PD-L1 expression >= 1%. This indication is based on CA209816, a randomized, open-label, phase 3 study where the selection of platinum-based chemotherapy was investigator's choice of paclitaxel and carboplatin, pemetrexed and cisplatin, or gemcitabine and cisplatin.",
        "evidence": "Approval",
        "implication_id": 94,
        "indication_id": 104,
        "last_updated": "2024-06-19",
        "deprecated": false
    },
    {
        "id": 256,
        "document_id": 42,
        "biomarkers": [
            33
        ],
        "context_id": 52,
        "description": "The European Medicines Agency (EMA) has authorized nivolumab as a monotherapy for the adjuvant treatment of adult patients with muscle invasive urothelial carcinoma (MIUC) with tumor cell PD-L1 expression >= 1%, who are at high risk of recurrence after undergoing radical resection of MIUC.",
        "evidence": "Approval",
        "implication_id": 95,
        "indication_id": 105,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 257,
        "document_id": 42,
        "biomarkers": [
            38
        ],
        "context_id": 9,
        "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.",
        "evidence": "Approval",
        "implication_id": 96,
        "indication_id": 106,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 258,
        "document_id": 42,
        "biomarkers": [
            36
        ],
        "context_id": 9,
        "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.",
        "evidence": "Approval",
        "implication_id": 96,
        "indication_id": 106,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 259,
        "document_id": 42,
        "biomarkers": [
            33
        ],
        "context_id": 53,
        "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression >= 1%.",
        "evidence": "Approval",
        "implication_id": 96,
        "indication_id": 107,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 260,
        "document_id": 42,
        "biomarkers": [
            33
        ],
        "context_id": 53,
        "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with unresectable, advanced, or recurrent metastatic esophageal squamous cell carcinoma with tumor cell PD-L1 expression >= 1%. This indication is based on CA209648, a randomized, active-controlled, and open-label study where the choice of chemotherapy was fluorouracil and cisplatin.",
        "evidence": "Approval",
        "implication_id": 97,
        "indication_id": 108,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 261,
        "document_id": 42,
        "biomarkers": [
            2,
            56
        ],
        "context_id": 54,
        "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).",
        "evidence": "Approval",
        "implication_id": 98,
        "indication_id": 109,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 262,
        "document_id": 42,
        "biomarkers": [
            2,
            56
        ],
        "context_id": 54,
        "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).",
        "evidence": "Approval",
        "implication_id": 99,
        "indication_id": 109,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 263,
        "document_id": 42,
        "biomarkers": [
            2,
            56
        ],
        "context_id": 55,
        "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).",
        "evidence": "Approval",
        "implication_id": 98,
        "indication_id": 109,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 264,
        "document_id": 42,
        "biomarkers": [
            2,
            56
        ],
        "context_id": 55,
        "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).",
        "evidence": "Approval",
        "implication_id": 99,
        "indication_id": 109,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 265,
        "document_id": 42,
        "biomarkers": [
            2,
            56
        ],
        "context_id": 56,
        "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).",
        "evidence": "Approval",
        "implication_id": 98,
        "indication_id": 109,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 266,
        "document_id": 42,
        "biomarkers": [
            2,
            56
        ],
        "context_id": 56,
        "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).",
        "evidence": "Approval",
        "implication_id": 99,
        "indication_id": 109,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 267,
        "document_id": 43,
        "biomarkers": [
            57
        ],
        "context_id": 8,
        "description": "The European Medicines Agency (EMA) has authorized Opdualag (relatlimab / nivolumab) for the first-line treatment of adults and adolescents 12 years of age and older with advanced (unresectable or metastatic) melanoma with tumor cell PD-L1 expression < 1%.",
        "evidence": "Approval",
        "implication_id": 100,
        "indication_id": 110,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 268,
        "document_id": 44,
        "biomarkers": [
            1,
            2,
            58
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized elacestrant for the treatment of postmenopausal women and men with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.",
        "evidence": "Approval",
        "implication_id": 101,
        "indication_id": 111,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 269,
        "document_id": 44,
        "biomarkers": [
            1,
            2,
            58
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized elacestrant for the treatment of postmenopausal women and men with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.",
        "evidence": "Approval",
        "implication_id": 101,
        "indication_id": 111,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 270,
        "document_id": 45,
        "biomarkers": [
            52
        ],
        "context_id": 45,
        "description": "The European Medicines Agency (EMA) has conditionally authorized pemigatinib for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.",
        "evidence": "Approval",
        "implication_id": 101,
        "indication_id": 112,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 271,
        "document_id": 45,
        "biomarkers": [
            53
        ],
        "context_id": 45,
        "description": "The European Medicines Agency (EMA) has conditionally authorized pemigatinib for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.",
        "evidence": "Approval",
        "implication_id": 101,
        "indication_id": 112,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 272,
        "document_id": 46,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. This indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.",
        "evidence": "Approval",
        "implication_id": 102,
        "indication_id": 113,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 273,
        "document_id": 46,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. This indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.",
        "evidence": "Approval",
        "implication_id": 103,
        "indication_id": 113,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 274,
        "document_id": 46,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.",
        "evidence": "Approval",
        "implication_id": 104,
        "indication_id": 114,
        "last_updated": "2024-05-16",
        "deprecated": false
    },
    {
        "id": 275,
        "document_id": 46,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.",
        "evidence": "Approval",
        "implication_id": 105,
        "indication_id": 114,
        "last_updated": "2024-05-16",
        "deprecated": false
    },
    {
        "id": 276,
        "document_id": 46,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.",
        "evidence": "Approval",
        "implication_id": 106,
        "indication_id": 114,
        "last_updated": "2024-05-16",
        "deprecated": false
    },
    {
        "id": 277,
        "document_id": 46,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.",
        "evidence": "Approval",
        "implication_id": 107,
        "indication_id": 114,
        "last_updated": "2024-05-16",
        "deprecated": false
    },
    {
        "id": 278,
        "document_id": 46,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.",
        "evidence": "Approval",
        "implication_id": 108,
        "indication_id": 114,
        "last_updated": "2024-05-16",
        "deprecated": false
    },
    {
        "id": 279,
        "document_id": 46,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and docetaxel for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.",
        "evidence": "Approval",
        "implication_id": 109,
        "indication_id": 115,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 280,
        "document_id": 47,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. This indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.",
        "evidence": "Approval",
        "implication_id": 110,
        "indication_id": 116,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 281,
        "document_id": 47,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. This indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.",
        "evidence": "Approval",
        "implication_id": 111,
        "indication_id": 116,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 282,
        "document_id": 47,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.",
        "evidence": "Approval",
        "implication_id": 112,
        "indication_id": 117,
        "last_updated": "2024-06-13",
        "deprecated": false
    },
    {
        "id": 283,
        "document_id": 47,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.",
        "evidence": "Approval",
        "implication_id": 113,
        "indication_id": 117,
        "last_updated": "2024-06-13",
        "deprecated": false
    },
    {
        "id": 284,
        "document_id": 47,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.",
        "evidence": "Approval",
        "implication_id": 114,
        "indication_id": 117,
        "last_updated": "2024-06-13",
        "deprecated": false
    },
    {
        "id": 285,
        "document_id": 47,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.",
        "evidence": "Approval",
        "implication_id": 115,
        "indication_id": 117,
        "last_updated": "2024-06-13",
        "deprecated": false
    },
    {
        "id": 286,
        "document_id": 47,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.",
        "evidence": "Approval",
        "implication_id": 116,
        "indication_id": 117,
        "last_updated": "2024-06-13",
        "deprecated": false
    },
    {
        "id": 287,
        "document_id": 47,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.",
        "evidence": "Approval",
        "implication_id": 117,
        "indication_id": 117,
        "last_updated": "2024-06-13",
        "deprecated": false
    },
    {
        "id": 288,
        "document_id": 47,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.",
        "evidence": "Approval",
        "implication_id": 118,
        "indication_id": 117,
        "last_updated": "2024-06-13",
        "deprecated": false
    },
    {
        "id": 289,
        "document_id": 47,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.",
        "evidence": "Approval",
        "implication_id": 119,
        "indication_id": 118,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 290,
        "document_id": 48,
        "biomarkers": [
            2,
            1,
            59
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized alpelisib in combination with fulvestrant for the treatment of patients who are either postmenopausal women or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as a monotherapy. This indication is based on C2301, a phase 3, randomized, double-blind, and placebo-controlled study that evaluated alpelisib in combination with fulvestrant based on the presence or absence of a PIK3CA. No survival benefit was shown in the group without PIK3CA variants and PIK3CA variants observed were: p.C420R, p.E542K, p.E545A, p.E545D (1635G>T), p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, and p.H1047Y.",
        "evidence": "Approval",
        "implication_id": 120,
        "indication_id": 119,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 291,
        "document_id": 48,
        "biomarkers": [
            2,
            3,
            59
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized alpelisib in combination with fulvestrant for the treatment of patients who are either postmenopausal women or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as a monotherapy. This indication is based on C2301, a phase 3, randomized, double-blind, and placebo-controlled study that evaluated alpelisib in combination with fulvestrant based on the presence or absence of a PIK3CA. No survival benefit was shown in the group without PIK3CA variants and PIK3CA variants observed were: p.C420R, p.E542K, p.E545A, p.E545D (1635G>T), p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, and p.H1047Y.",
        "evidence": "Approval",
        "implication_id": 120,
        "indication_id": 119,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 292,
        "document_id": 48,
        "biomarkers": [
            2,
            1,
            3,
            59
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized alpelisib in combination with fulvestrant for the treatment of patients who are either postmenopausal women or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as a monotherapy. This indication is based on C2301, a phase 3, randomized, double-blind, and placebo-controlled study that evaluated alpelisib in combination with fulvestrant based on the presence or absence of a PIK3CA. No survival benefit was shown in the group without PIK3CA variants and PIK3CA variants observed were: p.C420R, p.E542K, p.E545A, p.E545D (1635G>T), p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, and p.H1047Y.",
        "evidence": "Approval",
        "implication_id": 120,
        "indication_id": 119,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 293,
        "document_id": 48,
        "biomarkers": [
            2,
            1,
            59
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized alpelisib in combination with fulvestrant for the treatment of patients who are either postmenopausal women or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as a monotherapy. This indication is based on C2301, a phase 3, randomized, double-blind, and placebo-controlled study that evaluated alpelisib in combination with fulvestrant based on the presence or absence of a PIK3CA. No survival benefit was shown in the group without PIK3CA variants and PIK3CA variants observed were: p.C420R, p.E542K, p.E545A, p.E545D (1635G>T), p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, and p.H1047Y.",
        "evidence": "Approval",
        "implication_id": 120,
        "indication_id": 119,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 294,
        "document_id": 48,
        "biomarkers": [
            2,
            3,
            59
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized alpelisib in combination with fulvestrant for the treatment of patients who are either postmenopausal women or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as a monotherapy. This indication is based on C2301, a phase 3, randomized, double-blind, and placebo-controlled study that evaluated alpelisib in combination with fulvestrant based on the presence or absence of a PIK3CA. No survival benefit was shown in the group without PIK3CA variants and PIK3CA variants observed were: p.C420R, p.E542K, p.E545A, p.E545D (1635G>T), p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, and p.H1047Y.",
        "evidence": "Approval",
        "implication_id": 120,
        "indication_id": 119,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 295,
        "document_id": 48,
        "biomarkers": [
            2,
            1,
            3,
            59
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized alpelisib in combination with fulvestrant for the treatment of patients who are either postmenopausal women or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as a monotherapy. This indication is based on C2301, a phase 3, randomized, double-blind, and placebo-controlled study that evaluated alpelisib in combination with fulvestrant based on the presence or absence of a PIK3CA. No survival benefit was shown in the group without PIK3CA variants and PIK3CA variants observed were: p.C420R, p.E542K, p.E545A, p.E545D (1635G>T), p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, and p.H1047Y.",
        "evidence": "Approval",
        "implication_id": 120,
        "indication_id": 119,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 296,
        "document_id": 49,
        "biomarkers": [
            18
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult patients with advanced RET fusion-positive non-small cell lung cancer not previously treated with a RET inhibitor.",
        "evidence": "Approval",
        "implication_id": 121,
        "indication_id": 120,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 297,
        "document_id": 49,
        "biomarkers": [
            18
        ],
        "context_id": 57,
        "description": "The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult and adolescent (12 years and older) patients with advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate).",
        "evidence": "Approval",
        "implication_id": 121,
        "indication_id": 121,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 298,
        "document_id": 49,
        "biomarkers": [
            60
        ],
        "context_id": 10,
        "description": "The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult and adolescent (12 years and older) patients with advanced RET-mutant medullary thyroid cancer. This indication is based on LIBRETTO-001 (a phase 1/2, multicenter, open-label, single-arm clinical study), where the most common variant was p.M918T, followed by extracelluar cysteine mutations.",
        "evidence": "Approval",
        "implication_id": 121,
        "indication_id": 122,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 299,
        "document_id": 49,
        "biomarkers": [
            18
        ],
        "context_id": 58,
        "description": "The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult patients with advanced RET fusion-positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted.",
        "evidence": "Approval",
        "implication_id": 121,
        "indication_id": 123,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 300,
        "document_id": 50,
        "biomarkers": [
            61
        ],
        "context_id": 59,
        "description": "The European Medicines Agency (EMA) has authorized lenalidomide for the treatment of adult patients with transfusion-dependent anaemia due to low- or intermdeiate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.",
        "evidence": "Approval",
        "implication_id": 122,
        "indication_id": 124,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 301,
        "document_id": 51,
        "biomarkers": [
            62
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has conditionally authorized entrectinib for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.",
        "evidence": "Approval",
        "implication_id": 123,
        "indication_id": 125,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 302,
        "document_id": 51,
        "biomarkers": [
            63
        ],
        "context_id": 58,
        "description": "The European Medicines Agency (EMA) has conditionally authorized entrectinib for the treatment of adult and pediatric patients 12 years of age and older with solid tumors expressing a neuotrophic tyrosine receptor kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, and who have no satisfactory treatment options.",
        "evidence": "Approval",
        "implication_id": 124,
        "indication_id": 126,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 303,
        "document_id": 51,
        "biomarkers": [
            64
        ],
        "context_id": 58,
        "description": "The European Medicines Agency (EMA) has conditionally authorized entrectinib for the treatment of adult and pediatric patients 12 years of age and older with solid tumors expressing a neuotrophic tyrosine receptor kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, and who have no satisfactory treatment options.",
        "evidence": "Approval",
        "implication_id": 124,
        "indication_id": 126,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 304,
        "document_id": 51,
        "biomarkers": [
            65
        ],
        "context_id": 58,
        "description": "The European Medicines Agency (EMA) has conditionally authorized entrectinib for the treatment of adult and pediatric patients 12 years of age and older with solid tumors expressing a neuotrophic tyrosine receptor kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, and who have no satisfactory treatment options.",
        "evidence": "Approval",
        "implication_id": 124,
        "indication_id": 126,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 305,
        "document_id": 52,
        "biomarkers": [
            66
        ],
        "context_id": 51,
        "description": "The European Medicines Agency (EMA) has authorized midostaurin in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintence therapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive. Midostaurin's product information further states that AML patients must have confirmation of the FLT3 mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD]) using a validated test.",
        "evidence": "Approval",
        "implication_id": 125,
        "indication_id": 127,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 306,
        "document_id": 53,
        "biomarkers": [
            12
        ],
        "context_id": 20,
        "description": "The European Medicines Agency (EMA) has authorized asciminib for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors.",
        "evidence": "Approval",
        "implication_id": 126,
        "indication_id": 128,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 307,
        "document_id": 54,
        "biomarkers": [
            16
        ],
        "context_id": 60,
        "description": "The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of pediatric patients aged 1 year and older with low-grade glioma (LGG) with a BRAF p.V600E variant who require systemic therapy.",
        "evidence": "Approval",
        "implication_id": 127,
        "indication_id": 129,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 308,
        "document_id": 54,
        "biomarkers": [
            16
        ],
        "context_id": 61,
        "description": "The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of pediatric patients aged 1 year and older with high-grade glioma (HGG) with a BRAF p.V600E variant who have received at least one prior radiation and/or chemotherapy treatment.",
        "evidence": "Approval",
        "implication_id": 127,
        "indication_id": 130,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 309,
        "document_id": 55,
        "biomarkers": [
            12
        ],
        "context_id": 7,
        "description": "The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in the chronic phase.",
        "evidence": "Approval",
        "implication_id": 128,
        "indication_id": 131,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 310,
        "document_id": 55,
        "biomarkers": [
            12
        ],
        "context_id": 6,
        "description": "The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy.",
        "evidence": "Approval",
        "implication_id": 128,
        "indication_id": 132,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 311,
        "document_id": 55,
        "biomarkers": [
            12
        ],
        "context_id": 7,
        "description": "The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy.",
        "evidence": "Approval",
        "implication_id": 128,
        "indication_id": 132,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 312,
        "document_id": 55,
        "biomarkers": [
            12
        ],
        "context_id": 7,
        "description": "The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in the chronic phase (Ph+ CML-CP) or Ph+CML-CP with resistant or intolerant to prior therapy including imatinib.",
        "evidence": "Approval",
        "implication_id": 128,
        "indication_id": 133,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 313,
        "document_id": 55,
        "biomarkers": [
            12
        ],
        "context_id": 6,
        "description": "The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of pediatric patients with newly diagnosed Philadelphia acute lymphoblastic leukemia (ALL) in combination with chemotherapy. The product information for this indication further states that his indication is based on a multicenter, historically-controlled phase 2 study that followed the chemotherapy regime detailed in another clinical trial, AIEOP-BFM ALL 2000 (chemotherapeutic standard multi-agent chemotherapy protocol).",
        "evidence": "Approval",
        "implication_id": 129,
        "indication_id": 134,
        "last_updated": "2024-03-22",
        "deprecated": false
    },
    {
        "id": 314,
        "document_id": 56,
        "biomarkers": [
            67
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized capmatinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (MET exon 14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 130,
        "indication_id": 135,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 315,
        "document_id": 56,
        "biomarkers": [
            68
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized capmatinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (MET exon 14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 130,
        "indication_id": 135,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 316,
        "document_id": 57,
        "biomarkers": [
            16
        ],
        "context_id": 8,
        "description": "The European Medicines Agency (EMA) has authorized dabrafenib as a monotherapy or in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant.",
        "evidence": "Approval",
        "implication_id": 131,
        "indication_id": 136,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 317,
        "document_id": 57,
        "biomarkers": [
            17
        ],
        "context_id": 8,
        "description": "The European Medicines Agency (EMA) has authorized dabrafenib as a monotherapy or in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant.",
        "evidence": "Approval",
        "implication_id": 131,
        "indication_id": 136,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 318,
        "document_id": 57,
        "biomarkers": [
            16
        ],
        "context_id": 8,
        "description": "The European Medicines Agency (EMA) has authorized dabrafenib as a monotherapy or in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant.",
        "evidence": "Approval",
        "implication_id": 132,
        "indication_id": 136,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 319,
        "document_id": 57,
        "biomarkers": [
            17
        ],
        "context_id": 8,
        "description": "The European Medicines Agency (EMA) has authorized dabrafenib as a monotherapy or in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant.",
        "evidence": "Approval",
        "implication_id": 132,
        "indication_id": 136,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 320,
        "document_id": 57,
        "biomarkers": [
            16
        ],
        "context_id": 8,
        "description": "The European Medicines Agency (EMA) has authorized dabrafenib in combination with trametinib for the adjuvant treatment of adult patients with stage 3 melanoma with a BRAF V600 variant, following complete resection.",
        "evidence": "Approval",
        "implication_id": 132,
        "indication_id": 137,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 321,
        "document_id": 57,
        "biomarkers": [
            17
        ],
        "context_id": 8,
        "description": "The European Medicines Agency (EMA) has authorized dabrafenib in combination with trametinib for the adjuvant treatment of adult patients with stage 3 melanoma with a BRAF V600 variant, following complete resection.",
        "evidence": "Approval",
        "implication_id": 132,
        "indication_id": 137,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 322,
        "document_id": 57,
        "biomarkers": [
            16
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized dabrafenib in combination with trametinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 variant.",
        "evidence": "Approval",
        "implication_id": 132,
        "indication_id": 138,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 323,
        "document_id": 57,
        "biomarkers": [
            17
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized dabrafenib in combination with trametinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 variant.",
        "evidence": "Approval",
        "implication_id": 132,
        "indication_id": 138,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 324,
        "document_id": 58,
        "biomarkers": [
            69
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized osimertinib for the adjuvant treatment after complete tumor resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor (EGFR) exon 19 deletions or exon 21 (L858R) substitution variants.",
        "evidence": "Approval",
        "implication_id": 133,
        "indication_id": 139,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 325,
        "document_id": 58,
        "biomarkers": [
            9
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized osimertinib for the adjuvant treatment after complete tumor resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor (EGFR) exon 19 deletions or exon 21 (L858R) substitution variants.",
        "evidence": "Approval",
        "implication_id": 133,
        "indication_id": 139,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 326,
        "document_id": 58,
        "biomarkers": [
            19
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized osimertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGFR variants.",
        "evidence": "Approval",
        "implication_id": 133,
        "indication_id": 140,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 327,
        "document_id": 58,
        "biomarkers": [
            70
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized osimertinib for treatment of adult patients with locally advanced or metastatic EGFR p.T790M mutation-positive non-small cell lung cancer.",
        "evidence": "Approval",
        "implication_id": 133,
        "indication_id": 141,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 328,
        "document_id": 58,
        "biomarkers": [
            69
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions over exon 21 (L858R) substitution variants. This indication is based on the randomized, open-label, active-controlled trial FLAURA2 where the treatment arm with chemotherapy was investigator's choice of cisplatin (75 mg/m^2) or carboplatin (AUC).",
        "evidence": "Approval",
        "implication_id": 134,
        "indication_id": 189,
        "last_updated": "2024-08-22",
        "deprecated": false
    },
    {
        "id": 329,
        "document_id": 58,
        "biomarkers": [
            69
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions over exon 21 (L858R) substitution variants. This indication is based on the randomized, open-label, active-controlled trial FLAURA2 where the treatment arm with chemotherapy was investigator's choice of cisplatin (75 mg/m^2) or carboplatin (AUC).",
        "evidence": "Approval",
        "implication_id": 135,
        "indication_id": 189,
        "last_updated": "2024-08-22",
        "deprecated": false
    },
    {
        "id": 330,
        "document_id": 58,
        "biomarkers": [
            9
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions over exon 21 (L858R) substitution variants. This indication is based on the randomized, open-label, active-controlled trial FLAURA2 where the treatment arm with chemotherapy was investigator's choice of cisplatin (75 mg/m^2) or carboplatin (AUC).",
        "evidence": "Approval",
        "implication_id": 134,
        "indication_id": 189,
        "last_updated": "2024-08-22",
        "deprecated": false
    },
    {
        "id": 331,
        "document_id": 58,
        "biomarkers": [
            9
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions over exon 21 (L858R) substitution variants. This indication is based on the randomized, open-label, active-controlled trial FLAURA2 where the treatment arm with chemotherapy was investigator's choice of cisplatin (75 mg/m^2) or carboplatin (AUC).",
        "evidence": "Approval",
        "implication_id": 135,
        "indication_id": 189,
        "last_updated": "2024-08-22",
        "deprecated": false
    },
    {
        "id": 332,
        "document_id": 59,
        "biomarkers": [
            48,
            2
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized talazoparib for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endrocrine-based therapy, or be considered unsuitable for endocrine-based therapy.",
        "evidence": "Approval",
        "implication_id": 136,
        "indication_id": 142,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 333,
        "document_id": 59,
        "biomarkers": [
            50,
            2
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized talazoparib for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endrocrine-based therapy, or be considered unsuitable for endocrine-based therapy.",
        "evidence": "Approval",
        "implication_id": 136,
        "indication_id": 142,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 334,
        "document_id": 59,
        "biomarkers": [
            48,
            2
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized talazoparib for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endrocrine-based therapy, or be considered unsuitable for endocrine-based therapy.",
        "evidence": "Approval",
        "implication_id": 136,
        "indication_id": 142,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 335,
        "document_id": 59,
        "biomarkers": [
            50,
            2
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized talazoparib for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endrocrine-based therapy, or be considered unsuitable for endocrine-based therapy.",
        "evidence": "Approval",
        "implication_id": 136,
        "indication_id": 142,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 336,
        "document_id": 60,
        "biomarkers": [
            19
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized erlotinib for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating variants. Erlotinib's production information further states that factors associated with prolonged survival should be taken into account when prescribing erlotinib. It further states that no survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC negative tumors.",
        "evidence": "Approval",
        "implication_id": 137,
        "indication_id": 143,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 337,
        "document_id": 60,
        "biomarkers": [
            19
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized erlotinib for switch maintenance treatemnt of patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating variants and stable disease after first-line chemotherapy. Erlotinib's production information further states that factors associated with prolonged survival should be taken into account when prescribing erlotinib. It further states that no survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC negative tumors.",
        "evidence": "Approval",
        "implication_id": 137,
        "indication_id": 144,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 338,
        "document_id": 61,
        "biomarkers": [
            12
        ],
        "context_id": 7,
        "description": "The European Medicines Agency (EMA) has authorized nilotinib for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia (CML) in the chronic phase.",
        "evidence": "Approval",
        "implication_id": 138,
        "indication_id": 146,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 339,
        "document_id": 61,
        "biomarkers": [
            12
        ],
        "context_id": 7,
        "description": "The European Medicines Agency (EMA) has authorized nilotinib for the treatment of adult patients with chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy including imatinib. Nilotinib's product information further states that efficacy data in patients with CML in blast crisis are not available.",
        "evidence": "Approval",
        "implication_id": 138,
        "indication_id": 147,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 340,
        "document_id": 61,
        "biomarkers": [
            12
        ],
        "context_id": 7,
        "description": "The European Medicines Agency (EMA) has authorized nilotinib for the treatment of pediatric patients with chronic phase Phildelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.",
        "evidence": "Approval",
        "implication_id": 138,
        "indication_id": 148,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 341,
        "document_id": 62,
        "biomarkers": [
            71
        ],
        "context_id": 30,
        "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are considered cisplatin ineligible, and whose tumors have PD-L1 expression >= 5%.",
        "evidence": "Approval",
        "implication_id": 139,
        "indication_id": 149,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 342,
        "document_id": 62,
        "biomarkers": [
            39,
            34,
            35
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the adjuvant treatment following complete resection and platinum-based chemotherapy of adult patients with non-small cell lung cancer with a high risk of recurrence whose tumors have PD-L1 expression on >= 50% of tumor cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC.",
        "evidence": "Approval",
        "implication_id": 139,
        "indication_id": 150,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 343,
        "document_id": 62,
        "biomarkers": [
            72
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, atezolizumab, in combination with bevacizumab, paclitaxel, and carboplatin, is indicated only after failure of appropriate targeted therapies.",
        "evidence": "Approval",
        "implication_id": 140,
        "indication_id": 151,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 344,
        "document_id": 62,
        "biomarkers": [
            8
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, atezolizumab, in combination with bevacizumab, paclitaxel, and carboplatin, is indicated only after failure of appropriate targeted therapies.",
        "evidence": "Approval",
        "implication_id": 140,
        "indication_id": 151,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 345,
        "document_id": 62,
        "biomarkers": [
            35
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.",
        "evidence": "Approval",
        "implication_id": 141,
        "indication_id": 152,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 346,
        "document_id": 62,
        "biomarkers": [
            34
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.",
        "evidence": "Approval",
        "implication_id": 141,
        "indication_id": 152,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 347,
        "document_id": 62,
        "biomarkers": [
            34,
            35
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.",
        "evidence": "Approval",
        "implication_id": 141,
        "indication_id": 152,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 348,
        "document_id": 62,
        "biomarkers": [
            39,
            34,
            35
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% tumor cells or >= 10% tumor-infiltrating immune cells (IC) and who do not hvae EGFR mutant or ALK-positive NSCLC.",
        "evidence": "Approval",
        "implication_id": 139,
        "indication_id": 153,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 349,
        "document_id": 62,
        "biomarkers": [
            73,
            34,
            35
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% tumor cells or >= 10% tumor-infiltrating immune cells (IC) and who do not hvae EGFR mutant or ALK-positive NSCLC.",
        "evidence": "Approval",
        "implication_id": 139,
        "indication_id": 153,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 350,
        "document_id": 62,
        "biomarkers": [
            72
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving atezolizumab.",
        "evidence": "Approval",
        "implication_id": 139,
        "indication_id": 154,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 351,
        "document_id": 62,
        "biomarkers": [
            8
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving atezolizumab.",
        "evidence": "Approval",
        "implication_id": 139,
        "indication_id": 154,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 352,
        "document_id": 62,
        "biomarkers": [
            33,
            43,
            2,
            44
        ],
        "context_id": 37,
        "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with nab-paclitaxel for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors have PD-L1 expression >= 1% and who have not received prior chemotherapy for metastatic disease.",
        "evidence": "Approval",
        "implication_id": 142,
        "indication_id": 155,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 353,
        "document_id": 63,
        "biomarkers": [
            67
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (MET exon 14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 143,
        "indication_id": 156,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 354,
        "document_id": 63,
        "biomarkers": [
            68
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (MET exon 14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 143,
        "indication_id": 156,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 355,
        "document_id": 64,
        "biomarkers": [
            74
        ],
        "context_id": 51,
        "description": "The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.",
        "evidence": "Approval",
        "implication_id": 144,
        "indication_id": 157,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 356,
        "document_id": 64,
        "biomarkers": [
            75
        ],
        "context_id": 51,
        "description": "The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.",
        "evidence": "Approval",
        "implication_id": 144,
        "indication_id": 157,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 357,
        "document_id": 64,
        "biomarkers": [
            76
        ],
        "context_id": 51,
        "description": "The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.",
        "evidence": "Approval",
        "implication_id": 144,
        "indication_id": 157,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 358,
        "document_id": 64,
        "biomarkers": [
            77
        ],
        "context_id": 51,
        "description": "The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.",
        "evidence": "Approval",
        "implication_id": 144,
        "indication_id": 157,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 359,
        "document_id": 64,
        "biomarkers": [
            78
        ],
        "context_id": 51,
        "description": "The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.",
        "evidence": "Approval",
        "implication_id": 144,
        "indication_id": 157,
        "last_updated": "2024-03-23",
        "deprecated": false
    },
    {
        "id": 360,
        "document_id": 64,
        "biomarkers": [
            74
        ],
        "context_id": 62,
        "description": "The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.",
        "evidence": "Approval",
        "implication_id": 145,
        "indication_id": 158,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 361,
        "document_id": 64,
        "biomarkers": [
            75
        ],
        "context_id": 62,
        "description": "The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.",
        "evidence": "Approval",
        "implication_id": 145,
        "indication_id": 158,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 362,
        "document_id": 64,
        "biomarkers": [
            76
        ],
        "context_id": 62,
        "description": "The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.",
        "evidence": "Approval",
        "implication_id": 145,
        "indication_id": 158,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 363,
        "document_id": 64,
        "biomarkers": [
            77
        ],
        "context_id": 62,
        "description": "The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.",
        "evidence": "Approval",
        "implication_id": 145,
        "indication_id": 158,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 364,
        "document_id": 64,
        "biomarkers": [
            78
        ],
        "context_id": 62,
        "description": "The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.",
        "evidence": "Approval",
        "implication_id": 145,
        "indication_id": 158,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 365,
        "document_id": 65,
        "biomarkers": [
            34,
            35
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
        "evidence": "Approval",
        "implication_id": 146,
        "indication_id": 159,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 366,
        "document_id": 65,
        "biomarkers": [
            34,
            35
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
        "evidence": "Approval",
        "implication_id": 147,
        "indication_id": 159,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 367,
        "document_id": 65,
        "biomarkers": [
            34,
            35
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
        "evidence": "Approval",
        "implication_id": 148,
        "indication_id": 159,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 368,
        "document_id": 65,
        "biomarkers": [
            34,
            35
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
        "evidence": "Approval",
        "implication_id": 149,
        "indication_id": 159,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 369,
        "document_id": 65,
        "biomarkers": [
            34,
            35
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",
        "evidence": "Approval",
        "implication_id": 150,
        "indication_id": 159,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 370,
        "document_id": 66,
        "biomarkers": [
            79
        ],
        "context_id": 63,
        "description": "The European Medicines Agency (EMA) has authorized arsenic trioxide for induction of remission, and consolidation in adult patients with either newly diagnosed low-to-intermediate risk acute promyelocytic leukemia (APL) (white blood cell count, <= 10 x 10^3 / ul) in combination with all-trans-retinoic acid (ATRA) or relapsed / refractory acute promyelocytic leukemia (APL) (previous treatment should have included a retinoid and chemotherapy). Both contexts should be characterized by the presence of the t(15;17) translocation and/or the presence of the promyelocytic leukemia / retinoic-acid-receptor-alpha (PML/RAR-alpha) gene.",
        "evidence": "Approval",
        "implication_id": 151,
        "indication_id": 160,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 371,
        "document_id": 67,
        "biomarkers": [
            2,
            43,
            44
        ],
        "context_id": 64,
        "description": "The European Medicines Agency (EMA) has authorized sacituzumab govitecan for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease.",
        "evidence": "Approval",
        "implication_id": 152,
        "indication_id": 161,
        "last_updated": "2024-09-01",
        "deprecated": false
    },
    {
        "id": 372,
        "document_id": 67,
        "biomarkers": [
            2,
            43,
            44
        ],
        "context_id": 65,
        "description": "The European Medicines Agency (EMA) has authorized sacituzumab govitecan for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease.",
        "evidence": "Approval",
        "implication_id": 152,
        "indication_id": 161,
        "last_updated": "2024-09-01",
        "deprecated": false
    },
    {
        "id": 373,
        "document_id": 67,
        "biomarkers": [
            2,
            1
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized sacituzumab govitecan for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting (see section 5.1).",
        "evidence": "Approval",
        "implication_id": 152,
        "indication_id": 162,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 374,
        "document_id": 67,
        "biomarkers": [
            2,
            3
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized sacituzumab govitecan for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting (see section 5.1).",
        "evidence": "Approval",
        "implication_id": 152,
        "indication_id": 162,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 375,
        "document_id": 67,
        "biomarkers": [
            2,
            1,
            3
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized sacituzumab govitecan for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting (see section 5.1).",
        "evidence": "Approval",
        "implication_id": 152,
        "indication_id": 162,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 376,
        "document_id": 68,
        "biomarkers": [
            20
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized tucatinib in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have at least 2 prior anti-HER2 treatment regimens.",
        "evidence": "Approval",
        "implication_id": 153,
        "indication_id": 163,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 377,
        "document_id": 68,
        "biomarkers": [
            20
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized tucatinib in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have at least 2 prior anti-HER2 treatment regimens.",
        "evidence": "Approval",
        "implication_id": 153,
        "indication_id": 163,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 378,
        "document_id": 69,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with capecitabine for the treatment of adult patients with breast cancer, whose tumors overexpress HER2 (ErbB2), with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.",
        "evidence": "Approval",
        "implication_id": 154,
        "indication_id": 164,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 379,
        "document_id": 69,
        "biomarkers": [
            20,
            1,
            44
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with trastuzumab for the treatment of adult patients with breast cancer, whose tumors overexpress HER2 (ErbB2), with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy in combination with chemotherapy. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.",
        "evidence": "Approval",
        "implication_id": 155,
        "indication_id": 165,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 380,
        "document_id": 69,
        "biomarkers": [
            20,
            1,
            3
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy. This indication states that the patients in the registration study were not previosuly treated with trastuzumab or an aromatase inhibitor and that no data are available on the efficacy of this combination relative to trastuzumab in combination with an aromatase inhibitor in this patient population. This indication is based on the randomized, double-blind, and placebo controlled phase 3 study EGF30008, which used Letrozole as an aromatase inhibitor. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.",
        "evidence": "Approval",
        "implication_id": 156,
        "indication_id": 166,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 381,
        "document_id": 69,
        "biomarkers": [
            21
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with capecitabine for the treatment of adult patients with breast cancer, whose tumors overexpress HER2 (ErbB2), with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.",
        "evidence": "Inferential",
        "implication_id": 154,
        "indication_id": 164,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 382,
        "document_id": 69,
        "biomarkers": [
            21,
            1,
            44
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with trastuzumab for the treatment of adult patients with breast cancer, whose tumors overexpress HER2 (ErbB2), with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy in combination with chemotherapy. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.",
        "evidence": "Inferential",
        "implication_id": 155,
        "indication_id": 165,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 383,
        "document_id": 69,
        "biomarkers": [
            21,
            1,
            3
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy. This indication states that the patients in the registration study were not previosuly treated with trastuzumab or an aromatase inhibitor and that no data are available on the efficacy of this combination relative to trastuzumab in combination with an aromatase inhibitor in this patient population. This indication is based on the randomized, double-blind, and placebo controlled phase 3 study EGF30008, which used Letrozole as an aromatase inhibitor. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.",
        "evidence": "Inferential",
        "implication_id": 156,
        "indication_id": 166,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 384,
        "document_id": 70,
        "biomarkers": [
            25,
            27
        ],
        "context_id": 9,
        "description": "The European Medicines Agency (EMA) has authorized panitumumab in combination with FOLFOX or FOLFIRI for the first-line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRPC). Panitumumab's product information further states that evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with panitumumab and that mutational status should be deteremined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) variants.",
        "evidence": "Approval",
        "implication_id": 157,
        "indication_id": 167,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 385,
        "document_id": 70,
        "biomarkers": [
            25,
            27
        ],
        "context_id": 9,
        "description": "The European Medicines Agency (EMA) has authorized panitumumab in combination with FOLFOX or FOLFIRI for the first-line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRPC). Panitumumab's product information further states that evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with panitumumab and that mutational status should be deteremined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) variants.",
        "evidence": "Approval",
        "implication_id": 158,
        "indication_id": 167,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 386,
        "document_id": 70,
        "biomarkers": [
            25,
            27
        ],
        "context_id": 9,
        "description": "The European Medicines Agency (EMA) has authorized panitumumab in combination with FOLFIRI for the second-line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRPC) who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). Panitumumab's product information further states that evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with panitumumab and that mutational status should be deteremined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) variants.",
        "evidence": "Approval",
        "implication_id": 158,
        "indication_id": 168,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 387,
        "document_id": 70,
        "biomarkers": [
            25,
            27
        ],
        "context_id": 9,
        "description": "The European Medicines Agency (EMA) has authorized panitumumab as a monotherapy for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRPC) after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Panitumumab's product information further states that evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with panitumumab and that mutational status should be deteremined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) variants.",
        "evidence": "Approval",
        "implication_id": 159,
        "indication_id": 169,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 388,
        "document_id": 71,
        "biomarkers": [
            80
        ],
        "context_id": 66,
        "description": "The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.",
        "evidence": "Approval",
        "implication_id": 160,
        "indication_id": 170,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 389,
        "document_id": 71,
        "biomarkers": [
            81
        ],
        "context_id": 66,
        "description": "The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.",
        "evidence": "Approval",
        "implication_id": 160,
        "indication_id": 170,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 390,
        "document_id": 71,
        "biomarkers": [
            82
        ],
        "context_id": 66,
        "description": "The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.",
        "evidence": "Approval",
        "implication_id": 160,
        "indication_id": 170,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 391,
        "document_id": 71,
        "biomarkers": [
            83
        ],
        "context_id": 66,
        "description": "The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.",
        "evidence": "Approval",
        "implication_id": 160,
        "indication_id": 171,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 392,
        "document_id": 71,
        "biomarkers": [
            84
        ],
        "context_id": 66,
        "description": "The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.",
        "evidence": "Approval",
        "implication_id": 160,
        "indication_id": 171,
        "last_updated": "2024-05-16",
        "deprecated": false
    },
    {
        "id": 393,
        "document_id": 72,
        "biomarkers": [
            2,
            1
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.",
        "evidence": "Approval",
        "implication_id": 161,
        "indication_id": 172,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 394,
        "document_id": 72,
        "biomarkers": [
            2,
            3
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.",
        "evidence": "Approval",
        "implication_id": 161,
        "indication_id": 172,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 395,
        "document_id": 72,
        "biomarkers": [
            2,
            1,
            3
        ],
        "context_id": 2,
        "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.",
        "evidence": "Approval",
        "implication_id": 161,
        "indication_id": 172,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 396,
        "document_id": 72,
        "biomarkers": [
            2,
            1
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 162,
        "indication_id": 173,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 397,
        "document_id": 72,
        "biomarkers": [
            2,
            3
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 162,
        "indication_id": 173,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 398,
        "document_id": 72,
        "biomarkers": [
            2,
            1,
            3
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 162,
        "indication_id": 173,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 399,
        "document_id": 72,
        "biomarkers": [
            2,
            1
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 162,
        "indication_id": 173,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 400,
        "document_id": 72,
        "biomarkers": [
            2,
            3
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 162,
        "indication_id": 173,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 401,
        "document_id": 72,
        "biomarkers": [
            2,
            1,
            3
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 162,
        "indication_id": 173,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 402,
        "document_id": 72,
        "biomarkers": [
            2,
            1
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 163,
        "indication_id": 173,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 403,
        "document_id": 72,
        "biomarkers": [
            2,
            3
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 163,
        "indication_id": 173,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 404,
        "document_id": 72,
        "biomarkers": [
            2,
            1,
            3
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 163,
        "indication_id": 173,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 405,
        "document_id": 72,
        "biomarkers": [
            2,
            1
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 163,
        "indication_id": 173,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 406,
        "document_id": 72,
        "biomarkers": [
            2,
            3
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 163,
        "indication_id": 173,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 407,
        "document_id": 72,
        "biomarkers": [
            2,
            1,
            3
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 163,
        "indication_id": 173,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 408,
        "document_id": 72,
        "biomarkers": [
            2,
            1
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 164,
        "indication_id": 173,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 409,
        "document_id": 72,
        "biomarkers": [
            2,
            3
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 164,
        "indication_id": 173,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 410,
        "document_id": 72,
        "biomarkers": [
            2,
            1,
            3
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 164,
        "indication_id": 173,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 411,
        "document_id": 72,
        "biomarkers": [
            2,
            1
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 164,
        "indication_id": 173,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 412,
        "document_id": 72,
        "biomarkers": [
            2,
            3
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 164,
        "indication_id": 173,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 413,
        "document_id": 72,
        "biomarkers": [
            2,
            1,
            3
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 164,
        "indication_id": 173,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 414,
        "document_id": 73,
        "biomarkers": [
            63
        ],
        "context_id": 58,
        "description": "The European Medicines Agency (EMA) has conditionally authorized larotrectinib for the treatment of adult and pediatric patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity. It is also indicated for the treatment of adult and pediatric patients with solid tumors that display an NTRK gene fusion who have no satisfactory treatment options.",
        "evidence": "Approval",
        "implication_id": 165,
        "indication_id": 174,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 415,
        "document_id": 73,
        "biomarkers": [
            64
        ],
        "context_id": 58,
        "description": "The European Medicines Agency (EMA) has conditionally authorized larotrectinib for the treatment of adult and pediatric patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity. It is also indicated for the treatment of adult and pediatric patients with solid tumors that display an NTRK gene fusion who have no satisfactory treatment options.",
        "evidence": "Approval",
        "implication_id": 165,
        "indication_id": 174,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 416,
        "document_id": 73,
        "biomarkers": [
            65
        ],
        "context_id": 58,
        "description": "The European Medicines Agency (EMA) has conditionally authorized larotrectinib for the treatment of adult and pediatric patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity. It is also indicated for the treatment of adult and pediatric patients with solid tumors that display an NTRK gene fusion who have no satisfactory treatment options.",
        "evidence": "Approval",
        "implication_id": 165,
        "indication_id": 174,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 417,
        "document_id": 74,
        "biomarkers": [
            19
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized dacomitinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating variants.",
        "evidence": "Approval",
        "implication_id": 166,
        "indication_id": 175,
        "last_updated": "2024-03-25",
        "deprecated": false
    },
    {
        "id": 418,
        "document_id": 75,
        "biomarkers": [
            8
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized crizotinib for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).",
        "evidence": "Approval",
        "implication_id": 167,
        "indication_id": 176,
        "last_updated": "2024-03-26",
        "deprecated": false
    },
    {
        "id": 419,
        "document_id": 75,
        "biomarkers": [
            8
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized crizotinib for the treatment of adult patients with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).",
        "evidence": "Approval",
        "implication_id": 167,
        "indication_id": 177,
        "last_updated": "2024-03-26",
        "deprecated": false
    },
    {
        "id": 420,
        "document_id": 75,
        "biomarkers": [
            62
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized crizotinib for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).",
        "evidence": "Approval",
        "implication_id": 168,
        "indication_id": 178,
        "last_updated": "2024-03-26",
        "deprecated": false
    },
    {
        "id": 421,
        "document_id": 75,
        "biomarkers": [
            8
        ],
        "context_id": 67,
        "description": "The European Medicines Agency (EMA) has authorized crizotinib for the treatment of pediatric patients (age >= 1 to < 18 years) with relapsed or refractory systemic anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL).",
        "evidence": "Approval",
        "implication_id": 167,
        "indication_id": 179,
        "last_updated": "2024-10-20",
        "deprecated": false
    },
    {
        "id": 422,
        "document_id": 75,
        "biomarkers": [
            8
        ],
        "context_id": 68,
        "description": "The European Medicines Agency (EMA) has authorized crizotinib for the treatment of pediatric patients (age >= 1 to < 18 years) with recurrent or refractory anaplastic lymphoma kinase (ALK)-positive unresectable inflammatory myofibroblastic tumor (IMT).",
        "evidence": "Approval",
        "implication_id": 167,
        "indication_id": 180,
        "last_updated": "2024-10-20",
        "deprecated": false
    },
    {
        "id": 423,
        "document_id": 76,
        "biomarkers": [
            66
        ],
        "context_id": 51,
        "description": "The European Medicines Agency (EMA) has authorized gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. Gilteritinib's product information states that, before taking gilteritinib, relapsed or refactory AML patients must have confirmation of FMS-like tyrosine kinase 3 (FLT3) mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD]) using a validated test. The product information describes the mechanism of action for gilteritinib as inhibiting FLT3 receptor signaling and proliferation in cells exogenously expressing FLT3 including FLT3-ITD, FLT3-D835Y, and FLT3-ITD-D835Y, and that it induces apoptosis in leukemic cells expressing FLT3-ITD.",
        "evidence": "Approval",
        "implication_id": 169,
        "indication_id": 181,
        "last_updated": "2024-03-26",
        "deprecated": false
    },
    {
        "id": 424,
        "document_id": 76,
        "biomarkers": [
            85
        ],
        "context_id": 51,
        "description": "The European Medicines Agency (EMA) has authorized gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. Gilteritinib's product information states that, before taking gilteritinib, relapsed or refactory AML patients must have confirmation of FMS-like tyrosine kinase 3 (FLT3) mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD]) using a validated test. The product information describes the mechanism of action for gilteritinib as inhibiting FLT3 receptor signaling and proliferation in cells exogenously expressing FLT3 including FLT3-ITD, FLT3-D835Y, and FLT3-ITD-D835Y, and that it induces apoptosis in leukemic cells expressing FLT3-ITD.",
        "evidence": "Approval",
        "implication_id": 169,
        "indication_id": 181,
        "last_updated": "2024-03-26",
        "deprecated": false
    },
    {
        "id": 425,
        "document_id": 77,
        "biomarkers": [
            35,
            34
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",
        "evidence": "Approval",
        "implication_id": 170,
        "indication_id": 182,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 426,
        "document_id": 77,
        "biomarkers": [
            35,
            34
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",
        "evidence": "Approval",
        "implication_id": 171,
        "indication_id": 182,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 427,
        "document_id": 77,
        "biomarkers": [
            35,
            34
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",
        "evidence": "Approval",
        "implication_id": 172,
        "indication_id": 182,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 428,
        "document_id": 77,
        "biomarkers": [
            38
        ],
        "context_id": 9,
        "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.",
        "evidence": "Approval",
        "implication_id": 173,
        "indication_id": 183,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 429,
        "document_id": 77,
        "biomarkers": [
            36
        ],
        "context_id": 9,
        "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.",
        "evidence": "Approval",
        "implication_id": 173,
        "indication_id": 183,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 430,
        "document_id": 77,
        "biomarkers": [
            33
        ],
        "context_id": 53,
        "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma with tumor cell PD-L1 expression >= 1%.",
        "evidence": "Approval",
        "implication_id": 173,
        "indication_id": 184,
        "last_updated": "2024-03-28",
        "deprecated": false
    },
    {
        "id": 431,
        "document_id": 78,
        "biomarkers": [
            16
        ],
        "context_id": 8,
        "description": "The European Medicines Agency (EMA) has authorized vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. Vemurafenib's product information states the special warning and caution that the efficacy and safety of vemurafenib in patients with tumors expressing rare BRAF V600 mutations other than V600E and V600K have not been convincingly established.",
        "evidence": "Approval",
        "implication_id": 174,
        "indication_id": 185,
        "last_updated": "2024-03-26",
        "deprecated": false
    },
    {
        "id": 432,
        "document_id": 78,
        "biomarkers": [
            17
        ],
        "context_id": 8,
        "description": "The European Medicines Agency (EMA) has authorized vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. Vemurafenib's product information states the special warning and caution that the efficacy and safety of vemurafenib in patients with tumors expressing rare BRAF V600 mutations other than V600E and V600K have not been convincingly established.",
        "evidence": "Approval",
        "implication_id": 174,
        "indication_id": 185,
        "last_updated": "2024-03-26",
        "deprecated": false
    },
    {
        "id": 433,
        "document_id": 79,
        "biomarkers": [
            81
        ],
        "context_id": 66,
        "description": "The European Medicines Agency (EMA) has authorized idelalisib in combination with rituximab for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or a TP53 mutation who are not eligible for any other therapies.",
        "evidence": "Approval",
        "implication_id": 175,
        "indication_id": 186,
        "last_updated": "2024-03-26",
        "deprecated": false
    },
    {
        "id": 434,
        "document_id": 79,
        "biomarkers": [
            80
        ],
        "context_id": 66,
        "description": "The European Medicines Agency (EMA) has authorized idelalisib in combination with rituximab for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or a TP53 mutation who are not eligible for any other therapies.",
        "evidence": "Approval",
        "implication_id": 175,
        "indication_id": 186,
        "last_updated": "2024-03-26",
        "deprecated": false
    },
    {
        "id": 435,
        "document_id": 79,
        "biomarkers": [
            82
        ],
        "context_id": 66,
        "description": "The European Medicines Agency (EMA) has authorized idelalisib in combination with rituximab for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or a TP53 mutation who are not eligible for any other therapies.",
        "evidence": "Approval",
        "implication_id": 175,
        "indication_id": 186,
        "last_updated": "2024-03-26",
        "deprecated": false
    },
    {
        "id": 436,
        "document_id": 80,
        "biomarkers": [
            8
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized ceritinib for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).",
        "evidence": "Approval",
        "implication_id": 176,
        "indication_id": 187,
        "last_updated": "2024-03-26",
        "deprecated": false
    },
    {
        "id": 437,
        "document_id": 80,
        "biomarkers": [
            8
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized ceritinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.",
        "evidence": "Approval",
        "implication_id": 176,
        "indication_id": 188,
        "last_updated": "2024-03-26",
        "deprecated": false
    },
    {
        "id": 438,
        "document_id": 81,
        "biomarkers": [
            39,
            34,
            35
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized tislelizumab in combination with pemetrexed and platinum-containing chemotherapy for the first-line treatment of adult patients with non-squamous non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% of tumor cells with no EGFR or ALK positive mutations and who have either (i) locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or (ii) metastatic NSCLC. This indication is based on BGB-A317-304, a randomized, open-label, and multicenter phase 3 study where patients were randomized (2:1) to receive tislelizumab in combination with pemetrexed and carboplatin or cisplatin (n=223) or pemetrexed and carboplatin or cisplatin (n=111), where the choice of platinum (cisplatin or carboplatin) was the investigator's choice. Tislelizumab's product information further states that the study excluded patients with active brain or leptomeningeal metastases, known EGFR mutations or ALK translocations sensitive to available targeted inhibitor therapy, active autoimmune disease, or any condition requiring systemic treatment with either corticosteroids or other immunosuppressants.",
        "evidence": "Approval",
        "implication_id": 177,
        "indication_id": 190,
        "last_updated": "2024-08-23",
        "deprecated": false
    },
    {
        "id": 439,
        "document_id": 81,
        "biomarkers": [
            39,
            34,
            35
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized tislelizumab in combination with pemetrexed and platinum-containing chemotherapy for the first-line treatment of adult patients with non-squamous non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% of tumor cells with no EGFR or ALK positive mutations and who have either (i) locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or (ii) metastatic NSCLC. This indication is based on BGB-A317-304, a randomized, open-label, and multicenter phase 3 study where patients were randomized (2:1) to receive tislelizumab in combination with pemetrexed and carboplatin or cisplatin (n=223) or pemetrexed and carboplatin or cisplatin (n=111), where the choice of platinum (cisplatin or carboplatin) was the investigator's choice. Tislelizumab's product information further states that the study excluded patients with active brain or leptomeningeal metastases, known EGFR mutations or ALK translocations sensitive to available targeted inhibitor therapy, active autoimmune disease, or any condition requiring systemic treatment with either corticosteroids or other immunosuppressants.",
        "evidence": "Approval",
        "implication_id": 178,
        "indication_id": 190,
        "last_updated": "2024-08-22",
        "deprecated": false
    },
    {
        "id": 440,
        "document_id": 82,
        "biomarkers": [
            86
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized amivantamab in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations.",
        "evidence": "Approval",
        "implication_id": 179,
        "indication_id": 191,
        "last_updated": "2024-08-25",
        "deprecated": false
    },
    {
        "id": 441,
        "document_id": 82,
        "biomarkers": [
            86
        ],
        "context_id": 4,
        "description": "The European Medicines Agency (EMA) has authorized amivantamab as a monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations, after failure of platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 180,
        "indication_id": 192,
        "last_updated": "2024-08-25",
        "deprecated": false
    },
    {
        "id": 442,
        "document_id": 83,
        "biomarkers": [
            1,
            2,
            87
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.",
        "evidence": "Approval",
        "implication_id": 181,
        "indication_id": 194,
        "last_updated": "2024-10-18",
        "deprecated": false
    },
    {
        "id": 443,
        "document_id": 83,
        "biomarkers": [
            1,
            2,
            88
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.",
        "evidence": "Approval",
        "implication_id": 181,
        "indication_id": 194,
        "last_updated": "2024-10-18",
        "deprecated": false
    },
    {
        "id": 444,
        "document_id": 83,
        "biomarkers": [
            1,
            2,
            89
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.",
        "evidence": "Approval",
        "implication_id": 181,
        "indication_id": 194,
        "last_updated": "2024-10-18",
        "deprecated": false
    },
    {
        "id": 445,
        "document_id": 83,
        "biomarkers": [
            1,
            2,
            90
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.",
        "evidence": "Approval",
        "implication_id": 181,
        "indication_id": 194,
        "last_updated": "2024-10-18",
        "deprecated": false
    },
    {
        "id": 446,
        "document_id": 83,
        "biomarkers": [
            1,
            2,
            91
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.",
        "evidence": "Approval",
        "implication_id": 181,
        "indication_id": 194,
        "last_updated": "2024-10-18",
        "deprecated": false
    },
    {
        "id": 447,
        "document_id": 83,
        "biomarkers": [
            1,
            2,
            92
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.",
        "evidence": "Approval",
        "implication_id": 181,
        "indication_id": 194,
        "last_updated": "2024-10-18",
        "deprecated": false
    },
    {
        "id": 448,
        "document_id": 83,
        "biomarkers": [
            1,
            2,
            93
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.",
        "evidence": "Approval",
        "implication_id": 181,
        "indication_id": 194,
        "last_updated": "2024-10-18",
        "deprecated": false
    },
    {
        "id": 449,
        "document_id": 83,
        "biomarkers": [
            1,
            2,
            94
        ],
        "context_id": 14,
        "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.",
        "evidence": "Approval",
        "implication_id": 181,
        "indication_id": 194,
        "last_updated": "2024-10-18",
        "deprecated": false
    },
    {
        "id": 450,
        "document_id": 83,
        "biomarkers": [
            1,
            2,
            87
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.",
        "evidence": "Approval",
        "implication_id": 181,
        "indication_id": 194,
        "last_updated": "2024-10-18",
        "deprecated": false
    },
    {
        "id": 451,
        "document_id": 83,
        "biomarkers": [
            1,
            2,
            88
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.",
        "evidence": "Approval",
        "implication_id": 181,
        "indication_id": 194,
        "last_updated": "2024-10-18",
        "deprecated": false
    },
    {
        "id": 452,
        "document_id": 83,
        "biomarkers": [
            1,
            2,
            89
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.",
        "evidence": "Approval",
        "implication_id": 181,
        "indication_id": 194,
        "last_updated": "2024-10-18",
        "deprecated": false
    },
    {
        "id": 453,
        "document_id": 83,
        "biomarkers": [
            1,
            2,
            90
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.",
        "evidence": "Approval",
        "implication_id": 181,
        "indication_id": 194,
        "last_updated": "2024-10-18",
        "deprecated": false
    },
    {
        "id": 454,
        "document_id": 83,
        "biomarkers": [
            1,
            2,
            91
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.",
        "evidence": "Approval",
        "implication_id": 181,
        "indication_id": 194,
        "last_updated": "2024-10-18",
        "deprecated": false
    },
    {
        "id": 455,
        "document_id": 83,
        "biomarkers": [
            1,
            2,
            92
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.",
        "evidence": "Approval",
        "implication_id": 181,
        "indication_id": 194,
        "last_updated": "2024-10-18",
        "deprecated": false
    },
    {
        "id": 456,
        "document_id": 83,
        "biomarkers": [
            1,
            2,
            93
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.",
        "evidence": "Approval",
        "implication_id": 181,
        "indication_id": 194,
        "last_updated": "2024-10-18",
        "deprecated": false
    },
    {
        "id": 457,
        "document_id": 83,
        "biomarkers": [
            1,
            2,
            94
        ],
        "context_id": 15,
        "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.",
        "evidence": "Approval",
        "implication_id": 181,
        "indication_id": 194,
        "last_updated": "2024-10-18",
        "deprecated": false
    },
    {
        "id": 458,
        "document_id": 84,
        "biomarkers": [
            95
        ],
        "context_id": 30,
        "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.",
        "evidence": "Approval",
        "implication_id": 182,
        "indication_id": 195,
        "last_updated": "2024-10-19",
        "deprecated": false
    },
    {
        "id": 459,
        "document_id": 84,
        "biomarkers": [
            96
        ],
        "context_id": 30,
        "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.",
        "evidence": "Approval",
        "implication_id": 182,
        "indication_id": 195,
        "last_updated": "2024-10-19",
        "deprecated": false
    },
    {
        "id": 460,
        "document_id": 84,
        "biomarkers": [
            97
        ],
        "context_id": 30,
        "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.",
        "evidence": "Approval",
        "implication_id": 182,
        "indication_id": 195,
        "last_updated": "2024-10-19",
        "deprecated": false
    },
    {
        "id": 461,
        "document_id": 84,
        "biomarkers": [
            98
        ],
        "context_id": 30,
        "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.",
        "evidence": "Approval",
        "implication_id": 182,
        "indication_id": 195,
        "last_updated": "2024-10-19",
        "deprecated": false
    },
    {
        "id": 462,
        "document_id": 84,
        "biomarkers": [
            99
        ],
        "context_id": 30,
        "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.",
        "evidence": "Approval",
        "implication_id": 182,
        "indication_id": 195,
        "last_updated": "2024-10-19",
        "deprecated": false
    },
    {
        "id": 463,
        "document_id": 84,
        "biomarkers": [
            100
        ],
        "context_id": 30,
        "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.",
        "evidence": "Approval",
        "implication_id": 182,
        "indication_id": 195,
        "last_updated": "2024-10-19",
        "deprecated": false
    },
    {
        "id": 464,
        "document_id": 84,
        "biomarkers": [
            101
        ],
        "context_id": 30,
        "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.",
        "evidence": "Approval",
        "implication_id": 182,
        "indication_id": 195,
        "last_updated": "2024-10-19",
        "deprecated": false
    },
    {
        "id": 465,
        "document_id": 84,
        "biomarkers": [
            102
        ],
        "context_id": 30,
        "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.",
        "evidence": "Approval",
        "implication_id": 182,
        "indication_id": 195,
        "last_updated": "2024-10-19",
        "deprecated": false
    },
    {
        "id": 466,
        "document_id": 85,
        "biomarkers": [
            2,
            103
        ],
        "context_id": 13,
        "description": "The European Medicines Agency (EMA) has authorized zolbetuximab in combination with fluoropyrimidine- and platinum-containing chemotherapy is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction (GEJ) adenocracinoma whose tumors are Claudin (CLDN) 18.2 positive. The product information states that eligible patients should have CLDN18.2 positive tumor defined as >= 75% of tumor cells demonstrating moderate to strong membranous CLDN18 immunohistochemical staining, assessed by a CE-marked IVD with the corresponding intended purpose. The product information further states that this indication is based on Spotlight (8951-CL-0301) and Glow (8951-CL-0302), both phase 3, double-blind, randomized, multicenter studies that enrolled 1072 patients where the choice of either mFOLFOX6 (oxaliplatin, folinic acid, and fluorouracil) or CAPOX (oxaliplatin and capecitabine).",
        "evidence": "Approval",
        "implication_id": 183,
        "indication_id": 198,
        "last_updated": "2024-10-20",
        "deprecated": false
    },
    {
        "id": 467,
        "document_id": 85,
        "biomarkers": [
            2,
            103
        ],
        "context_id": 13,
        "description": "The European Medicines Agency (EMA) has authorized zolbetuximab in combination with fluoropyrimidine- and platinum-containing chemotherapy is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction (GEJ) adenocracinoma whose tumors are Claudin (CLDN) 18.2 positive. The product information states that eligible patients should have CLDN18.2 positive tumor defined as >= 75% of tumor cells demonstrating moderate to strong membranous CLDN18 immunohistochemical staining, assessed by a CE-marked IVD with the corresponding intended purpose. The product information further states that this indication is based on Spotlight (8951-CL-0301) and Glow (8951-CL-0302), both phase 3, double-blind, randomized, multicenter studies that enrolled 1072 patients where the choice of either mFOLFOX6 (oxaliplatin, folinic acid, and fluorouracil) or CAPOX (oxaliplatin and capecitabine).",
        "evidence": "Approval",
        "implication_id": 184,
        "indication_id": 198,
        "last_updated": "2024-10-20",
        "deprecated": false
    },
    {
        "id": 468,
        "document_id": 86,
        "biomarkers": [
            19
        ],
        "context_id": 69,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved afatinib for reimbursement as a monotherapy treatment option for the treatment of EGFR TKI-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor activating EGFR mutation(s), as demonstrated by a validated test method.",
        "evidence": "Approval",
        "implication_id": 185,
        "indication_id": 199,
        "last_updated": "2023-12-16",
        "deprecated": false
    },
    {
        "id": 469,
        "document_id": 87,
        "biomarkers": [
            8
        ],
        "context_id": 69,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved alectinib for reimbursement as a treatment option for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. This indication is specifically for patients whose tumors have been historically confirmed to be NSCLC with an ALK rearrangement identified by an approved and validated test method.",
        "evidence": "Approval",
        "implication_id": 186,
        "indication_id": 200,
        "last_updated": "2023-12-16",
        "deprecated": false
    },
    {
        "id": 470,
        "document_id": 87,
        "biomarkers": [
            8
        ],
        "context_id": 69,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved alectinib for reimbursement as a monotherapy treatment option for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). This indication is specifically for patients whose tumors have been historically confirmed to be NSCLC with an ALK rearrangement identified by an approved and validated test method.",
        "evidence": "Approval",
        "implication_id": 186,
        "indication_id": 201,
        "last_updated": "2023-12-16",
        "deprecated": false
    },
    {
        "id": 471,
        "document_id": 88,
        "biomarkers": [
            12
        ],
        "context_id": 20,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved asciminib for reimbursement as a monotherapy treatment option for the treatment of adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in the chronic phase, who have been previously treated with two or more tyrosine kinase inhibitors (TKIs). The therapy regimen further states that hypersensitivity to asciminib or to any of the excipients, presence of the T315I mutation, and pregnancy / breastfeeding are exclusion criteria.",
        "evidence": "Approval",
        "implication_id": 187,
        "indication_id": 202,
        "last_updated": "2023-12-16",
        "deprecated": false
    },
    {
        "id": 472,
        "document_id": 89,
        "biomarkers": [
            12
        ],
        "context_id": 7,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved bosutinib for reimbursement as a treatment option for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotonib, and dasatinib are not considered appropriate treatment options.",
        "evidence": "Approval",
        "implication_id": 188,
        "indication_id": 203,
        "last_updated": "2023-12-19",
        "deprecated": false
    },
    {
        "id": 473,
        "document_id": 90,
        "biomarkers": [
            8
        ],
        "context_id": 69,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved brigatinib for reimbursement as a treatment option for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib, and whose ALK rearrangement has been demonstrated by an accurate and validated test method.",
        "evidence": "Approval",
        "implication_id": 189,
        "indication_id": 204,
        "last_updated": "2023-12-19",
        "deprecated": false
    },
    {
        "id": 474,
        "document_id": 90,
        "biomarkers": [
            8
        ],
        "context_id": 69,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved brigatinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor, and whose ALK rearrangement has been demonstrated by an accurate and validated test method.",
        "evidence": "Approval",
        "implication_id": 189,
        "indication_id": 205,
        "last_updated": "2023-12-19",
        "deprecated": false
    },
    {
        "id": 475,
        "document_id": 91,
        "biomarkers": [
            8
        ],
        "context_id": 69,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved ceritinib for reimbursement as a treatment option for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib, and whose ALK rearrangement has been demonstrated by an accurate and validated test method.",
        "evidence": "Approval",
        "implication_id": 190,
        "indication_id": 206,
        "last_updated": "2023-12-19",
        "deprecated": false
    },
    {
        "id": 476,
        "document_id": 92,
        "biomarkers": [
            16
        ],
        "context_id": 8,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved cobimetinib in combination with vemurafenib for reimbursement as a treatment option for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF p.V600 mutation, as demonstrated by a validated test method.",
        "evidence": "Approval",
        "implication_id": 191,
        "indication_id": 207,
        "last_updated": "2023-12-19",
        "deprecated": false
    },
    {
        "id": 477,
        "document_id": 92,
        "biomarkers": [
            17
        ],
        "context_id": 8,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved cobimetinib in combination with vemurafenib for reimbursement as a treatment option for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF p.V600 mutation, as demonstrated by a validated test method.",
        "evidence": "Approval",
        "implication_id": 191,
        "indication_id": 207,
        "last_updated": "2023-12-19",
        "deprecated": false
    },
    {
        "id": 478,
        "document_id": 93,
        "biomarkers": [
            8
        ],
        "context_id": 69,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved crizotinib for reimbursement as a treatment option for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer, and whose ALK rearrangement has been demonstrated by an accurate and validate test method.",
        "evidence": "Approval",
        "implication_id": 192,
        "indication_id": 208,
        "last_updated": "2023-12-19",
        "deprecated": false
    },
    {
        "id": 479,
        "document_id": 94,
        "biomarkers": [
            16
        ],
        "context_id": 8,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved dabrafenib for reimbursement as a treatment option for the treatment of adults with unresectable or metastatic melanoma that harbor a BRAF V600 mutation.",
        "evidence": "Approval",
        "implication_id": 193,
        "indication_id": 209,
        "last_updated": "2024-01-08",
        "deprecated": false
    },
    {
        "id": 480,
        "document_id": 94,
        "biomarkers": [
            17
        ],
        "context_id": 8,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved dabrafenib for reimbursement as a treatment option for the treatment of adults with unresectable or metastatic melanoma that harbor a BRAF V600 mutation.",
        "evidence": "Approval",
        "implication_id": 193,
        "indication_id": 209,
        "last_updated": "2024-01-08",
        "deprecated": false
    },
    {
        "id": 481,
        "document_id": 95,
        "biomarkers": [
            19
        ],
        "context_id": 69,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved dacomitinib for reimbursement as a monotherapy treatment option for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.",
        "evidence": "Approval",
        "implication_id": 194,
        "indication_id": 210,
        "last_updated": "2024-01-08",
        "deprecated": false
    },
    {
        "id": 482,
        "document_id": 96,
        "biomarkers": [
            16
        ],
        "context_id": 8,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved encorafenib in combination with binimetinib for reimbursement as a treatment option for the treatment of adult patients with advanced (unresectable or metastatic) melanoma with a BRAF V600 mutation.",
        "evidence": "Approval",
        "implication_id": 11,
        "indication_id": 211,
        "last_updated": "2024-01-08",
        "deprecated": false
    },
    {
        "id": 483,
        "document_id": 96,
        "biomarkers": [
            17
        ],
        "context_id": 8,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved encorafenib in combination with binimetinib for reimbursement as a treatment option for the treatment of adult patients with advanced (unresectable or metastatic) melanoma with a BRAF V600 mutation.",
        "evidence": "Approval",
        "implication_id": 11,
        "indication_id": 211,
        "last_updated": "2024-01-08",
        "deprecated": false
    },
    {
        "id": 484,
        "document_id": 97,
        "biomarkers": [
            62
        ],
        "context_id": 69,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved entrectinib for reimbursement as a monotherapy treatment option for adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.",
        "evidence": "Approval",
        "implication_id": 195,
        "indication_id": 212,
        "last_updated": "2024-01-08",
        "deprecated": false
    },
    {
        "id": 485,
        "document_id": 98,
        "biomarkers": [
            8
        ],
        "context_id": 69,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved loralatinib for reimbursement as a monotherapy treatment option for adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), following disease progression on (i) alectinib or ceritinib as the first ALK-targeted treatment or (ii) crizotinib and at least one other ALK-targeted treatment.",
        "evidence": "Approval",
        "implication_id": 196,
        "indication_id": 213,
        "last_updated": "2024-01-08",
        "deprecated": false
    },
    {
        "id": 486,
        "document_id": 98,
        "biomarkers": [
            8
        ],
        "context_id": 69,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved loralatinib for reimbursement as a monotherapy treatment option for adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.",
        "evidence": "Approval",
        "implication_id": 196,
        "indication_id": 214,
        "last_updated": "2024-01-08",
        "deprecated": false
    },
    {
        "id": 487,
        "document_id": 99,
        "biomarkers": [
            66
        ],
        "context_id": 70,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved midostaurin in combination with standard daunorubicin and cytarabine induction chemotherapy for reimbursement as a treatment option for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive.",
        "evidence": "Approval",
        "implication_id": 197,
        "indication_id": 215,
        "last_updated": "2024-01-08",
        "deprecated": false
    },
    {
        "id": 488,
        "document_id": 100,
        "biomarkers": [
            20,
            1,
            3
        ],
        "context_id": 71,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved neratinib for reimbursement as a treatment option for the extended adjuvant treatment of adults with early-stage hormone-receptor positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.",
        "evidence": "Approval",
        "implication_id": 198,
        "indication_id": 216,
        "last_updated": "2024-01-11",
        "deprecated": false
    },
    {
        "id": 489,
        "document_id": 100,
        "biomarkers": [
            20,
            1
        ],
        "context_id": 71,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved neratinib for reimbursement as a treatment option for the extended adjuvant treatment of adults with early-stage hormone-receptor positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.",
        "evidence": "Approval",
        "implication_id": 198,
        "indication_id": 216,
        "last_updated": "2024-01-11",
        "deprecated": false
    },
    {
        "id": 490,
        "document_id": 100,
        "biomarkers": [
            20,
            3
        ],
        "context_id": 71,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved neratinib for reimbursement as a treatment option for the extended adjuvant treatment of adults with early-stage hormone-receptor positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.",
        "evidence": "Approval",
        "implication_id": 198,
        "indication_id": 216,
        "last_updated": "2024-01-11",
        "deprecated": false
    },
    {
        "id": 491,
        "document_id": 100,
        "biomarkers": [
            21,
            1,
            3
        ],
        "context_id": 71,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved neratinib for reimbursement as a treatment option for the extended adjuvant treatment of adults with early-stage hormone-receptor positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.",
        "evidence": "Inferential",
        "implication_id": 198,
        "indication_id": 216,
        "last_updated": "2024-01-11",
        "deprecated": false
    },
    {
        "id": 492,
        "document_id": 100,
        "biomarkers": [
            21,
            1
        ],
        "context_id": 71,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved neratinib for reimbursement as a treatment option for the extended adjuvant treatment of adults with early-stage hormone-receptor positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.",
        "evidence": "Inferential",
        "implication_id": 198,
        "indication_id": 216,
        "last_updated": "2024-01-11",
        "deprecated": false
    },
    {
        "id": 493,
        "document_id": 100,
        "biomarkers": [
            21,
            3
        ],
        "context_id": 71,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved neratinib for reimbursement as a treatment option for the extended adjuvant treatment of adults with early-stage hormone-receptor positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.",
        "evidence": "Inferential",
        "implication_id": 198,
        "indication_id": 216,
        "last_updated": "2024-01-11",
        "deprecated": false
    },
    {
        "id": 494,
        "document_id": 101,
        "biomarkers": [
            47
        ],
        "context_id": 72,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved niraparib in combination with abiraterone acetate and prednisolone for reimbursement as a treatment option for the treatment of adults with metastatic castration resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.",
        "evidence": "Approval",
        "implication_id": 199,
        "indication_id": 217,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 495,
        "document_id": 101,
        "biomarkers": [
            49
        ],
        "context_id": 72,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved niraparib in combination with abiraterone acetate and prednisolone for reimbursement as a treatment option for the treatment of adults with metastatic castration resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.",
        "evidence": "Approval",
        "implication_id": 199,
        "indication_id": 217,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 496,
        "document_id": 101,
        "biomarkers": [
            48
        ],
        "context_id": 72,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved niraparib in combination with abiraterone acetate and prednisolone for reimbursement as a treatment option for the treatment of adults with metastatic castration resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.",
        "evidence": "Approval",
        "implication_id": 199,
        "indication_id": 217,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 497,
        "document_id": 101,
        "biomarkers": [
            104
        ],
        "context_id": 72,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved niraparib in combination with abiraterone acetate and prednisolone for reimbursement as a treatment option for the treatment of adults with metastatic castration resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.",
        "evidence": "Approval",
        "implication_id": 199,
        "indication_id": 217,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 498,
        "document_id": 102,
        "biomarkers": [
            47
        ],
        "context_id": 73,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 200,
        "indication_id": 218,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 499,
        "document_id": 102,
        "biomarkers": [
            49
        ],
        "context_id": 73,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 200,
        "indication_id": 218,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 500,
        "document_id": 102,
        "biomarkers": [
            48
        ],
        "context_id": 73,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 200,
        "indication_id": 218,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 501,
        "document_id": 102,
        "biomarkers": [
            50
        ],
        "context_id": 73,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 200,
        "indication_id": 218,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 502,
        "document_id": 102,
        "biomarkers": [
            47
        ],
        "context_id": 74,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 200,
        "indication_id": 218,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 503,
        "document_id": 102,
        "biomarkers": [
            49
        ],
        "context_id": 74,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 200,
        "indication_id": 218,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 504,
        "document_id": 102,
        "biomarkers": [
            48
        ],
        "context_id": 74,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 200,
        "indication_id": 218,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 505,
        "document_id": 102,
        "biomarkers": [
            50
        ],
        "context_id": 74,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 200,
        "indication_id": 218,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 506,
        "document_id": 102,
        "biomarkers": [
            47
        ],
        "context_id": 75,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 200,
        "indication_id": 218,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 507,
        "document_id": 102,
        "biomarkers": [
            105
        ],
        "context_id": 75,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 200,
        "indication_id": 218,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 508,
        "document_id": 102,
        "biomarkers": [
            48
        ],
        "context_id": 75,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 200,
        "indication_id": 218,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 509,
        "document_id": 102,
        "biomarkers": [
            50
        ],
        "context_id": 75,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 200,
        "indication_id": 218,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 510,
        "document_id": 102,
        "biomarkers": [
            51
        ],
        "context_id": 73,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 200,
        "indication_id": 218,
        "last_updated": "2024-04-01",
        "deprecated": false
    },
    {
        "id": 511,
        "document_id": 102,
        "biomarkers": [
            51
        ],
        "context_id": 74,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 200,
        "indication_id": 218,
        "last_updated": "2024-04-01",
        "deprecated": false
    },
    {
        "id": 512,
        "document_id": 102,
        "biomarkers": [
            51
        ],
        "context_id": 75,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) in combination with bevacizumab for reimbursement as a treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.",
        "evidence": "Approval",
        "implication_id": 200,
        "indication_id": 218,
        "last_updated": "2024-04-01",
        "deprecated": false
    },
    {
        "id": 513,
        "document_id": 103,
        "biomarkers": [
            47
        ],
        "context_id": 73,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, or primary peritoneal carcinoma who are in response (complete or partial) following first-line platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 201,
        "indication_id": 219,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 514,
        "document_id": 103,
        "biomarkers": [
            49
        ],
        "context_id": 73,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, or primary peritoneal carcinoma who are in response (complete or partial) following first-line platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 201,
        "indication_id": 219,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 515,
        "document_id": 103,
        "biomarkers": [
            48
        ],
        "context_id": 73,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, or primary peritoneal carcinoma who are in response (complete or partial) following first-line platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 201,
        "indication_id": 219,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 516,
        "document_id": 103,
        "biomarkers": [
            50
        ],
        "context_id": 73,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, or primary peritoneal carcinoma who are in response (complete or partial) following first-line platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 201,
        "indication_id": 219,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 517,
        "document_id": 103,
        "biomarkers": [
            47
        ],
        "context_id": 74,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, or primary peritoneal carcinoma who are in response (complete or partial) following first-line platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 201,
        "indication_id": 219,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 518,
        "document_id": 103,
        "biomarkers": [
            49
        ],
        "context_id": 74,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, or primary peritoneal carcinoma who are in response (complete or partial) following first-line platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 201,
        "indication_id": 219,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 519,
        "document_id": 103,
        "biomarkers": [
            48
        ],
        "context_id": 74,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, or primary peritoneal carcinoma who are in response (complete or partial) following first-line platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 201,
        "indication_id": 219,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 520,
        "document_id": 103,
        "biomarkers": [
            50
        ],
        "context_id": 74,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, or primary peritoneal carcinoma who are in response (complete or partial) following first-line platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 201,
        "indication_id": 219,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 521,
        "document_id": 103,
        "biomarkers": [
            47
        ],
        "context_id": 75,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, or primary peritoneal carcinoma who are in response (complete or partial) following first-line platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 202,
        "indication_id": 219,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 522,
        "document_id": 103,
        "biomarkers": [
            49
        ],
        "context_id": 75,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, or primary peritoneal carcinoma who are in response (complete or partial) following first-line platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 201,
        "indication_id": 219,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 523,
        "document_id": 103,
        "biomarkers": [
            48
        ],
        "context_id": 75,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, or primary peritoneal carcinoma who are in response (complete or partial) following first-line platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 201,
        "indication_id": 219,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 524,
        "document_id": 103,
        "biomarkers": [
            50
        ],
        "context_id": 75,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, or primary peritoneal carcinoma who are in response (complete or partial) following first-line platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 201,
        "indication_id": 219,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 525,
        "document_id": 103,
        "biomarkers": [
            47
        ],
        "context_id": 76,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 201,
        "indication_id": 220,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 526,
        "document_id": 103,
        "biomarkers": [
            49
        ],
        "context_id": 76,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 201,
        "indication_id": 220,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 527,
        "document_id": 103,
        "biomarkers": [
            48
        ],
        "context_id": 76,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 201,
        "indication_id": 220,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 528,
        "document_id": 103,
        "biomarkers": [
            50
        ],
        "context_id": 76,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 201,
        "indication_id": 220,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 529,
        "document_id": 103,
        "biomarkers": [
            47
        ],
        "context_id": 77,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 201,
        "indication_id": 220,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 530,
        "document_id": 103,
        "biomarkers": [
            49
        ],
        "context_id": 77,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 201,
        "indication_id": 220,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 531,
        "document_id": 103,
        "biomarkers": [
            48
        ],
        "context_id": 77,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 201,
        "indication_id": 220,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 532,
        "document_id": 103,
        "biomarkers": [
            50
        ],
        "context_id": 77,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 201,
        "indication_id": 220,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 533,
        "document_id": 103,
        "biomarkers": [
            47
        ],
        "context_id": 78,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 202,
        "indication_id": 220,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 534,
        "document_id": 103,
        "biomarkers": [
            49
        ],
        "context_id": 78,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 201,
        "indication_id": 220,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 535,
        "document_id": 103,
        "biomarkers": [
            48
        ],
        "context_id": 78,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 201,
        "indication_id": 220,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 536,
        "document_id": 103,
        "biomarkers": [
            50
        ],
        "context_id": 78,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 201,
        "indication_id": 220,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 537,
        "document_id": 103,
        "biomarkers": [
            47
        ],
        "context_id": 79,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the treatment of adult patients with metastatic castration-resistant prostate cancer whose tumors harbor BRCA1/2 mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.",
        "evidence": "Approval",
        "implication_id": 201,
        "indication_id": 221,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 538,
        "document_id": 103,
        "biomarkers": [
            49
        ],
        "context_id": 79,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the treatment of adult patients with metastatic castration-resistant prostate cancer whose tumors harbor BRCA1/2 mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.",
        "evidence": "Approval",
        "implication_id": 201,
        "indication_id": 221,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 539,
        "document_id": 103,
        "biomarkers": [
            48
        ],
        "context_id": 79,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the treatment of adult patients with metastatic castration-resistant prostate cancer whose tumors harbor BRCA1/2 mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.",
        "evidence": "Approval",
        "implication_id": 201,
        "indication_id": 221,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 540,
        "document_id": 103,
        "biomarkers": [
            50
        ],
        "context_id": 79,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the treatment of adult patients with metastatic castration-resistant prostate cancer whose tumors harbor BRCA1/2 mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.",
        "evidence": "Approval",
        "implication_id": 201,
        "indication_id": 221,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 541,
        "document_id": 104,
        "biomarkers": [
            70
        ],
        "context_id": 80,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved osimertinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).",
        "evidence": "Approval",
        "implication_id": 203,
        "indication_id": 222,
        "last_updated": "2024-04-04",
        "deprecated": false
    },
    {
        "id": 542,
        "document_id": 104,
        "biomarkers": [
            19
        ],
        "context_id": 80,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved osimertinib for reimbursement as a monotherapy treatment option as a first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.",
        "evidence": "Approval",
        "implication_id": 203,
        "indication_id": 223,
        "last_updated": "2024-04-04",
        "deprecated": false
    },
    {
        "id": 543,
        "document_id": 104,
        "biomarkers": [
            69
        ],
        "context_id": 81,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved osimertinib for reimbursement as a monotherapy treatment option for the adjuvant treatment after complete tumor resection for adult patients with stae IB-IIIA non-small cell lung cancer (NSCLC) whose tumor has epidermal growth factor receptor (EGFR) exon 19 deletions (Ex19del) or exon 21 (L858R) substitution mutations.",
        "evidence": "Approval",
        "implication_id": 203,
        "indication_id": 224,
        "last_updated": "2024-04-15",
        "deprecated": false
    },
    {
        "id": 544,
        "document_id": 104,
        "biomarkers": [
            9
        ],
        "context_id": 81,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved osimertinib for reimbursement as a monotherapy treatment option for the adjuvant treatment after complete tumor resection for adult patients with stae IB-IIIA non-small cell lung cancer (NSCLC) whose tumor has epidermal growth factor receptor (EGFR) exon 19 deletions (Ex19del) or exon 21 (L858R) substitution mutations.",
        "evidence": "Approval",
        "implication_id": 203,
        "indication_id": 224,
        "last_updated": "2024-04-15",
        "deprecated": false
    },
    {
        "id": 545,
        "document_id": 105,
        "biomarkers": [
            32
        ],
        "context_id": 82,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved ponatinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib, nilotinib, and bosutinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.",
        "evidence": "Approval",
        "implication_id": 204,
        "indication_id": 225,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 546,
        "document_id": 105,
        "biomarkers": [
            12
        ],
        "context_id": 83,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved ponatinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.",
        "evidence": "Approval",
        "implication_id": 204,
        "indication_id": 226,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 547,
        "document_id": 105,
        "biomarkers": [
            32,
            12
        ],
        "context_id": 83,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved ponatinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.",
        "evidence": "Approval",
        "implication_id": 204,
        "indication_id": 226,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 548,
        "document_id": 106,
        "biomarkers": [
            48,
            2
        ],
        "context_id": 14,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved talazoparib for reimbursement as a monotherapy treatment option for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with prior endocrine-based therapy or be considered unsuitable for endocrine-based therapy.",
        "evidence": "Approval",
        "implication_id": 205,
        "indication_id": 227,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 549,
        "document_id": 106,
        "biomarkers": [
            50,
            2
        ],
        "context_id": 14,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved talazoparib for reimbursement as a monotherapy treatment option for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with prior endocrine-based therapy or be considered unsuitable for endocrine-based therapy.",
        "evidence": "Approval",
        "implication_id": 205,
        "indication_id": 227,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 550,
        "document_id": 106,
        "biomarkers": [
            48,
            2
        ],
        "context_id": 15,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved talazoparib for reimbursement as a monotherapy treatment option for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with prior endocrine-based therapy or be considered unsuitable for endocrine-based therapy.",
        "evidence": "Approval",
        "implication_id": 205,
        "indication_id": 227,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 551,
        "document_id": 106,
        "biomarkers": [
            50,
            2
        ],
        "context_id": 15,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved talazoparib for reimbursement as a monotherapy treatment option for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with prior endocrine-based therapy or be considered unsuitable for endocrine-based therapy.",
        "evidence": "Approval",
        "implication_id": 205,
        "indication_id": 227,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 552,
        "document_id": 107,
        "biomarkers": [
            16
        ],
        "context_id": 8,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trametinib in combination with dabrafenib for reimbursement as a treatment option for the treatment of adult patients with unresectable or metastatic melanoma that harbor a BRAF V600 mutation.",
        "evidence": "Approval",
        "implication_id": 206,
        "indication_id": 228,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 553,
        "document_id": 107,
        "biomarkers": [
            16
        ],
        "context_id": 8,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trametinib in combination with dabrafenib for reimbursement as a treatment option for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection.",
        "evidence": "Approval",
        "implication_id": 206,
        "indication_id": 229,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 554,
        "document_id": 107,
        "biomarkers": [
            106
        ],
        "context_id": 8,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trametinib in combination with dabrafenib for reimbursement as a treatment option for the treatment of adult patients with unresectable or metastatic melanoma that harbor a BRAF V600 mutation.",
        "evidence": "Approval",
        "implication_id": 206,
        "indication_id": 228,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 555,
        "document_id": 107,
        "biomarkers": [
            106
        ],
        "context_id": 8,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trametinib in combination with dabrafenib for reimbursement as a treatment option for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection.",
        "evidence": "Approval",
        "implication_id": 206,
        "indication_id": 229,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 556,
        "document_id": 108,
        "biomarkers": [
            16
        ],
        "context_id": 8,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved vemurafenib for reimbursement as a monotherapy treatment option for the treatment of adult patients with unresectable or metastatic melanoma whose tumors are BRAF V600 positive.",
        "evidence": "Approval",
        "implication_id": 207,
        "indication_id": 230,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 557,
        "document_id": 108,
        "biomarkers": [
            17
        ],
        "context_id": 8,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved vemurafenib for reimbursement as a monotherapy treatment option for the treatment of adult patients with unresectable or metastatic melanoma whose tumors are BRAF V600 positive.",
        "evidence": "Approval",
        "implication_id": 207,
        "indication_id": 230,
        "last_updated": "2024-01-08",
        "deprecated": false
    },
    {
        "id": 558,
        "document_id": 109,
        "biomarkers": [
            80
        ],
        "context_id": 66,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved venetoclax for reimbursement as a monotherapy treatment option for the treatment of patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.",
        "evidence": "Approval",
        "implication_id": 208,
        "indication_id": 231,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 559,
        "document_id": 109,
        "biomarkers": [
            81
        ],
        "context_id": 66,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved venetoclax for reimbursement as a monotherapy treatment option for the treatment of patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.",
        "evidence": "Approval",
        "implication_id": 208,
        "indication_id": 231,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 560,
        "document_id": 109,
        "biomarkers": [
            82
        ],
        "context_id": 66,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved venetoclax for reimbursement as a monotherapy treatment option for the treatment of patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.",
        "evidence": "Approval",
        "implication_id": 208,
        "indication_id": 231,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 561,
        "document_id": 109,
        "biomarkers": [
            83
        ],
        "context_id": 66,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved venetoclax for reimbursement as a monotherapy treatment option for the treatment of patients with chronic lymphocytic leukemia (CLL) in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.",
        "evidence": "Approval",
        "implication_id": 208,
        "indication_id": 232,
        "last_updated": "2024-04-03",
        "deprecated": false
    },
    {
        "id": 562,
        "document_id": 110,
        "biomarkers": [
            80
        ],
        "context_id": 66,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved zanubrutinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who are treatment naive and whose tumors have 17p deletion and/or TP53 mutated disease.",
        "evidence": "Approval",
        "implication_id": 209,
        "indication_id": 233,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 563,
        "document_id": 110,
        "biomarkers": [
            81
        ],
        "context_id": 66,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved zanubrutinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who are treatment naive and whose tumors have 17p deletion and/or TP53 mutated disease.",
        "evidence": "Approval",
        "implication_id": 209,
        "indication_id": 233,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 564,
        "document_id": 110,
        "biomarkers": [
            82
        ],
        "context_id": 66,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved zanubrutinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who are treatment naive and whose tumors have 17p deletion and/or TP53 mutated disease.",
        "evidence": "Approval",
        "implication_id": 209,
        "indication_id": 233,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 565,
        "document_id": 111,
        "biomarkers": [
            80
        ],
        "context_id": 66,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved acalabrutinib (tablets) for reimbursement as a monotherapy treatment option for the treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation who are unsuitable for chemoimmunotherapy.",
        "evidence": "Approval",
        "implication_id": 210,
        "indication_id": 234,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 566,
        "document_id": 111,
        "biomarkers": [
            81
        ],
        "context_id": 66,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved acalabrutinib (tablets) for reimbursement as a monotherapy treatment option for the treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation who are unsuitable for chemoimmunotherapy.",
        "evidence": "Approval",
        "implication_id": 210,
        "indication_id": 234,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 567,
        "document_id": 111,
        "biomarkers": [
            82
        ],
        "context_id": 66,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved acalabrutinib (tablets) for reimbursement as a monotherapy treatment option for the treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation who are unsuitable for chemoimmunotherapy.",
        "evidence": "Approval",
        "implication_id": 210,
        "indication_id": 234,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 568,
        "document_id": 112,
        "biomarkers": [
            80
        ],
        "context_id": 66,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved ibrutinib for reimbursement as a monotherapy, first-line treatment option for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who are unsuitable for chemoimmunotherapy and whose tumors have 17p deletion or TP53 mutated disease.",
        "evidence": "Approval",
        "implication_id": 211,
        "indication_id": 235,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 569,
        "document_id": 112,
        "biomarkers": [
            81
        ],
        "context_id": 66,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved ibrutinib for reimbursement as a monotherapy, first-line treatment option for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who are unsuitable for chemoimmunotherapy and whose tumors have 17p deletion or TP53 mutated disease.",
        "evidence": "Approval",
        "implication_id": 211,
        "indication_id": 235,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 570,
        "document_id": 112,
        "biomarkers": [
            82
        ],
        "context_id": 66,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved ibrutinib for reimbursement as a monotherapy, first-line treatment option for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who are unsuitable for chemoimmunotherapy and whose tumors have 17p deletion or TP53 mutated disease.",
        "evidence": "Approval",
        "implication_id": 211,
        "indication_id": 235,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 571,
        "document_id": 113,
        "biomarkers": [
            80
        ],
        "context_id": 66,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved idelalisib in combination with rituximab for reimbursement as a treatment option for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) who are not eligible for any other therapies and whose tumors have 17p deletion or TP53 mutated disease.",
        "evidence": "Approval",
        "implication_id": 212,
        "indication_id": 236,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 572,
        "document_id": 113,
        "biomarkers": [
            81
        ],
        "context_id": 66,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved idelalisib in combination with rituximab for reimbursement as a treatment option for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) who are not eligible for any other therapies and whose tumors have 17p deletion or TP53 mutated disease.",
        "evidence": "Approval",
        "implication_id": 212,
        "indication_id": 236,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 573,
        "document_id": 113,
        "biomarkers": [
            82
        ],
        "context_id": 66,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved idelalisib in combination with rituximab for reimbursement as a treatment option for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) who are not eligible for any other therapies and whose tumors have 17p deletion or TP53 mutated disease.",
        "evidence": "Approval",
        "implication_id": 212,
        "indication_id": 236,
        "last_updated": "2024-04-03",
        "deprecated": false
    },
    {
        "id": 574,
        "document_id": 114,
        "biomarkers": [
            38
        ],
        "context_id": 9,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with ipilimumab for reimbursement as a treatment option for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer (MSI-H mCRC) after prior fluoropyrimidine-based combination chemotherapy.",
        "evidence": "Approval",
        "implication_id": 213,
        "indication_id": 237,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 575,
        "document_id": 114,
        "biomarkers": [
            36
        ],
        "context_id": 9,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with ipilimumab for reimbursement as a treatment option for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer (MSI-H mCRC) after prior fluoropyrimidine-based combination chemotherapy.",
        "evidence": "Approval",
        "implication_id": 213,
        "indication_id": 237,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 576,
        "document_id": 115,
        "biomarkers": [
            39,
            35,
            34
        ],
        "context_id": 29,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a first-line treatment option for the treatment of adult patients with metastatic non-small cell lung carcinoma (NSCLC) whose tumors express PD-L1 with a >= 50% tumor proportion score (TPS) with no EGFR mutations or ALK translocations.",
        "evidence": "Approval",
        "implication_id": 214,
        "indication_id": 238,
        "last_updated": "2024-04-01",
        "deprecated": false
    },
    {
        "id": 577,
        "document_id": 115,
        "biomarkers": [
            40,
            35,
            34
        ],
        "context_id": 29,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a first-line treatment option for the treatment of adult patients with metastatic non-small cell lung carcinoma (NSCLC) whose tumors express PD-L1 with a >= 50% tumor proportion score (TPS) with no EGFR mutations or ALK translocations.",
        "evidence": "Inferential",
        "implication_id": 214,
        "indication_id": 238,
        "last_updated": "2024-04-01",
        "deprecated": false
    },
    {
        "id": 578,
        "document_id": 115,
        "biomarkers": [
            41
        ],
        "context_id": 30,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a monotherapy treatment option for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy whose tumors express PD-L1 with a combined positive score (CPS) >= 10.",
        "evidence": "Approval",
        "implication_id": 214,
        "indication_id": 239,
        "last_updated": "2024-04-01",
        "deprecated": false
    },
    {
        "id": 579,
        "document_id": 115,
        "biomarkers": [
            42
        ],
        "context_id": 31,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a monotherapy treatment option for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 with a CPS >= 1.",
        "evidence": "Approval",
        "implication_id": 214,
        "indication_id": 240,
        "last_updated": "2024-04-01",
        "deprecated": false
    },
    {
        "id": 580,
        "document_id": 115,
        "biomarkers": [
            42
        ],
        "context_id": 38,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a monotherapy treatment option for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 with a CPS >= 1. Pembrolizumab (200mg) monotherapy's regime notes that this indication is an unlicensed dosing posology of pembrolizumab in Ireland, and that patients should be informed of this and consented to treatment in line with the hospital's policy on the use of unlicensed medication and unlicensed or 'off-label' indications. Please refer to this therapy's regime by the HSE for more information.",
        "evidence": "Approval",
        "implication_id": 214,
        "indication_id": 241,
        "last_updated": "2024-04-01",
        "deprecated": false
    },
    {
        "id": 581,
        "document_id": 115,
        "biomarkers": [
            38
        ],
        "context_id": 9,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a first-line treatment option for the treatment of adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).",
        "evidence": "Approval",
        "implication_id": 214,
        "indication_id": 242,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 582,
        "document_id": 115,
        "biomarkers": [
            36
        ],
        "context_id": 9,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a first-line treatment option for the treatment of adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).",
        "evidence": "Approval",
        "implication_id": 214,
        "indication_id": 242,
        "last_updated": "2024-01-18",
        "deprecated": false
    },
    {
        "id": 583,
        "document_id": 116,
        "biomarkers": [
            63
        ],
        "context_id": 58,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved larotrectinib monotherapy for reimbursement for the treatment of pediatric patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. This indication is for patients whose disease is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.",
        "evidence": "Approval",
        "implication_id": 215,
        "indication_id": 243,
        "last_updated": "2024-02-13",
        "deprecated": false
    },
    {
        "id": 584,
        "document_id": 116,
        "biomarkers": [
            64
        ],
        "context_id": 58,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved larotrectinib monotherapy for reimbursement for the treatment of pediatric patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. This indication is for patients whose disease is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.",
        "evidence": "Approval",
        "implication_id": 215,
        "indication_id": 243,
        "last_updated": "2024-02-13",
        "deprecated": false
    },
    {
        "id": 585,
        "document_id": 116,
        "biomarkers": [
            65
        ],
        "context_id": 58,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved larotrectinib monotherapy for reimbursement for the treatment of pediatric patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. This indication is for patients whose disease is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.",
        "evidence": "Approval",
        "implication_id": 215,
        "indication_id": 243,
        "last_updated": "2024-02-13",
        "deprecated": false
    },
    {
        "id": 586,
        "document_id": 117,
        "biomarkers": [
            63
        ],
        "context_id": 58,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved larotrectinib monotherapy for reimbursement for the treatment of adult patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. This indication is for patients whose disease is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.",
        "evidence": "Approval",
        "implication_id": 215,
        "indication_id": 244,
        "last_updated": "2024-02-13",
        "deprecated": false
    },
    {
        "id": 587,
        "document_id": 117,
        "biomarkers": [
            64
        ],
        "context_id": 58,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved larotrectinib monotherapy for reimbursement for the treatment of adult patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. This indication is for patients whose disease is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.",
        "evidence": "Approval",
        "implication_id": 215,
        "indication_id": 244,
        "last_updated": "2024-02-13",
        "deprecated": false
    },
    {
        "id": 588,
        "document_id": 117,
        "biomarkers": [
            65
        ],
        "context_id": 58,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved larotrectinib monotherapy for reimbursement for the treatment of adult patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. This indication is for patients whose disease is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.",
        "evidence": "Approval",
        "implication_id": 215,
        "indication_id": 244,
        "last_updated": "2024-02-13",
        "deprecated": false
    },
    {
        "id": 589,
        "document_id": 118,
        "biomarkers": [
            19
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved gefitinib monotherapy for reimbursement for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK.",
        "evidence": "Approval",
        "implication_id": 216,
        "indication_id": 245,
        "last_updated": "2024-02-22",
        "deprecated": false
    },
    {
        "id": 590,
        "document_id": 119,
        "biomarkers": [
            19
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved erlotinib for reimbursement as a treatment option for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations.",
        "evidence": "Approval",
        "implication_id": 217,
        "indication_id": 246,
        "last_updated": "2024-02-22",
        "deprecated": false
    },
    {
        "id": 591,
        "document_id": 119,
        "biomarkers": [
            19
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved erlotinib for reimbursement as a treatment option for switch maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations and stable disease after first-line chemotherapy.",
        "evidence": "Approval",
        "implication_id": 217,
        "indication_id": 247,
        "last_updated": "2024-02-22",
        "deprecated": false
    },
    {
        "id": 592,
        "document_id": 120,
        "biomarkers": [
            20
        ],
        "context_id": 14,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab emtansine for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either (i) received prior therapy for locally advanced or metastatic disease or (ii) developed disease recurrence during or within six months of completing adjuvant therapy.",
        "evidence": "Approval",
        "implication_id": 218,
        "indication_id": 248,
        "last_updated": "2024-04-01",
        "deprecated": false
    },
    {
        "id": 593,
        "document_id": 120,
        "biomarkers": [
            20
        ],
        "context_id": 15,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab emtansine for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either (i) received prior therapy for locally advanced or metastatic disease or (ii) developed disease recurrence during or within six months of completing adjuvant therapy.",
        "evidence": "Approval",
        "implication_id": 218,
        "indication_id": 248,
        "last_updated": "2024-04-01",
        "deprecated": false
    },
    {
        "id": 594,
        "document_id": 121,
        "biomarkers": [
            2,
            1
        ],
        "context_id": 14,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved palbociclib in combination with an aromatase inhibitor as a treatment option for the treatment of patients with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.",
        "evidence": "Approval",
        "implication_id": 219,
        "indication_id": 249,
        "last_updated": "2024-04-01",
        "deprecated": false
    },
    {
        "id": 595,
        "document_id": 121,
        "biomarkers": [
            2,
            3
        ],
        "context_id": 14,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved palbociclib in combination with an aromatase inhibitor as a treatment option for the treatment of patients with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.",
        "evidence": "Approval",
        "implication_id": 219,
        "indication_id": 249,
        "last_updated": "2024-04-01",
        "deprecated": false
    },
    {
        "id": 596,
        "document_id": 121,
        "biomarkers": [
            2,
            1,
            3
        ],
        "context_id": 14,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved palbociclib in combination with an aromatase inhibitor as a treatment option for the treatment of patients with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.",
        "evidence": "Approval",
        "implication_id": 219,
        "indication_id": 249,
        "last_updated": "2024-04-01",
        "deprecated": false
    },
    {
        "id": 597,
        "document_id": 121,
        "biomarkers": [
            2,
            1
        ],
        "context_id": 15,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved palbociclib in combination with an aromatase inhibitor as a treatment option for the treatment of patients with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.",
        "evidence": "Approval",
        "implication_id": 219,
        "indication_id": 249,
        "last_updated": "2024-04-01",
        "deprecated": false
    },
    {
        "id": 598,
        "document_id": 121,
        "biomarkers": [
            2,
            3
        ],
        "context_id": 15,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved palbociclib in combination with an aromatase inhibitor as a treatment option for the treatment of patients with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.",
        "evidence": "Approval",
        "implication_id": 219,
        "indication_id": 249,
        "last_updated": "2024-04-01",
        "deprecated": false
    },
    {
        "id": 599,
        "document_id": 121,
        "biomarkers": [
            2,
            1,
            3
        ],
        "context_id": 15,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved palbociclib in combination with an aromatase inhibitor as a treatment option for the treatment of patients with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.",
        "evidence": "Approval",
        "implication_id": 219,
        "indication_id": 249,
        "last_updated": "2024-04-01",
        "deprecated": false
    },
    {
        "id": 600,
        "document_id": 121,
        "biomarkers": [
            2,
            1
        ],
        "context_id": 14,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved palbociclib in combination with fulvestrant as a treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.",
        "evidence": "Approval",
        "implication_id": 220,
        "indication_id": 250,
        "last_updated": "2024-04-01",
        "deprecated": false
    },
    {
        "id": 601,
        "document_id": 121,
        "biomarkers": [
            2,
            3
        ],
        "context_id": 14,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved palbociclib in combination with fulvestrant as a treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.",
        "evidence": "Approval",
        "implication_id": 220,
        "indication_id": 250,
        "last_updated": "2024-04-01",
        "deprecated": false
    },
    {
        "id": 602,
        "document_id": 121,
        "biomarkers": [
            2,
            1,
            3
        ],
        "context_id": 14,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved palbociclib in combination with fulvestrant as a treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.",
        "evidence": "Approval",
        "implication_id": 220,
        "indication_id": 250,
        "last_updated": "2024-04-01",
        "deprecated": false
    },
    {
        "id": 603,
        "document_id": 121,
        "biomarkers": [
            2,
            1
        ],
        "context_id": 15,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved palbociclib in combination with fulvestrant as a treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.",
        "evidence": "Approval",
        "implication_id": 220,
        "indication_id": 250,
        "last_updated": "2024-04-01",
        "deprecated": false
    },
    {
        "id": 604,
        "document_id": 121,
        "biomarkers": [
            2,
            3
        ],
        "context_id": 15,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved palbociclib in combination with fulvestrant as a treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.",
        "evidence": "Approval",
        "implication_id": 220,
        "indication_id": 250,
        "last_updated": "2024-04-01",
        "deprecated": false
    },
    {
        "id": 605,
        "document_id": 121,
        "biomarkers": [
            2,
            1,
            3
        ],
        "context_id": 15,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved palbociclib in combination with fulvestrant as a treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.",
        "evidence": "Approval",
        "implication_id": 220,
        "indication_id": 250,
        "last_updated": "2024-04-01",
        "deprecated": false
    },
    {
        "id": 606,
        "document_id": 122,
        "biomarkers": [
            2,
            1
        ],
        "context_id": 14,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor as an initial endocrine-based treatment option for the treatment of patients who are postmenopausal women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.",
        "evidence": "Approval",
        "implication_id": 221,
        "indication_id": 251,
        "last_updated": "2024-04-03",
        "deprecated": false
    },
    {
        "id": 607,
        "document_id": 122,
        "biomarkers": [
            2,
            3
        ],
        "context_id": 14,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor as an initial endocrine-based treatment option for the treatment of patients who are postmenopausal women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.",
        "evidence": "Approval",
        "implication_id": 221,
        "indication_id": 251,
        "last_updated": "2024-04-03",
        "deprecated": false
    },
    {
        "id": 608,
        "document_id": 122,
        "biomarkers": [
            2,
            1,
            3
        ],
        "context_id": 14,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor as an initial endocrine-based treatment option for the treatment of patients who are postmenopausal women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.",
        "evidence": "Approval",
        "implication_id": 221,
        "indication_id": 251,
        "last_updated": "2024-04-03",
        "deprecated": false
    },
    {
        "id": 609,
        "document_id": 122,
        "biomarkers": [
            2,
            1
        ],
        "context_id": 15,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor as an initial endocrine-based treatment option for the treatment of patients who are postmenopausal women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.",
        "evidence": "Approval",
        "implication_id": 221,
        "indication_id": 251,
        "last_updated": "2024-04-03",
        "deprecated": false
    },
    {
        "id": 610,
        "document_id": 122,
        "biomarkers": [
            2,
            3
        ],
        "context_id": 15,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor as an initial endocrine-based treatment option for the treatment of patients who are postmenopausal women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.",
        "evidence": "Approval",
        "implication_id": 221,
        "indication_id": 251,
        "last_updated": "2024-04-03",
        "deprecated": false
    },
    {
        "id": 611,
        "document_id": 122,
        "biomarkers": [
            2,
            1,
            3
        ],
        "context_id": 15,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor as an initial endocrine-based treatment option for the treatment of patients who are postmenopausal women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.",
        "evidence": "Approval",
        "implication_id": 221,
        "indication_id": 251,
        "last_updated": "2024-04-03",
        "deprecated": false
    },
    {
        "id": 612,
        "document_id": 122,
        "biomarkers": [
            2,
            1
        ],
        "context_id": 14,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer or in women who have received prior endocrine therapy. In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.",
        "evidence": "Approval",
        "implication_id": 221,
        "indication_id": 252,
        "last_updated": "2024-04-03",
        "deprecated": false
    },
    {
        "id": 613,
        "document_id": 122,
        "biomarkers": [
            2,
            3
        ],
        "context_id": 14,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer or in women who have received prior endocrine therapy. In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.",
        "evidence": "Approval",
        "implication_id": 221,
        "indication_id": 252,
        "last_updated": "2024-04-03",
        "deprecated": false
    },
    {
        "id": 614,
        "document_id": 122,
        "biomarkers": [
            2,
            1,
            3
        ],
        "context_id": 14,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer or in women who have received prior endocrine therapy. In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.",
        "evidence": "Approval",
        "implication_id": 221,
        "indication_id": 252,
        "last_updated": "2024-04-03",
        "deprecated": false
    },
    {
        "id": 615,
        "document_id": 122,
        "biomarkers": [
            2,
            1
        ],
        "context_id": 15,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer or in women who have received prior endocrine therapy. In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.",
        "evidence": "Approval",
        "implication_id": 221,
        "indication_id": 252,
        "last_updated": "2024-04-03",
        "deprecated": false
    },
    {
        "id": 616,
        "document_id": 122,
        "biomarkers": [
            2,
            3
        ],
        "context_id": 15,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer or in women who have received prior endocrine therapy. In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.",
        "evidence": "Approval",
        "implication_id": 221,
        "indication_id": 252,
        "last_updated": "2024-04-03",
        "deprecated": false
    },
    {
        "id": 617,
        "document_id": 122,
        "biomarkers": [
            2,
            1,
            3
        ],
        "context_id": 15,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer or in women who have received prior endocrine therapy. In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.",
        "evidence": "Approval",
        "implication_id": 221,
        "indication_id": 252,
        "last_updated": "2024-04-03",
        "deprecated": false
    },
    {
        "id": 618,
        "document_id": 122,
        "biomarkers": [
            2,
            1
        ],
        "context_id": 14,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer or in women who have received prior endocrine therapy. In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.",
        "evidence": "Approval",
        "implication_id": 222,
        "indication_id": 252,
        "last_updated": "2024-04-03",
        "deprecated": false
    },
    {
        "id": 619,
        "document_id": 122,
        "biomarkers": [
            2,
            3
        ],
        "context_id": 14,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer or in women who have received prior endocrine therapy. In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.",
        "evidence": "Approval",
        "implication_id": 222,
        "indication_id": 252,
        "last_updated": "2024-04-03",
        "deprecated": false
    },
    {
        "id": 620,
        "document_id": 122,
        "biomarkers": [
            2,
            1,
            3
        ],
        "context_id": 14,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer or in women who have received prior endocrine therapy. In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.",
        "evidence": "Approval",
        "implication_id": 222,
        "indication_id": 252,
        "last_updated": "2024-04-03",
        "deprecated": false
    },
    {
        "id": 621,
        "document_id": 122,
        "biomarkers": [
            2,
            1
        ],
        "context_id": 15,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer or in women who have received prior endocrine therapy. In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.",
        "evidence": "Approval",
        "implication_id": 222,
        "indication_id": 252,
        "last_updated": "2024-04-03",
        "deprecated": false
    },
    {
        "id": 622,
        "document_id": 122,
        "biomarkers": [
            2,
            3
        ],
        "context_id": 15,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer or in women who have received prior endocrine therapy. In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.",
        "evidence": "Approval",
        "implication_id": 222,
        "indication_id": 252,
        "last_updated": "2024-04-03",
        "deprecated": false
    },
    {
        "id": 623,
        "document_id": 122,
        "biomarkers": [
            2,
            1,
            3
        ],
        "context_id": 15,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer or in women who have received prior endocrine therapy. In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.",
        "evidence": "Approval",
        "implication_id": 222,
        "indication_id": 252,
        "last_updated": "2024-04-03",
        "deprecated": false
    },
    {
        "id": 624,
        "document_id": 123,
        "biomarkers": [
            13
        ],
        "context_id": 6,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved inotuzumab ozogamicin for reimbursement as a monotherapy treatment option for the treatment of adult patients with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukemia (ALL). The indication further states that adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).",
        "evidence": "Approval",
        "implication_id": 223,
        "indication_id": 253,
        "last_updated": "2024-04-03",
        "deprecated": false
    },
    {
        "id": 625,
        "document_id": 123,
        "biomarkers": [
            13,
            12
        ],
        "context_id": 6,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved inotuzumab ozogamicin for reimbursement as a monotherapy treatment option for the treatment of adult patients with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukemia (ALL). The indication further states that adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).",
        "evidence": "Approval",
        "implication_id": 223,
        "indication_id": 253,
        "last_updated": "2024-04-03",
        "deprecated": false
    },
    {
        "id": 626,
        "document_id": 124,
        "biomarkers": [
            14,
            15
        ],
        "context_id": 6,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved blinatumomab for reimbursement as a monotherapy treatment option for the treatment of pediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation.",
        "evidence": "Approval",
        "implication_id": 224,
        "indication_id": 254,
        "last_updated": "2024-04-03",
        "deprecated": false
    },
    {
        "id": 627,
        "document_id": 125,
        "biomarkers": [
            0
        ],
        "context_id": 0,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin in combination with ESHAP (etoposide, cisplatin, and cytarabine) for reimbursement as a treatment option for the treatment of adult patients with relapsed/refractory CD30+ Hodgkin's lymphoma.",
        "evidence": "Approval",
        "implication_id": 225,
        "indication_id": 255,
        "last_updated": "2024-04-06",
        "deprecated": false
    },
    {
        "id": 628,
        "document_id": 126,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. According to the EMA product information for this indication, this indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.",
        "evidence": "Approval",
        "implication_id": 226,
        "indication_id": 257,
        "last_updated": "2024-09-01",
        "deprecated": false
    },
    {
        "id": 629,
        "document_id": 126,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. According to the EMA product information for this indication, this indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.",
        "evidence": "Approval",
        "implication_id": 227,
        "indication_id": 257,
        "last_updated": "2024-09-01",
        "deprecated": false
    },
    {
        "id": 630,
        "document_id": 126,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab and chemotherapy partially for reimbursement as a treatment option for the adjuvant treatment of adult patients with HER2-positive breast cancer at high risk of recurrence. The therapy regimen states that pertuzumab is not currently approved for reimbursement for this indication, and that trastuzumab and chemotherapy are available for reimbursement through the hospital scheme. According to the EMA product information for this indication, this indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.",
        "evidence": "Approval",
        "implication_id": 228,
        "indication_id": 394,
        "last_updated": "2024-09-01",
        "deprecated": false
    },
    {
        "id": 631,
        "document_id": 126,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab and chemotherapy partially for reimbursement as a treatment option for the adjuvant treatment of adult patients with HER2-positive breast cancer at high risk of recurrence. The therapy regimen states that pertuzumab is not currently approved for reimbursement for this indication, and that trastuzumab and chemotherapy are available for reimbursement through the hospital scheme. According to the EMA product information for this indication, this indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.",
        "evidence": "Approval",
        "implication_id": 229,
        "indication_id": 394,
        "last_updated": "2024-09-01",
        "deprecated": false
    },
    {
        "id": 632,
        "document_id": 126,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab and chemotherapy partially for reimbursement as a treatment option for the adjuvant treatment of adult patients with HER2-positive breast cancer at high risk of recurrence. The therapy regimen states that pertuzumab is not currently approved for reimbursement for this indication, and that trastuzumab and chemotherapy are available for reimbursement through the hospital scheme. According to the EMA product information for this indication, this indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.",
        "evidence": "Approval",
        "implication_id": 230,
        "indication_id": 394,
        "last_updated": "2024-09-01",
        "deprecated": false
    },
    {
        "id": 633,
        "document_id": 126,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab and chemotherapy partially for reimbursement as a treatment option for the adjuvant treatment of adult patients with HER2-positive breast cancer at high risk of recurrence. The therapy regimen states that pertuzumab is not currently approved for reimbursement for this indication, and that trastuzumab and chemotherapy are available for reimbursement through the hospital scheme. According to the EMA product information for this indication, this indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.",
        "evidence": "Approval",
        "implication_id": 231,
        "indication_id": 394,
        "last_updated": "2024-09-01",
        "deprecated": false
    },
    {
        "id": 634,
        "document_id": 126,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab and chemotherapy partially for reimbursement as a treatment option for the adjuvant treatment of adult patients with HER2-positive breast cancer at high risk of recurrence. The therapy regimen states that pertuzumab is not currently approved for reimbursement for this indication, and that trastuzumab and chemotherapy are available for reimbursement through the hospital scheme. According to the EMA product information for this indication, this indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.",
        "evidence": "Approval",
        "implication_id": 232,
        "indication_id": 394,
        "last_updated": "2024-09-01",
        "deprecated": false
    },
    {
        "id": 635,
        "document_id": 127,
        "biomarkers": [
            55
        ],
        "context_id": 6,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved gemtuzumab ozogamicin in combination with daunorubicin and cytarabine for reimbursement as a treatment option for the treatment of patients aged 15 years and above with previously untreated, de novo CD33 positive Acute Myeloid Leukemia (AML), except acute promyelocytic leukemia.",
        "evidence": "Approval",
        "implication_id": 233,
        "indication_id": 258,
        "last_updated": "2024-04-06",
        "deprecated": false
    },
    {
        "id": 636,
        "document_id": 128,
        "biomarkers": [
            35,
            34
        ],
        "context_id": 29,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with pemetrexed and carboplatin for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have no EGFR or ALK positive mutations.",
        "evidence": "Approval",
        "implication_id": 234,
        "indication_id": 259,
        "last_updated": "2024-04-06",
        "deprecated": false
    },
    {
        "id": 637,
        "document_id": 129,
        "biomarkers": [
            35,
            34
        ],
        "context_id": 29,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with pemetrexed and cisplatin for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have no EGFR or ALK positive mutations.",
        "evidence": "Approval",
        "implication_id": 235,
        "indication_id": 260,
        "last_updated": "2024-04-06",
        "deprecated": false
    },
    {
        "id": 638,
        "document_id": 130,
        "biomarkers": [
            33
        ],
        "context_id": 29,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved durvalumab as a monotherapy for reimbursement as a treatment option for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) whose tumors express PD-L1 >= 1% on tumor cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT).",
        "evidence": "Approval",
        "implication_id": 236,
        "indication_id": 261,
        "last_updated": "2024-04-06",
        "deprecated": false
    },
    {
        "id": 639,
        "document_id": 131,
        "biomarkers": [
            72
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab for reimbursement as a monotherapy treatment option for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. The regimen further states that patients with EGFR mutations or an ALK fusion oncogene are required to have received prior tyrosine kinase inhibitor therapy.",
        "evidence": "Approval",
        "implication_id": 139,
        "indication_id": 396,
        "last_updated": "2024-09-01",
        "deprecated": false
    },
    {
        "id": 640,
        "document_id": 131,
        "biomarkers": [
            8
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab for reimbursement as a monotherapy treatment option for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. The regimen further states that patients with EGFR mutations or an ALK fusion oncogene are required to have received prior tyrosine kinase inhibitor therapy.",
        "evidence": "Approval",
        "implication_id": 139,
        "indication_id": 396,
        "last_updated": "2024-09-01",
        "deprecated": false
    },
    {
        "id": 641,
        "document_id": 131,
        "biomarkers": [
            71
        ],
        "context_id": 30,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab 1200mg as a monotherapy for reimbursement as a treatment option for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible and whose tumors have PD-L1 expression >= 5%.",
        "evidence": "Approval",
        "implication_id": 237,
        "indication_id": 262,
        "last_updated": "2024-04-06",
        "deprecated": false
    },
    {
        "id": 642,
        "document_id": 131,
        "biomarkers": [
            39,
            34,
            35
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab 1200mg as a monotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% tumor cells (TC) or >= 10% tumor-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.",
        "evidence": "Approval",
        "implication_id": 237,
        "indication_id": 263,
        "last_updated": "2024-04-06",
        "deprecated": false
    },
    {
        "id": 643,
        "document_id": 131,
        "biomarkers": [
            73,
            34,
            35
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab 1200mg as a monotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% tumor cells (TC) or >= 10% tumor-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.",
        "evidence": "Approval",
        "implication_id": 237,
        "indication_id": 263,
        "last_updated": "2024-04-06",
        "deprecated": false
    },
    {
        "id": 644,
        "document_id": 131,
        "biomarkers": [
            39,
            34,
            35
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab 1200mg as a monotherapy for reimbursement as a treatment option for the adjuvant treatment following complete resection and platinum-baesd chemotherapy for adult patients with non-small cell lung cancer (NSCLC) with a high risk of recurrence whose tumors have PD-L1 expression on >= 50% of tumor cells and who do not have EGFR mutant or ALK-positive mutations.",
        "evidence": "Approval",
        "implication_id": 237,
        "indication_id": 264,
        "last_updated": "2024-04-06",
        "deprecated": false
    },
    {
        "id": 645,
        "document_id": 132,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab emtansine as a single agent for reimbursement as a treatment option for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.",
        "evidence": "Approval",
        "implication_id": 238,
        "indication_id": 265,
        "last_updated": "2024-04-06",
        "deprecated": false
    },
    {
        "id": 646,
        "document_id": 133,
        "biomarkers": [
            42
        ],
        "context_id": 31,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with carboplatin and 5-fluorouracil for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 with a CPS >= 1.",
        "evidence": "Approval",
        "implication_id": 239,
        "indication_id": 266,
        "last_updated": "2024-04-06",
        "deprecated": false
    },
    {
        "id": 647,
        "document_id": 134,
        "biomarkers": [
            42
        ],
        "context_id": 31,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with cisplatin and 5-fluorouracil for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 with a CPS >= 1.",
        "evidence": "Approval",
        "implication_id": 240,
        "indication_id": 267,
        "last_updated": "2024-04-06",
        "deprecated": false
    },
    {
        "id": 648,
        "document_id": 135,
        "biomarkers": [
            34,
            35
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with ipililumab, carboplatin, and paclitaxel for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic squamous non-small cell lung cancer (NSCLC) whose tumors have no sensitising EGFR mutation or ALK translocation.",
        "evidence": "Approval",
        "implication_id": 241,
        "indication_id": 268,
        "last_updated": "2024-04-06",
        "deprecated": false
    },
    {
        "id": 649,
        "document_id": 136,
        "biomarkers": [
            34,
            35
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with ipililumab, carboplatin, and pemetrexed for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have no sensitising EGFR mutation or ALK translocation.",
        "evidence": "Approval",
        "implication_id": 242,
        "indication_id": 269,
        "last_updated": "2024-04-06",
        "deprecated": false
    },
    {
        "id": 650,
        "document_id": 137,
        "biomarkers": [
            34,
            35
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with ipililumab, cisplatin, and pemetrexed for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have no sensitising EGFR mutation or ALK translocation.",
        "evidence": "Approval",
        "implication_id": 243,
        "indication_id": 270,
        "last_updated": "2024-04-06",
        "deprecated": false
    },
    {
        "id": 651,
        "document_id": 138,
        "biomarkers": [
            33,
            43,
            2,
            44
        ],
        "context_id": 37,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab in combination with nab-paclitaxel for reimbursement as a treatment option for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors have PD-L1 expression >= 1% and who have not received prior chemotherapy for metastatic disease.",
        "evidence": "Approval",
        "implication_id": 244,
        "indication_id": 271,
        "last_updated": "2024-04-06",
        "deprecated": false
    },
    {
        "id": 652,
        "document_id": 139,
        "biomarkers": [
            15,
            14
        ],
        "context_id": 6,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved blinatumomab for reimbursement as a monotherapy treatment option for the treatment of adult patients with Philadelphia chromosome negative CD19 positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.",
        "evidence": "Approval",
        "implication_id": 224,
        "indication_id": 272,
        "last_updated": "2024-04-15",
        "deprecated": false
    },
    {
        "id": 653,
        "document_id": 140,
        "biomarkers": [
            15,
            14
        ],
        "context_id": 6,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved blinatumomab for reimbursement as a monotherapy treatment option for the treatment of pediatric patients aged 1 year or older with high-risk first relapsed with Philadelphia chromosome negative CD19 positive B-precursor acute lymphoblastic leukemia (ALL) as part of the consolidation therapy.",
        "evidence": "Approval",
        "implication_id": 224,
        "indication_id": 273,
        "last_updated": "2024-04-15",
        "deprecated": false
    },
    {
        "id": 654,
        "document_id": 141,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab and trastuzumab (phesgo) in combination with paclitaxel and carboplatin for reimbursement as a treatment option for the treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.",
        "evidence": "Approval",
        "implication_id": 245,
        "indication_id": 274,
        "last_updated": "2024-04-06",
        "deprecated": false
    },
    {
        "id": 655,
        "document_id": 142,
        "biomarkers": [
            0
        ],
        "context_id": 1,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin for reimbursement as a treatment option for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.",
        "evidence": "Approval",
        "implication_id": 246,
        "indication_id": 275,
        "last_updated": "2024-04-06",
        "deprecated": false
    },
    {
        "id": 656,
        "document_id": 142,
        "biomarkers": [
            0
        ],
        "context_id": 0,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin for reimbursement as a treatment option for the treatment of adult patients with CD30+ Hodgkins Lymphoma (HL) at increased risk of relapse or progression following an autologous hematopoietic stem cell transplant (ASCT).",
        "evidence": "Approval",
        "implication_id": 246,
        "indication_id": 276,
        "last_updated": "2024-04-06",
        "deprecated": false
    },
    {
        "id": 657,
        "document_id": 142,
        "biomarkers": [
            0
        ],
        "context_id": 0,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin for reimbursement as a treatment option for the treatment of adult patients with relapsed or refractory CD30+ Hodgkins Lymphoma (HL) following autologous stem cell transplant (ASCT).",
        "evidence": "Approval",
        "implication_id": 246,
        "indication_id": 296,
        "last_updated": "2024-04-06",
        "deprecated": false
    },
    {
        "id": 658,
        "document_id": 142,
        "biomarkers": [
            0
        ],
        "context_id": 0,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin for reimbursement as a treatment option for the treatment of adult patients with relapsed or refractory CD30+ Hodgkins Lymphoma (HL) following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.",
        "evidence": "Approval",
        "implication_id": 246,
        "indication_id": 277,
        "last_updated": "2024-04-06",
        "deprecated": false
    },
    {
        "id": 659,
        "document_id": 143,
        "biomarkers": [
            0,
            2
        ],
        "context_id": 0,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin in combination with ICE (etoposide, carboplatin, and ifosfamide) for reimbursement as a treatment option for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin's lymphoma (HL).",
        "evidence": "Approval",
        "implication_id": 247,
        "indication_id": 278,
        "last_updated": "2024-04-06",
        "deprecated": false
    },
    {
        "id": 660,
        "document_id": 144,
        "biomarkers": [
            41
        ],
        "context_id": 84,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg) in combination with platinum and flouropyrimidine-based chemotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastro-oesophageal junction adenocarcinoma whose tumors express PD-L1 with CPS >= 10.",
        "evidence": "Approval",
        "implication_id": 248,
        "indication_id": 279,
        "last_updated": "2024-04-07",
        "deprecated": false
    },
    {
        "id": 661,
        "document_id": 144,
        "biomarkers": [
            41,
            2
        ],
        "context_id": 85,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg) in combination with platinum and flouropyrimidine-based chemotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastro-oesophageal junction adenocarcinoma whose tumors express PD-L1 with CPS >= 10.",
        "evidence": "Approval",
        "implication_id": 248,
        "indication_id": 279,
        "last_updated": "2024-04-07",
        "deprecated": false
    },
    {
        "id": 662,
        "document_id": 145,
        "biomarkers": [
            33
        ],
        "context_id": 86,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab (480mg) in combination with flouropyrimidine and platinum-based chemotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (OSCC) with tumor cell programmed death ligang 1 (PD-L1) expression >= 1%.",
        "evidence": "Approval",
        "implication_id": 249,
        "indication_id": 280,
        "last_updated": "2024-04-07",
        "deprecated": false
    },
    {
        "id": 663,
        "document_id": 146,
        "biomarkers": [
            72
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab (1680 mg) for reimbursement as a monotherapy treatment option for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. The regimen further states that patients with EGFR mutations or an ALK fusion oncogene are required to have received prior tyrosine kinase inhibitor therapy.",
        "evidence": "Approval",
        "implication_id": 139,
        "indication_id": 395,
        "last_updated": "2024-09-01",
        "deprecated": false
    },
    {
        "id": 664,
        "document_id": 146,
        "biomarkers": [
            8
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab (1680 mg) for reimbursement as a monotherapy treatment option for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. The regimen further states that patients with EGFR mutations or an ALK fusion oncogene are required to have received prior tyrosine kinase inhibitor therapy.",
        "evidence": "Approval",
        "implication_id": 139,
        "indication_id": 395,
        "last_updated": "2024-09-01",
        "deprecated": false
    },
    {
        "id": 665,
        "document_id": 146,
        "biomarkers": [
            71
        ],
        "context_id": 30,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab (1680mg) as a monotherapy for reimbursement as a treatment option for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible, and whose tumors have a PD-L1 expression >= 5%.",
        "evidence": "Approval",
        "implication_id": 237,
        "indication_id": 281,
        "last_updated": "2024-04-07",
        "deprecated": false
    },
    {
        "id": 666,
        "document_id": 146,
        "biomarkers": [
            39,
            34,
            35
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab (1680mg) as a monotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a PD-L1 expression >= 50% tumor cells (TC) or >= 10% tumor-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.",
        "evidence": "Approval",
        "implication_id": 237,
        "indication_id": 282,
        "last_updated": "2024-04-10",
        "deprecated": false
    },
    {
        "id": 667,
        "document_id": 146,
        "biomarkers": [
            73,
            34,
            35
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab (1680mg) as a monotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a PD-L1 expression >= 50% tumor cells (TC) or >= 10% tumor-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.",
        "evidence": "Approval",
        "implication_id": 237,
        "indication_id": 282,
        "last_updated": "2024-04-10",
        "deprecated": false
    },
    {
        "id": 668,
        "document_id": 146,
        "biomarkers": [
            39,
            34,
            35
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab (1680mg) as a monotherapy for reimbursement as a treatment option for the adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on >= 50% tumor cells and who do not have EGFR mutant or ALK-positive NSCLC.",
        "evidence": "Approval",
        "implication_id": 237,
        "indication_id": 283,
        "last_updated": "2024-04-10",
        "deprecated": false
    },
    {
        "id": 669,
        "document_id": 147,
        "biomarkers": [
            41,
            2
        ],
        "context_id": 39,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy for for reimbursement as a treatment option for the first-line treatment of adult patients with unresectable or metastatic carcinoma of the oesophagus or HER2-negative gastro-osophageal junction adenocarcinoma whose tumors express PD-L1 with CPS >= 10.",
        "evidence": "Approval",
        "implication_id": 250,
        "indication_id": 284,
        "last_updated": "2024-04-15",
        "deprecated": false
    },
    {
        "id": 670,
        "document_id": 148,
        "biomarkers": [
            15
        ],
        "context_id": 6,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved blinatumomab for reimbursement as a monotherapy treatment option for the treatment of adult patients with relapsed or refractory B cell precusor (BCP) Philadelphia chromosome negative acute lymphoblastic leukemia (ALL) who have received no prior salvage treatment for relapsed / refractory (R/R) disease and are considered eligible for transplant (e.g., as a bridge-to-transplant).",
        "evidence": "Approval",
        "implication_id": 251,
        "indication_id": 285,
        "last_updated": "2024-04-15",
        "deprecated": false
    },
    {
        "id": 671,
        "document_id": 149,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab / trastuzumab (phesgo) in combination with paclitaxel for reimbursement as a treatment option for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease where patients are intolerant of, have had significant toxicity to, or are deemed clinically unsuitable for docetaxel.",
        "evidence": "Approval",
        "implication_id": 252,
        "indication_id": 286,
        "last_updated": "2024-04-15",
        "deprecated": false
    },
    {
        "id": 672,
        "document_id": 150,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab and paclitaxel for reimbursement as a treatment option for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease where patients are intolerant of, have had significant toxicity to, or are deemed clinically unsuitable for docetaxel.",
        "evidence": "Approval",
        "implication_id": 253,
        "indication_id": 287,
        "last_updated": "2024-04-15",
        "deprecated": false
    },
    {
        "id": 673,
        "document_id": 151,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab / trastuzumab (phesgo) in combination with docetaxel for reimbursement as a treatment option for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.",
        "evidence": "Approval",
        "implication_id": 254,
        "indication_id": 288,
        "last_updated": "2024-04-15",
        "deprecated": false
    },
    {
        "id": 674,
        "document_id": 152,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab and docetaxel for reimbursement as a treatment option for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.",
        "evidence": "Approval",
        "implication_id": 255,
        "indication_id": 289,
        "last_updated": "2024-04-15",
        "deprecated": false
    },
    {
        "id": 675,
        "document_id": 153,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab / trastuzumab (phesgo) in combination with vinorelbine for reimbursement as a treatment option for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease where patients are deemed clinically unsuitable for taxane based therapy.",
        "evidence": "Approval",
        "implication_id": 256,
        "indication_id": 290,
        "last_updated": "2024-04-15",
        "deprecated": false
    },
    {
        "id": 676,
        "document_id": 154,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab and vinorelbine for reimbursement as a treatment option for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease where patients are deemed clinically unsuitable for taxane based therapy.",
        "evidence": "Approval",
        "implication_id": 257,
        "indication_id": 291,
        "last_updated": "2024-04-15",
        "deprecated": false
    },
    {
        "id": 677,
        "document_id": 155,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab / trastuzumab (phesgo) for reimbursement as a treatment option for the maintenance treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, where this is a continuation of treatment for patients who have completed the chemotherapy component of the treatment. The regime further states that patients should have already been treated with pertuzumab and trastuzumab in combination with DOCEtaxel, PACLItaxel, or vinorelbine.",
        "evidence": "Approval",
        "implication_id": 258,
        "indication_id": 292,
        "last_updated": "2024-04-15",
        "deprecated": false
    },
    {
        "id": 678,
        "document_id": 156,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved docetaxel in combination with carboplatin, pertuzumab, and trastuzumab for reimbursement as a treatment option for the neoadjuvant treatment of adult patients with HER2-positive locally advanced, inflammatory, or early breast cancer at high risk of recurrence.",
        "evidence": "Approval",
        "implication_id": 259,
        "indication_id": 293,
        "last_updated": "2024-04-15",
        "deprecated": false
    },
    {
        "id": 679,
        "document_id": 157,
        "biomarkers": [
            33
        ],
        "context_id": 69,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors have PD-L1 expression >= 1%. The treatment regimen contians five treatment schedules: (1) nivolumab 360 mg, CARBOplatin (AUC6), and PAClitaxel (200 mg/m^2); (2) nivolumab 360mg, gemcitabine (1000 mg/m^2), and CARBOplatin (AUC5); (3) nivolumab 360 mg, gemcitabine 1250 mg/m^2, and CISplatin 75 mg/m^2; (4) nivolumab 360 mg, PEMEtrexed, and CARBOplatin with folic acid or multivtamin containig 350-1000 micrograms of folic acid; and (5) nivolumab 360 mg, PEMEtrexed, and CISplatin along with folic acid or multivitamin containig 350-1000 mg of folic acid.",
        "evidence": "Approval",
        "implication_id": 260,
        "indication_id": 294,
        "last_updated": "2024-06-19",
        "deprecated": false
    },
    {
        "id": 680,
        "document_id": 157,
        "biomarkers": [
            33
        ],
        "context_id": 69,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors have PD-L1 expression >= 1%. The treatment regimen contians five treatment schedules: (1) nivolumab 360 mg, CARBOplatin (AUC6), and PAClitaxel (200 mg/m^2); (2) nivolumab 360mg, gemcitabine (1000 mg/m^2), and CARBOplatin (AUC5); (3) nivolumab 360 mg, gemcitabine 1250 mg/m^2, and CISplatin 75 mg/m^2; (4) nivolumab 360 mg, PEMEtrexed, and CARBOplatin with folic acid or multivtamin containig 350-1000 micrograms of folic acid; and (5) nivolumab 360 mg, PEMEtrexed, and CISplatin along with folic acid or multivitamin containig 350-1000 mg of folic acid.",
        "evidence": "Approval",
        "implication_id": 261,
        "indication_id": 294,
        "last_updated": "2024-06-19",
        "deprecated": false
    },
    {
        "id": 681,
        "document_id": 157,
        "biomarkers": [
            33
        ],
        "context_id": 69,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors have PD-L1 expression >= 1%. The treatment regimen contians five treatment schedules: (1) nivolumab 360 mg, CARBOplatin (AUC6), and PAClitaxel (200 mg/m^2); (2) nivolumab 360mg, gemcitabine (1000 mg/m^2), and CARBOplatin (AUC5); (3) nivolumab 360 mg, gemcitabine 1250 mg/m^2, and CISplatin 75 mg/m^2; (4) nivolumab 360 mg, PEMEtrexed, and CARBOplatin with folic acid or multivtamin containig 350-1000 micrograms of folic acid; and (5) nivolumab 360 mg, PEMEtrexed, and CISplatin along with folic acid or multivitamin containig 350-1000 mg of folic acid.",
        "evidence": "Approval",
        "implication_id": 262,
        "indication_id": 294,
        "last_updated": "2024-06-19",
        "deprecated": false
    },
    {
        "id": 682,
        "document_id": 157,
        "biomarkers": [
            33
        ],
        "context_id": 69,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors have PD-L1 expression >= 1%. The treatment regimen contians five treatment schedules: (1) nivolumab 360 mg, CARBOplatin (AUC6), and PAClitaxel (200 mg/m^2); (2) nivolumab 360mg, gemcitabine (1000 mg/m^2), and CARBOplatin (AUC5); (3) nivolumab 360 mg, gemcitabine 1250 mg/m^2, and CISplatin 75 mg/m^2; (4) nivolumab 360 mg, PEMEtrexed, and CARBOplatin with folic acid or multivtamin containig 350-1000 micrograms of folic acid; and (5) nivolumab 360 mg, PEMEtrexed, and CISplatin along with folic acid or multivitamin containig 350-1000 mg of folic acid.",
        "evidence": "Approval",
        "implication_id": 263,
        "indication_id": 294,
        "last_updated": "2024-06-19",
        "deprecated": false
    },
    {
        "id": 683,
        "document_id": 157,
        "biomarkers": [
            33
        ],
        "context_id": 69,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors have PD-L1 expression >= 1%. The treatment regimen contians five treatment schedules: (1) nivolumab 360 mg, CARBOplatin (AUC6), and PAClitaxel (200 mg/m^2); (2) nivolumab 360mg, gemcitabine (1000 mg/m^2), and CARBOplatin (AUC5); (3) nivolumab 360 mg, gemcitabine 1250 mg/m^2, and CISplatin 75 mg/m^2; (4) nivolumab 360 mg, PEMEtrexed, and CARBOplatin with folic acid or multivtamin containig 350-1000 micrograms of folic acid; and (5) nivolumab 360 mg, PEMEtrexed, and CISplatin along with folic acid or multivitamin containig 350-1000 mg of folic acid.",
        "evidence": "Approval",
        "implication_id": 264,
        "indication_id": 294,
        "last_updated": "2024-06-19",
        "deprecated": false
    },
    {
        "id": 684,
        "document_id": 158,
        "biomarkers": [
            43,
            2,
            44
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with weekly carboplatin and paclitaxel followed by doxorubicin and cyclophosphamide for the neoadjuvant treatment, and then continued monotherapy as adjuvant treatment after surgery, of adult patients with locally advanced or early stage triple negative breast cancer at high risk of recurrence.",
        "evidence": "Approval",
        "implication_id": 265,
        "indication_id": 295,
        "last_updated": "2024-06-19",
        "deprecated": false
    },
    {
        "id": 685,
        "document_id": 159,
        "biomarkers": [
            20
        ],
        "context_id": 12,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (IV) for reimbursement as a monotherapy treatment option for the treatment of patients with HER2 positive metastatic breast cancer.",
        "evidence": "Approval",
        "implication_id": 266,
        "indication_id": 327,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 686,
        "document_id": 159,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (IV) for reimbursement as a monotherapy treatment option for the treatment of patients with HER2 positive early breast cancer.",
        "evidence": "Approval",
        "implication_id": 266,
        "indication_id": 328,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 687,
        "document_id": 160,
        "biomarkers": [
            20
        ],
        "context_id": 12,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (IV) for reimbursement as a monotherapy treatment option for the treatment of patients with HER2 positive metastatic breast cancer.",
        "evidence": "Approval",
        "implication_id": 266,
        "indication_id": 329,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 688,
        "document_id": 161,
        "biomarkers": [
            2
        ],
        "context_id": 12,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved bevacizumab in combination with paclitaxel for reimbursement as a treatment option for the treatment of patients with HER2-negative metastatic breast cancer.",
        "evidence": "Approval",
        "implication_id": 267,
        "indication_id": 300,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 689,
        "document_id": 162,
        "biomarkers": [
            2
        ],
        "context_id": 12,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved bevacizumab in combination with paclitaxel for reimbursement as a treatment option for the first-line treatment of patients with HER2-negative metastatic breast cancer.",
        "evidence": "Approval",
        "implication_id": 267,
        "indication_id": 301,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 690,
        "document_id": 162,
        "biomarkers": [
            19
        ],
        "context_id": 69,
        "description": "The Republic of Ireland's Health Service Executive has approved bevacizumab in combination with erlotinib for reimbursement as a treatment option for the first-line treatment of adult patients with unresectable advanced, metastatic, or recurrent non-small cell lung cancer with EGFR activating variants.",
        "evidence": "Approval",
        "implication_id": 268,
        "indication_id": 302,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 691,
        "document_id": 163,
        "biomarkers": [
            43,
            2,
            44
        ],
        "context_id": 37,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved capecitabine for reimbursement as a treatment option for the adjuvant treatment of stage I to IIIB triple negative breast cancer (TNBC) in patients with residual invasive disease after neoadjuvant chemotherapy treatment.",
        "evidence": "Approval",
        "implication_id": 269,
        "indication_id": 303,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 692,
        "document_id": 164,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved lapatinib in combination with capecitabine for reimbursement as a treatment option for the treatment of adult patients with advanced or metastatic breast cancer whose tumors overexpress HER2 with disease progression following prior therapy, which should have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting.",
        "evidence": "Approval",
        "implication_id": 270,
        "indication_id": 318,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 693,
        "document_id": 165,
        "biomarkers": [
            1
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved tamoxifen for reimbursement as a treatment option for the adjuvant treatment of estrogen receptor positive breast cancer in patients who are pre- or post-menopausal women.",
        "evidence": "Approval",
        "implication_id": 271,
        "indication_id": 325,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 694,
        "document_id": 165,
        "biomarkers": [
            1
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved tamoxifen for reimbursement as a treatment option for estrogen receptor positive advanced breast cancer in pre- or post-menopausal women.",
        "evidence": "Approval",
        "implication_id": 271,
        "indication_id": 326,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 695,
        "document_id": 166,
        "biomarkers": [
            20,
            1,
            3
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive has approved anastrozole for reimbursement as a treatment option for the treatment of hormone receptor positive locally advanced or metastatic breast cancer in post-menopausal women.",
        "evidence": "Approval",
        "implication_id": 272,
        "indication_id": 298,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 696,
        "document_id": 166,
        "biomarkers": [
            20,
            1
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive has approved anastrozole for reimbursement as a treatment option for the treatment of hormone receptor positive locally advanced or metastatic breast cancer in post-menopausal women.",
        "evidence": "Approval",
        "implication_id": 272,
        "indication_id": 298,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 697,
        "document_id": 166,
        "biomarkers": [
            20,
            3
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive has approved anastrozole for reimbursement as a treatment option for the treatment of hormone receptor positive locally advanced or metastatic breast cancer in post-menopausal women.",
        "evidence": "Approval",
        "implication_id": 272,
        "indication_id": 298,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 698,
        "document_id": 166,
        "biomarkers": [
            20,
            1,
            3
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive has approved anastrozole for reimbursement as a treatment option for the adjuvant treatment of hormone receptor positive invasive early breast cancer in postmenopausal women.",
        "evidence": "Approval",
        "implication_id": 272,
        "indication_id": 299,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 699,
        "document_id": 166,
        "biomarkers": [
            20,
            1
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive has approved anastrozole for reimbursement as a treatment option for the adjuvant treatment of hormone receptor positive invasive early breast cancer in postmenopausal women.",
        "evidence": "Approval",
        "implication_id": 272,
        "indication_id": 299,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 700,
        "document_id": 166,
        "biomarkers": [
            20,
            3
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive has approved anastrozole for reimbursement as a treatment option for the adjuvant treatment of hormone receptor positive invasive early breast cancer in postmenopausal women.",
        "evidence": "Approval",
        "implication_id": 272,
        "indication_id": 299,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 701,
        "document_id": 167,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab in combination with carboplatin and docetaxel (TCH) - 21 days for reimbursement as a treamtent option for the adjuvant treatment of HER2 positive early breast cancer.",
        "evidence": "Approval",
        "implication_id": 273,
        "indication_id": 307,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 702,
        "document_id": 168,
        "biomarkers": [
            20
        ],
        "context_id": 12,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) for reimbursement as a monotherapy treatment option for the treatment of HER2 positive metastatic breast cancer (MBC) in patients who have received at least two chemotherapy regimens for their metastatic disease. The indication further notes that prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.",
        "evidence": "Approval",
        "implication_id": 266,
        "indication_id": 334,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 703,
        "document_id": 168,
        "biomarkers": [
            20
        ],
        "context_id": 12,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) in combination with paclitaxel for reimbursement as a treatment option for the treatment of HER2 positive metastatic breast cancer in patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.",
        "evidence": "Approval",
        "implication_id": 274,
        "indication_id": 335,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 704,
        "document_id": 168,
        "biomarkers": [
            20
        ],
        "context_id": 12,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) in combination with docetaxel as a treatment option for the treatment of HER2 positive metastatic breast cancer for patients who have not received chemotherapy for their metastatic disease.",
        "evidence": "Approval",
        "implication_id": 275,
        "indication_id": 336,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 705,
        "document_id": 168,
        "biomarkers": [
            20,
            1,
            3
        ],
        "context_id": 12,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) in combination with an aromatase inhibitor as a treatment option for the treatment of HER2 positive, hormone-receptor positive metastatic breast cancer not previously treated with trastuzumab for patients who are postmenopausal. The corresponding European Medicines Agency approval for this indication cites the clinical trial BO16216 as rationale for the approval where Herceptin (trastuzumab) and anastrozole were administered.",
        "evidence": "Approval",
        "implication_id": 276,
        "indication_id": 337,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 706,
        "document_id": 168,
        "biomarkers": [
            20,
            1
        ],
        "context_id": 12,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) in combination with an aromatase inhibitor as a treatment option for the treatment of HER2 positive, hormone-receptor positive metastatic breast cancer not previously treated with trastuzumab for patients who are postmenopausal. The corresponding European Medicines Agency approval for this indication cites the clinical trial BO16216 as rationale for the approval where Herceptin (trastuzumab) and anastrozole were administered.",
        "evidence": "Approval",
        "implication_id": 276,
        "indication_id": 337,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 707,
        "document_id": 168,
        "biomarkers": [
            20,
            3
        ],
        "context_id": 12,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) in combination with an aromatase inhibitor as a treatment option for the treatment of HER2 positive, hormone-receptor positive metastatic breast cancer not previously treated with trastuzumab for patients who are postmenopausal. The corresponding European Medicines Agency approval for this indication cites the clinical trial BO16216 as rationale for the approval where Herceptin (trastuzumab) and anastrozole were administered.",
        "evidence": "Approval",
        "implication_id": 276,
        "indication_id": 337,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 708,
        "document_id": 168,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) for reimbursement as a monotherapy treatment option for the treatment of HER2 positive metastatic breast cancer (MBC) in patients who have received at least two chemotherapy regimens for their metastatic disease. The indication further notes that prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.",
        "evidence": "Approval",
        "implication_id": 266,
        "indication_id": 334,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 709,
        "document_id": 168,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) in combination with paclitaxel for reimbursement as a treatment option for the treatment of HER2 positive metastatic breast cancer in patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.",
        "evidence": "Approval",
        "implication_id": 274,
        "indication_id": 335,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 710,
        "document_id": 168,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) in combination with docetaxel as a treatment option for the treatment of HER2 positive metastatic breast cancer for patients who have not received chemotherapy for their metastatic disease.",
        "evidence": "Approval",
        "implication_id": 275,
        "indication_id": 336,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 711,
        "document_id": 168,
        "biomarkers": [
            20,
            1,
            3
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) in combination with an aromatase inhibitor as a treatment option for the treatment of HER2 positive, hormone-receptor positive metastatic breast cancer not previously treated with trastuzumab for patients who are postmenopausal. The corresponding European Medicines Agency approval for this indication cites the clinical trial BO16216 as rationale for the approval where Herceptin (trastuzumab) and anastrozole were administered.",
        "evidence": "Approval",
        "implication_id": 276,
        "indication_id": 337,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 712,
        "document_id": 168,
        "biomarkers": [
            20,
            1
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) in combination with an aromatase inhibitor as a treatment option for the treatment of HER2 positive, hormone-receptor positive metastatic breast cancer not previously treated with trastuzumab for patients who are postmenopausal. The corresponding European Medicines Agency approval for this indication cites the clinical trial BO16216 as rationale for the approval where Herceptin (trastuzumab) and anastrozole were administered.",
        "evidence": "Approval",
        "implication_id": 276,
        "indication_id": 337,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 713,
        "document_id": 168,
        "biomarkers": [
            20,
            3
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) in combination with an aromatase inhibitor as a treatment option for the treatment of HER2 positive, hormone-receptor positive metastatic breast cancer not previously treated with trastuzumab for patients who are postmenopausal. The corresponding European Medicines Agency approval for this indication cites the clinical trial BO16216 as rationale for the approval where Herceptin (trastuzumab) and anastrozole were administered.",
        "evidence": "Approval",
        "implication_id": 276,
        "indication_id": 337,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 714,
        "document_id": 169,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) for reimbursement as a treatment option for the treatment of HER2 positive early breast cancer following surgery, chemotherapy (neoadjuvant or adjuvant), and radiotherapy (if applicable).",
        "evidence": "Approval",
        "implication_id": 277,
        "indication_id": 330,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 715,
        "document_id": 169,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) in combination with either paclitaxel or docetaxel for reimbursement as a treatment option for the treatment of HER2 positive early breast cancer following adjuvant chemotherapy with doxorubicin and cyclophosphamide.",
        "evidence": "Approval",
        "implication_id": 278,
        "indication_id": 331,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 716,
        "document_id": 169,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) in combination with either paclitaxel or docetaxel for reimbursement as a treatment option for the treatment of HER2 positive early breast cancer following adjuvant chemotherapy with doxorubicin and cyclophosphamide.",
        "evidence": "Approval",
        "implication_id": 279,
        "indication_id": 331,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 717,
        "document_id": 169,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) in combination with adjuvant chemotherapy consisting of carboplatin and docetaxel for reimbursement as a treatment option for the treatment of HER2 positive early breast cancer.",
        "evidence": "Approval",
        "implication_id": 280,
        "indication_id": 332,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 718,
        "document_id": 169,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved neoadjuvant chemotherapy followed by adjuvant trastuzumab for reimbursement as a treatment option for the treatment of HER2 positive early breast cancer for locally advanced (including inflammatory) disease or tumors > 2 cm in diameter. The corresponding European Medicines Agency approval for this indication cites the multicenter randomized trial MO16432, which used doxorubicin in combination with paclitaxel for the neoadjuvant chemotherapy, in the rationale for this approval.",
        "evidence": "Approval",
        "implication_id": 281,
        "indication_id": 333,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 719,
        "document_id": 170,
        "biomarkers": [
            2,
            1,
            3
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved everolimus in combination with exemestane for reimbursement as a treatment option for the treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer in patients who are postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 282,
        "indication_id": 313,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 720,
        "document_id": 170,
        "biomarkers": [
            2,
            1
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved everolimus in combination with exemestane for reimbursement as a treatment option for the treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer in patients who are postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 282,
        "indication_id": 313,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 721,
        "document_id": 170,
        "biomarkers": [
            2,
            3
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved everolimus in combination with exemestane for reimbursement as a treatment option for the treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer in patients who are postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.",
        "evidence": "Approval",
        "implication_id": 282,
        "indication_id": 313,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 722,
        "document_id": 171,
        "biomarkers": [
            2,
            43,
            44
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved carboplatin (AUC 6) and weekly packlitaxel (80 mg/m^2) followed by dose dense doxorubicin cyclophosphamide for reimbursement as a treatment option for the neoadjuvant treatment of triple negative breast carcinoma.",
        "evidence": "Approval",
        "implication_id": 283,
        "indication_id": 305,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 723,
        "document_id": 172,
        "biomarkers": [
            43
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved fulvestrant for reimbursement as a treatment option for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-estrogen therapy in patients who are postmenopausal women.",
        "evidence": "Approval",
        "implication_id": 284,
        "indication_id": 315,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 724,
        "document_id": 172,
        "biomarkers": [
            43
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved fulvestrant for reimbursement as a treatment option for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer for disease progression on or after adjuvant anti-estrogen therapy in patients who are postmenopausal women.",
        "evidence": "Approval",
        "implication_id": 284,
        "indication_id": 316,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 725,
        "document_id": 173,
        "biomarkers": [
            1,
            3
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved letrozole for reimbursement as a treatment option for the adjuvant treatment of hormone receptor positive invasive early breast cancer in patients who are postmenopausal women.",
        "evidence": "Approval",
        "implication_id": 285,
        "indication_id": 319,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 726,
        "document_id": 173,
        "biomarkers": [
            1
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved letrozole for reimbursement as a treatment option for the adjuvant treatment of hormone receptor positive invasive early breast cancer in patients who are postmenopausal women.",
        "evidence": "Approval",
        "implication_id": 285,
        "indication_id": 319,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 727,
        "document_id": 173,
        "biomarkers": [
            3
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved letrozole for reimbursement as a treatment option for the adjuvant treatment of hormone receptor positive invasive early breast cancer in patients who are postmenopausal women.",
        "evidence": "Approval",
        "implication_id": 285,
        "indication_id": 319,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 728,
        "document_id": 173,
        "biomarkers": [
            1,
            3
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved letrozole for reimbursement as a treatment option for the neoadjuvant treatment of hormone receptor positive breast cancer in patients who are postmenopausal women.",
        "evidence": "Approval",
        "implication_id": 285,
        "indication_id": 320,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 729,
        "document_id": 173,
        "biomarkers": [
            1
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved letrozole for reimbursement as a treatment option for the neoadjuvant treatment of hormone receptor positive breast cancer in patients who are postmenopausal women.",
        "evidence": "Approval",
        "implication_id": 285,
        "indication_id": 320,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 730,
        "document_id": 173,
        "biomarkers": [
            3
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved letrozole for reimbursement as a treatment option for the neoadjuvant treatment of hormone receptor positive breast cancer in patients who are postmenopausal women.",
        "evidence": "Approval",
        "implication_id": 285,
        "indication_id": 320,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 731,
        "document_id": 174,
        "biomarkers": [
            1,
            3
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved exemestane for reimbursement as a monotherapy treatment option for the adjuvant treatment of hormone receptor positive invasive early breast cancer in patients who are postmenopausal women.",
        "evidence": "Approval",
        "implication_id": 286,
        "indication_id": 314,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 732,
        "document_id": 174,
        "biomarkers": [
            1
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved exemestane for reimbursement as a monotherapy treatment option for the adjuvant treatment of hormone receptor positive invasive early breast cancer in patients who are postmenopausal women.",
        "evidence": "Approval",
        "implication_id": 286,
        "indication_id": 314,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 733,
        "document_id": 174,
        "biomarkers": [
            3
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved exemestane for reimbursement as a monotherapy treatment option for the adjuvant treatment of hormone receptor positive invasive early breast cancer in patients who are postmenopausal women.",
        "evidence": "Approval",
        "implication_id": 286,
        "indication_id": 314,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 734,
        "document_id": 175,
        "biomarkers": [
            43,
            2,
            44
        ],
        "context_id": 37,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved gemcitabine in combination with carboplatin (AUC2) - 21 days for reimbursement as a treatment option for the treatment of locally recurrent metastatic triple negative breast cancer.",
        "evidence": "Approval",
        "implication_id": 287,
        "indication_id": 317,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 735,
        "document_id": 176,
        "biomarkers": [
            20
        ],
        "context_id": 87,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved doxorubicin in combination with cyclophosphamide (AC 60/600) 21 day followed by weekly paclitaxel (80) and weekly trastuzumab therapy (ac-th) for reimbursement as a treatment option for the adjuvant treatment of HER2 positive, high risk node negative or node positive breast cancer.",
        "evidence": "Approval",
        "implication_id": 288,
        "indication_id": 311,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 736,
        "document_id": 176,
        "biomarkers": [
            20
        ],
        "context_id": 87,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved doxorubicin in combination with cyclophosphamide (AC 60/600) 21 day followed by weekly paclitaxel (80) and weekly trastuzumab therapy (ac-th) for reimbursement as a treatment option for the neoadjuvant treatment of HER2 positive, high risk node negative or node positive breast cancer.",
        "evidence": "Approval",
        "implication_id": 288,
        "indication_id": 312,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 737,
        "document_id": 177,
        "biomarkers": [
            20
        ],
        "context_id": 87,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved paclitaxel (80) in combination with trastuzumab therapy - 7 day (12 weeks) for reimbursement as a treatment option for the adjuvant treatment of HER2 positive, node-negative breast cancer of tumor size <= 3 cm.",
        "evidence": "Approval",
        "implication_id": 289,
        "indication_id": 321,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 738,
        "document_id": 178,
        "biomarkers": [
            1,
            2,
            3
        ],
        "context_id": 18,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved abemaciclib in combination with endocrine therapy for reimbursement as a treatment option for the adjuvant treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence in adult patients. According to the European Medicine Agency's product information for abemaciclib, this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.",
        "evidence": "Approval",
        "implication_id": 290,
        "indication_id": 297,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 739,
        "document_id": 178,
        "biomarkers": [
            1,
            2
        ],
        "context_id": 18,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved abemaciclib in combination with endocrine therapy for reimbursement as a treatment option for the adjuvant treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence in adult patients. According to the European Medicine Agency's product information for abemaciclib, this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.",
        "evidence": "Approval",
        "implication_id": 290,
        "indication_id": 297,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 740,
        "document_id": 178,
        "biomarkers": [
            2,
            3
        ],
        "context_id": 18,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved abemaciclib in combination with endocrine therapy for reimbursement as a treatment option for the adjuvant treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence in adult patients. According to the European Medicine Agency's product information for abemaciclib, this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.",
        "evidence": "Approval",
        "implication_id": 290,
        "indication_id": 297,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 741,
        "document_id": 179,
        "biomarkers": [
            20
        ],
        "context_id": 88,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab for reimbursement as a treatment option for the maintenance treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer in adult patients, where this is a continuation of treatment for patients who have completed the chemotherapy component of the treatment.",
        "evidence": "Approval",
        "implication_id": 291,
        "indication_id": 323,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 742,
        "document_id": 179,
        "biomarkers": [
            20
        ],
        "context_id": 89,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab for reimbursement as a treatment option for the maintenance treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer in adult patients, where this is a continuation of treatment for patients who have completed the chemotherapy component of the treatment.",
        "evidence": "Approval",
        "implication_id": 291,
        "indication_id": 323,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 743,
        "document_id": 180,
        "biomarkers": [
            20
        ],
        "context_id": 90,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved docetaxel in combination with carboplatin, trastuzumab (s/c), and pertuzumab (tch(s/c)p) therapy for reimbursement as a treatment option for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory, or early breast cancer at high risk of recurrence in adult patients.",
        "evidence": "Approval",
        "implication_id": 292,
        "indication_id": 308,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 744,
        "document_id": 181,
        "biomarkers": [
            43,
            2,
            44
        ],
        "context_id": 37,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved carboplatin (AUC2) weekly in combination with paclitaxel 80 mg/m^2 followed by dose dense doxorubicin cyclophosphamide therapy for reimbursement as a treatment option for the neoadjuvant treatment of triple negative breast carcinoma.",
        "evidence": "Approval",
        "implication_id": 293,
        "indication_id": 304,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 745,
        "document_id": 182,
        "biomarkers": [
            20
        ],
        "context_id": 91,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab, paclitaxel, and carboplatin (TRAIN-2) for reimbursement as a treatment option for the neoadjuvant treatment of HER2-positive, locally advanced, inflammastory, or early stage breast cancer at high risk of recurrence in adult patients.",
        "evidence": "Approval",
        "implication_id": 294,
        "indication_id": 324,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 746,
        "document_id": 183,
        "biomarkers": [
            20
        ],
        "context_id": 91,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab / trastuzumab (phesgo) in combination with carboplatin and docetaxel (TCHP) for reimbursement as a treatment option for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory, or early breast cancer at high risk of recurrence in adult patients.",
        "evidence": "Approval",
        "implication_id": 295,
        "indication_id": 306,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 747,
        "document_id": 184,
        "biomarkers": [
            43,
            2,
            44
        ],
        "context_id": 37,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab 200mg in combination with carboplatin (AUC 5) and weekly paclitaxel 80mg/m^2 followed by doxorubicin and cyclophosphamide (AC 60/600) for reimbursement as a treatment option for the neoadjuvant treatment, and then pembrolizumab as a monotherapy treatment as an adjuvant treatment after surgery, of locally advanced or early stage triple negative breast cancer at high risk of recurrence in adult patients.",
        "evidence": "Approval",
        "implication_id": 296,
        "indication_id": 322,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 748,
        "document_id": 185,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved dose dense doxorubicin in combination with cyclophosphamide (AC 60/600) 14 day followed by weekly paclitaxel (80) and weekly trastuzumab (DD AC-TH) for reimbursement as a treatment option for the adjuvant treatment of HER2 positive, high risk node negative or node positive breast cancer.",
        "evidence": "Approval",
        "implication_id": 297,
        "indication_id": 309,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 749,
        "document_id": 185,
        "biomarkers": [
            20
        ],
        "context_id": 2,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved dose dense doxorubicin in combination with cyclophosphamide (AC 60/600) 14 day followed by weekly paclitaxel (80) and weekly trastuzumab (DD AC-TH) for reimbursement as a treatment option for the neoadjuvant treatment of HER2 positive, high risk node negative or node positive breast cancer.",
        "evidence": "Approval",
        "implication_id": 297,
        "indication_id": 310,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 750,
        "document_id": 186,
        "biomarkers": [
            24,
            25,
            27
        ],
        "context_id": 9,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved cetuximab (7 day) for reimbursement as a monotherapy treatment option for the treatment of epidermal growth factor (EGFR)-expressing RAS wild-type metastatic colorectal cancer (mCRC) which has failed oxaliplatin- and irinotecan-based therapy that is intolerant to irinotecan in adult patients. The European Medicine Agency's product information for Erbitux (cetuximab) defines RAS wild type as considering mutational status of KRAS and NRAS exons 2, 3, and 4, and that mutational status should be determined by an experienced laboratory using validated test methods.",
        "evidence": "Approval",
        "implication_id": 298,
        "indication_id": 341,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 751,
        "document_id": 187,
        "biomarkers": [
            25,
            27
        ],
        "context_id": 9,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved panitumumab for reimbursement as a monotherapy treatment option for the treatment of wild-type RAS metastatic colorectal cancer (mCRC) after failure of fluoropyrimidine, oxaliplatin, and irinotecan containig chemotherapy regimens in adult patients. The European Medicine Agency's product information for Vectibix (panitumumab) defines RAS wild type as considering mutational status of KRAS and NRAS exons 2, 3, and 4, and that mutational status should be determined by an experienced laboratory using validated test methods.",
        "evidence": "Approval",
        "implication_id": 299,
        "indication_id": 348,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 752,
        "document_id": 188,
        "biomarkers": [
            25,
            27
        ],
        "context_id": 9,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved cetuximab (7 days) in combination with FOLFIRI (14 days) for reimbursement as a treatment option for the treatment of adult patients with RAS wild type metastatic colorectal cancer. The European Medicine Agency's product information for Erbitux (cetuximab) defines RAS wild type as considering mutational status of KRAS and NRAS exons 2, 3, and 4, and that mutational status should be determined by an experienced laboratory using validated test methods.",
        "evidence": "Approval",
        "implication_id": 300,
        "indication_id": 342,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 753,
        "document_id": 189,
        "biomarkers": [
            25,
            27
        ],
        "context_id": 9,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved cetuximab (7 days) in combination with irinotecan (14 days) for reimbursement as a treatment option for the second line treatment of adult patients with metastatic colorectal cancer with non-mutated (wild type) RAS after failure of or contraindication to oxaliplatin based therapy. The European Medicine Agency's product information for Erbitux (cetuximab) defines RAS wild type as considering mutational status of KRAS and NRAS exons 2, 3, and 4, and that mutational status should be determined by an experienced laboratory using validated test methods.",
        "evidence": "Approval",
        "implication_id": 301,
        "indication_id": 340,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 754,
        "document_id": 190,
        "biomarkers": [
            25,
            27
        ],
        "context_id": 9,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved cetuximab (7 days) in combination with irinotecan (14 days) for reimbursement as a treatment option for the second line treatment of adult patients with metastatic colorectal cancer with non-mutated (wild type) RAS after failure of or contraindication to oxaliplatin based therapy. The European Medicine Agency's product information for Erbitux (cetuximab) defines RAS wild type as considering mutational status of KRAS and NRAS exons 2, 3, and 4, and that mutational status should be determined by an experienced laboratory using validated test methods.",
        "evidence": "Approval",
        "implication_id": 301,
        "indication_id": 339,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 755,
        "document_id": 191,
        "biomarkers": [
            25,
            27
        ],
        "context_id": 9,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved panitumumab 6 mg/kg in combination with modified FOLFOX-6 (14 day) for reimbursement as a treatment option for the first line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC). The European Medicine Agency's product information for Vectibix (panitumumab) defines RAS wild type as considering mutational status of KRAS and NRAS exons 2, 3, and 4, and that mutational status should be determined by an experienced laboratory using validated test methods.",
        "evidence": "Approval",
        "implication_id": 302,
        "indication_id": 347,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 756,
        "document_id": 192,
        "biomarkers": [
            25,
            27
        ],
        "context_id": 9,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved panitumumab 6mg/kg in combination with FOLFIRI (14 day) for reimbursement as a treatment option for the first line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC). The European Medicine Agency's product information for Vectibix (panitumumab) defines RAS wild type as considering mutational status of KRAS and NRAS exons 2, 3, and 4, and that mutational status should be determined by an experienced laboratory using validated test methods.",
        "evidence": "Approval",
        "implication_id": 303,
        "indication_id": 345,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 757,
        "document_id": 192,
        "biomarkers": [
            25,
            27
        ],
        "context_id": 9,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved panitumumab 6mg/kg in combination with FOLFIRI (14 day) for reimbursement as a treatment option for the second line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) who have received first-line fluoropyrimidine\u2013based chemotherapy (excluding irinotecan). The European Medicine Agency's product information for Vectibix (panitumumab) defines RAS wild type as considering mutational status of KRAS and NRAS exons 2, 3, and 4, and that mutational status should be determined by an experienced laboratory using validated test methods.",
        "evidence": "Approval",
        "implication_id": 303,
        "indication_id": 346,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 758,
        "document_id": 193,
        "biomarkers": [
            20
        ],
        "context_id": 19,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab in combination with 5-fluorouracil and cisplatin (21 days) as a treatment option for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.",
        "evidence": "Approval",
        "implication_id": 304,
        "indication_id": 354,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 759,
        "document_id": 194,
        "biomarkers": [
            25,
            27
        ],
        "context_id": 9,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved cetuximab (14 days) in combination with FOLFIRI (14 days) for reimbursement as a treatment option for the treatment of adult patients with RAS wild type metastatic colorectal cancer. The European Medicine Agency's product information for Erbitux (cetuximab) defines RAS wild type as considering mutational status of KRAS and NRAS exons 2, 3, and 4, and that mutational status should be determined by an experienced laboratory using validated test methods.",
        "evidence": "Approval",
        "implication_id": 305,
        "indication_id": 338,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 760,
        "document_id": 195,
        "biomarkers": [
            33
        ],
        "context_id": 53,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab (240 mg) in combination with fluoropyrimidine and platinum-based combination chemotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma with tumor cell programmed death ligand 1 (PD-L1) expression >= 1%. This regimen specifically cites cisplatin and 5-fluorouracil as the chemotherapy.",
        "evidence": "Approval",
        "implication_id": 306,
        "indication_id": 343,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 761,
        "document_id": 196,
        "biomarkers": [
            33
        ],
        "context_id": 53,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with fluoropyrimidine and platinum-based combination chemotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma with tumor cell programmed death ligand 1 (PD-L1) expression >= 1%. This regimen specifically cites cisplatin and 5-fluorouracil as the chemotherapy.",
        "evidence": "Approval",
        "implication_id": 307,
        "indication_id": 344,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 762,
        "document_id": 197,
        "biomarkers": [
            39,
            35,
            34
        ],
        "context_id": 29,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-small cell lung carcinoma (NSCLC) whose tumors express PD-L1 with a >= 50% tumor proportion score (TPS) with no EGFR mutations or ALK translocations.",
        "evidence": "Approval",
        "implication_id": 308,
        "indication_id": 349,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 763,
        "document_id": 197,
        "biomarkers": [
            41
        ],
        "context_id": 30,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a monotherapy treatment option for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy whose tumors express PD-L1 with a combined positive score (CPS) >= 10.",
        "evidence": "Approval",
        "implication_id": 308,
        "indication_id": 350,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 764,
        "document_id": 197,
        "biomarkers": [
            42
        ],
        "context_id": 31,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a monotherapy treatment option for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 with a CPS >= 1.",
        "evidence": "Approval",
        "implication_id": 308,
        "indication_id": 351,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 765,
        "document_id": 197,
        "biomarkers": [
            42
        ],
        "context_id": 38,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a monotherapy treatment option for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 with a CPS >= 1. Pembrolizumab (200mg) monotherapy's regime notes that this indication is an unlicensed dosing posology of pembrolizumab in Ireland, and that patients should be informed of this and consented to treatment in line with the hospital's policy on the use of unlicensed medication and unlicensed or 'off-label' indications. Please refer to this therapy's regime by the HSE for more information.",
        "evidence": "Approval",
        "implication_id": 308,
        "indication_id": 352,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 766,
        "document_id": 197,
        "biomarkers": [
            38
        ],
        "context_id": 9,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a first-line treatment option for the treatment of adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).",
        "evidence": "Approval",
        "implication_id": 308,
        "indication_id": 353,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 767,
        "document_id": 198,
        "biomarkers": [
            42
        ],
        "context_id": 38,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with paclitaxel (175 mg/m^2), carboplatin (AUC-5), and bevacizumab for reimbursement as a treatment option for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 1.",
        "evidence": "Approval",
        "implication_id": 309,
        "indication_id": 358,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 768,
        "document_id": 199,
        "biomarkers": [
            42
        ],
        "context_id": 38,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with paclitaxel (175 mg/m^2) and carboplatin (AUC-5) for reimbursement as a treatment option for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 1.",
        "evidence": "Approval",
        "implication_id": 310,
        "indication_id": 359,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 769,
        "document_id": 200,
        "biomarkers": [
            80
        ],
        "context_id": 66,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved idelalisib in combination with ofatumumab for reimbursement as a treatment option for the first line treatment of adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.",
        "evidence": "Approval",
        "implication_id": 311,
        "indication_id": 386,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 770,
        "document_id": 200,
        "biomarkers": [
            81
        ],
        "context_id": 66,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved idelalisib in combination with ofatumumab for reimbursement as a treatment option for the first line treatment of adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.",
        "evidence": "Approval",
        "implication_id": 311,
        "indication_id": 386,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 771,
        "document_id": 200,
        "biomarkers": [
            82
        ],
        "context_id": 66,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved idelalisib in combination with ofatumumab for reimbursement as a treatment option for the first line treatment of adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.",
        "evidence": "Approval",
        "implication_id": 311,
        "indication_id": 386,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 772,
        "document_id": 201,
        "biomarkers": [
            66
        ],
        "context_id": 51,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved midostaurin as a single agent for reimbursement as a treatment option for the maintenance treatment of adult patients with FLT3 mutation positive acute myeloid leukemia (AML) in complete response after completion of induction and consolidation chemotherapy.",
        "evidence": "Approval",
        "implication_id": 312,
        "indication_id": 361,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 773,
        "document_id": 202,
        "biomarkers": [
            66
        ],
        "context_id": 51,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved midostaurin in combination with intermediate dose cytarabine consolidation chemotherapy for reimbursement as a treatment option for the treatment of adult patients newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation positive",
        "evidence": "Approval",
        "implication_id": 312,
        "indication_id": 360,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 774,
        "document_id": 203,
        "biomarkers": [
            33
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved gemcitabine (1250mg/m^2) in combination with cisplatin (75mg/m^2) (21 day) and nivolumab for reimbursement as a treatment option for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1% (3 cycles only). The regimen further states that this combination is available in NCIS (00849.3).",
        "evidence": "Approval",
        "implication_id": 313,
        "indication_id": 365,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 775,
        "document_id": 204,
        "biomarkers": [
            33
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved paclitaxel (200mg/m^2) in combination with carboplatin (AUC 6) and nivolumab for reimbursement as a treatment option for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1% (3 cycles only). The regimen further states that this combination is available in NCIS (00849.1).",
        "evidence": "Approval",
        "implication_id": 314,
        "indication_id": 362,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 776,
        "document_id": 205,
        "biomarkers": [
            33
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved gemcitabine (1000mg/m^2) in combination with carboplatin (AUC 5) (21 day) and nivolumab for reimbursement as a treatment option for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1% (3 cycles only). The regimen further states that this combination is available in NCIS (00849.2).",
        "evidence": "Approval",
        "implication_id": 315,
        "indication_id": 364,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 777,
        "document_id": 206,
        "biomarkers": [
            33
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with cisplatin and pemetrexed for reimbursement as a treatment option for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1% (3 cycles only). The regimen further states that this combination is available in NCIS (00849.5).",
        "evidence": "Approval",
        "implication_id": 316,
        "indication_id": 367,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 778,
        "document_id": 207,
        "biomarkers": [
            33
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with carboplatin and pemetrexed for reimbursement as a treatment option for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1% (3 cycles only). The regimen further states that this combination is available in NCIS (00849.4).",
        "evidence": "Approval",
        "implication_id": 317,
        "indication_id": 366,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 779,
        "document_id": 208,
        "biomarkers": [
            71
        ],
        "context_id": 30,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab 840 mg as a monotherapy for reimbursement as a treatment option for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible and whose tumors have PD-L1 expression >= 5%.",
        "evidence": "Approval",
        "implication_id": 237,
        "indication_id": 355,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 780,
        "document_id": 208,
        "biomarkers": [
            39,
            34,
            35
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab 840 mg as a monotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% tumor cells (TC) or >= 10% tumor-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.",
        "evidence": "Approval",
        "implication_id": 237,
        "indication_id": 356,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 781,
        "document_id": 208,
        "biomarkers": [
            73,
            34,
            35
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab 840 mg as a monotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% tumor cells (TC) or >= 10% tumor-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.",
        "evidence": "Approval",
        "implication_id": 237,
        "indication_id": 356,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 782,
        "document_id": 208,
        "biomarkers": [
            39,
            34,
            35
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab 840 mg as a monotherapy for reimbursement as a treatment option for the adjuvant treatment following complete resection and platinum-baesd chemotherapy for adult patients with non-small cell lung cancer (NSCLC) with a high risk of recurrence whose tumors have PD-L1 expression on >= 50% of tumor cells and who do not have EGFR mutant or ALK-positive mutations.",
        "evidence": "Approval",
        "implication_id": 237,
        "indication_id": 357,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 783,
        "document_id": 209,
        "biomarkers": [
            33
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved durvalumab for reimbursement as a monotherapy treatment option for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 >= 1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT).",
        "evidence": "Approval",
        "implication_id": 236,
        "indication_id": 363,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 784,
        "document_id": 210,
        "biomarkers": [
            54
        ],
        "context_id": 92,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone (21 days) for reimbursement as a treatment option for the treatemnt of patients with CD20 positive non-Hodgkin's lymphoma. This indication is also generally for cyclophosphamide, doxorubicin, vincristine, and prednisolone as a treatment option for patients non-Hodgkin's lymphoma, and the treatment regimen notes that rituximab should be included for CD20+ patients.",
        "evidence": "Approval",
        "implication_id": 318,
        "indication_id": 371,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 785,
        "document_id": 211,
        "biomarkers": [
            54
        ],
        "context_id": 92,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved rituximab in combination with bendamustine for reimbursement as a treatment option for the treatment of patients with previously untreated indolent CD20-positive, stage III-IV non-hodgkin lymphoma (NHL).",
        "evidence": "Approval",
        "implication_id": 319,
        "indication_id": 384,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 786,
        "document_id": 211,
        "biomarkers": [
            54
        ],
        "context_id": 92,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved rituximab in combination with bendamustine for reimbursement as a treatment option for the treatment of patients with previously untreated CD20-positive, stage III-IV mantle cell lymphoma (MCL), ineligible for autologous stem cell transplant.",
        "evidence": "Approval",
        "implication_id": 319,
        "indication_id": 385,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 787,
        "document_id": 212,
        "biomarkers": [
            54
        ],
        "context_id": 92,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved cisplatin in combination with cytarabine, dexamethasone, and granulocyte colony stimulating factor (G-CSF) (DHAP Therapy) for reimbursement as a treatment option for the treatment of patients with relapsed Non Hodgkin Lymphoma (NHL). The regimen specification also states that rituximab should be included for treatment of CD20 positive patients.",
        "evidence": "Approval",
        "implication_id": 320,
        "indication_id": 373,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 788,
        "document_id": 213,
        "biomarkers": [
            54
        ],
        "context_id": 93,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved dose adjusted rituximab in combination with etoposide, prednisolone, doxorubicin, cyclophosphamide and vincristine (DA-R EPOCH) therapy for reimbursement as a treatment option for the treatment of patients with CD20 positive diffuse large B-cell Non Hodgkins Lymphoma (NHL).",
        "evidence": "Approval",
        "implication_id": 321,
        "indication_id": 376,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 789,
        "document_id": 213,
        "biomarkers": [
            54
        ],
        "context_id": 94,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved dose adjusted rituximab in combination with etoposide, prednisolone, doxorubicin, cyclophosphamide and vincristine (DA-R EPOCH) therapy for reimbursement as a treatment option for the treatment of patients with CD20 positive diffuse large B-cell Non Hodgkins Lymphoma (NHL).",
        "evidence": "Approval",
        "implication_id": 321,
        "indication_id": 376,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 790,
        "document_id": 214,
        "biomarkers": [
            54
        ],
        "context_id": 92,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved carboplatin in combination with ifosfamide and etoposide (ICE) for reimbursement as a treatment option for the treatment of relapsed/refractory Non Hodgkin's Lymphoma. The therapy regimen further states that rituximab is to be included for the treatment of CD20 positive patients.",
        "evidence": "Approval",
        "implication_id": 322,
        "indication_id": 374,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 791,
        "document_id": 215,
        "biomarkers": [
            54
        ],
        "context_id": 92,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved cyclophosphamide in combination with doxorubicin, vincristine, and prednisolone (CHOP Therapy) (14 days) for the treatment of non-hodgkin's lymphoma (NHL). The therapy regimen further states that rituximab is to be included for the treatment of CD20 positive patients.",
        "evidence": "Approval",
        "implication_id": 323,
        "indication_id": 370,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 792,
        "document_id": 216,
        "biomarkers": [
            54
        ],
        "context_id": 92,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved cyclophosphamide in combination with doxorubicin, vincristine, and prednisolone (mini-CHOP Therapy) (21 days) for the treatment of non-hodgkin lymphoma (NHL) in patients aged greater than 80 or with significant co-morbidities. The therapy regimen further states that rituximab is to be included for the treatment of CD20 positive patients.",
        "evidence": "Approval",
        "implication_id": 324,
        "indication_id": 372,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 793,
        "document_id": 217,
        "biomarkers": [
            54
        ],
        "context_id": 95,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved rituximab in combination with gemcitabine and oxaliplatin for reimbursement as a treatment option for the treatment of relapsed or refractory CD20 positive diffuse large B cell lymphoma in patients ineligible for stem cell transplant.",
        "evidence": "Approval",
        "implication_id": 325,
        "indication_id": 378,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 794,
        "document_id": 217,
        "biomarkers": [
            54
        ],
        "context_id": 96,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved rituximab in combination with gemcitabine and oxaliplatin for reimbursement as a treatment option for the treatment of relapsed or refractory CD20 positive diffuse large B cell lymphoma in patients ineligible for stem cell transplant.",
        "evidence": "Approval",
        "implication_id": 325,
        "indication_id": 378,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 795,
        "document_id": 218,
        "biomarkers": [
            54
        ],
        "context_id": 97,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved rituximab in combination with cyclophosphamide, etoposide, prednisolone, and vincristine for reimbursement as a treatment option for the treatment of Non Hodgkin CD20 positive Lymphoma for patients not suitable for anthracycline therapy.",
        "evidence": "Approval",
        "implication_id": 326,
        "indication_id": 377,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 796,
        "document_id": 219,
        "biomarkers": [
            0
        ],
        "context_id": 0,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin in combination with bendamustine for reimbursement as a treatment option for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL).",
        "evidence": "Approval",
        "implication_id": 327,
        "indication_id": 256,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 797,
        "document_id": 220,
        "biomarkers": [
            54
        ],
        "context_id": 98,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (375 mg/m^2) in combination with chemotherapy (21 day) for reimbursement as a treatment option for the induction treatment of previously untreated or relapsed / refractory CD20 positive patients with follicular lymphoma. The European Medicine Agency's product information for rituximab includes an indication for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy, and the product information cites four clinical trials that showed significant improvements in response rates in treating this indication with chemotherapy in combination with rituximab versus just chemotherapy alone. The four clinical trials and chemotherapy regimens evaluated are: M39021 with CVP, GLSG'00 and CHOP, OSHO-39 and MCP, and FL2000 and CHVP-IFN.",
        "evidence": "Approval",
        "implication_id": 328,
        "indication_id": 381,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 798,
        "document_id": 220,
        "biomarkers": [
            54
        ],
        "context_id": 98,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (375 mg/m^2) in combination with chemotherapy (21 day) for reimbursement as a treatment option for the induction treatment of previously untreated or relapsed / refractory CD20 positive patients with follicular lymphoma. The European Medicine Agency's product information for rituximab includes an indication for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy, and the product information cites four clinical trials that showed significant improvements in response rates in treating this indication with chemotherapy in combination with rituximab versus just chemotherapy alone. The four clinical trials and chemotherapy regimens evaluated are: M39021 with CVP, GLSG'00 and CHOP, OSHO-39 and MCP, and FL2000 and CHVP-IFN.",
        "evidence": "Approval",
        "implication_id": 329,
        "indication_id": 381,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 799,
        "document_id": 220,
        "biomarkers": [
            54
        ],
        "context_id": 98,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (375 mg/m^2) in combination with chemotherapy (21 day) for reimbursement as a treatment option for the induction treatment of previously untreated or relapsed / refractory CD20 positive patients with follicular lymphoma. The European Medicine Agency's product information for rituximab includes an indication for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy, and the product information cites four clinical trials that showed significant improvements in response rates in treating this indication with chemotherapy in combination with rituximab versus just chemotherapy alone. The four clinical trials and chemotherapy regimens evaluated are: M39021 with CVP, GLSG'00 and CHOP, OSHO-39 and MCP, and FL2000 and CHVP-IFN.",
        "evidence": "Approval",
        "implication_id": 330,
        "indication_id": 381,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 800,
        "document_id": 220,
        "biomarkers": [
            54
        ],
        "context_id": 98,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (375 mg/m^2) in combination with chemotherapy (21 day) for reimbursement as a treatment option for the induction treatment of previously untreated or relapsed / refractory CD20 positive patients with follicular lymphoma. The European Medicine Agency's product information for rituximab includes an indication for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy, and the product information cites four clinical trials that showed significant improvements in response rates in treating this indication with chemotherapy in combination with rituximab versus just chemotherapy alone. The four clinical trials and chemotherapy regimens evaluated are: M39021 with CVP, GLSG'00 and CHOP, OSHO-39 and MCP, and FL2000 and CHVP-IFN.",
        "evidence": "Approval",
        "implication_id": 331,
        "indication_id": 381,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 801,
        "document_id": 221,
        "biomarkers": [
            54
        ],
        "context_id": 99,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (375 mg/m^2) (56 day) for reimbursement as a treatment option for the maintenance treatment of previously untreated follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients responding to induction therapy.",
        "evidence": "Approval",
        "implication_id": 332,
        "indication_id": 382,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 802,
        "document_id": 221,
        "biomarkers": [
            54
        ],
        "context_id": 100,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (375 mg/m^2) (56 day) for reimbursement as a treatment option for the maintenance treatment of previously untreated follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients responding to induction therapy.",
        "evidence": "Approval",
        "implication_id": 332,
        "indication_id": 382,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 803,
        "document_id": 222,
        "biomarkers": [
            54
        ],
        "context_id": 99,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (S/C 1400 mg) (84 day) for reimbursement as a treatment option for the maintenance treatment of relapsed / refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients who have responded to induction therapy.",
        "evidence": "Approval",
        "implication_id": 332,
        "indication_id": 380,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 804,
        "document_id": 222,
        "biomarkers": [
            54
        ],
        "context_id": 100,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (S/C 1400 mg) (84 day) for reimbursement as a treatment option for the maintenance treatment of relapsed / refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients who have responded to induction therapy.",
        "evidence": "Approval",
        "implication_id": 332,
        "indication_id": 380,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 805,
        "document_id": 223,
        "biomarkers": [
            54
        ],
        "context_id": 99,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (S/C 1400 mg) (56 day) for reimbursement as a treatment option for the maintenance treatment of previously untreated follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients responding to induction therapy.",
        "evidence": "Approval",
        "implication_id": 332,
        "indication_id": 379,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 806,
        "document_id": 223,
        "biomarkers": [
            54
        ],
        "context_id": 100,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (S/C 1400 mg) (56 day) for reimbursement as a treatment option for the maintenance treatment of previously untreated follicular CD20 positive, B-cell Non Hodgkin Lymphoma patients responding to induction therapy.",
        "evidence": "Approval",
        "implication_id": 332,
        "indication_id": 379,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 807,
        "document_id": 224,
        "biomarkers": [
            54
        ],
        "context_id": 101,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved dose adjusted rituximab S/C in combination with cyclophosphamide, doxorubicin, etoposide, prednisolone, and vincristine for reimbursement as a treatment option for the treatment of patients with CD20 positive diffuse large B-cell Non Hodgkin's Lymphoma.",
        "evidence": "Approval",
        "implication_id": 333,
        "indication_id": 375,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 808,
        "document_id": 224,
        "biomarkers": [
            54
        ],
        "context_id": 102,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved dose adjusted rituximab S/C in combination with cyclophosphamide, doxorubicin, etoposide, prednisolone, and vincristine for reimbursement as a treatment option for the treatment of patients with CD20 positive diffuse large B-cell Non Hodgkin's Lymphoma.",
        "evidence": "Approval",
        "implication_id": 333,
        "indication_id": 375,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 809,
        "document_id": 225,
        "biomarkers": [
            54
        ],
        "context_id": 97,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved cyclophosphamide in combination with prednisolone and vincristine for reimbursement as a treatment option for the first line treatment of patients with low grade B cell Non Hodgkin's Lymphoma (NHL). The regimen states that rituximab is to be included for the treatment of CD20 positive patients.",
        "evidence": "Approval",
        "implication_id": 334,
        "indication_id": 368,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 810,
        "document_id": 225,
        "biomarkers": [
            54
        ],
        "context_id": 97,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved cyclophosphamide in combination with prednisolone and vincristine for reimbursement as a treatment option for the treatment of patients with relapsed / refractory low grade B cell Non Hodgkin's Lymphoma (NHL). The regimen states that rituximab is to be included for the treatment of CD20 positive patients.",
        "evidence": "Approval",
        "implication_id": 334,
        "indication_id": 369,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 811,
        "document_id": 226,
        "biomarkers": [
            54
        ],
        "context_id": 99,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (375 mg/m^2) for reimbursement as a treatment option for the maintenance treatment (84 day) of relapsed / refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma (NHL) in patients who have responded to induction therapy.",
        "evidence": "Approval",
        "implication_id": 332,
        "indication_id": 383,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 812,
        "document_id": 226,
        "biomarkers": [
            54
        ],
        "context_id": 100,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved rituximab (375 mg/m^2) for reimbursement as a treatment option for the maintenance treatment (84 day) of relapsed / refractory follicular CD20 positive, B-cell Non Hodgkin Lymphoma (NHL) in patients who have responded to induction therapy.",
        "evidence": "Approval",
        "implication_id": 332,
        "indication_id": 383,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 813,
        "document_id": 227,
        "biomarkers": [
            31
        ],
        "context_id": 25,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved imatinib for reimbursement as a treatment option for the treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).",
        "evidence": "Approval",
        "implication_id": 41,
        "indication_id": 387,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 814,
        "document_id": 227,
        "biomarkers": [
            31
        ],
        "context_id": 25,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved imatinib for reimbursement as a treatment option for the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive gastrointestinal stromal tumors (GIST).",
        "evidence": "Approval",
        "implication_id": 41,
        "indication_id": 388,
        "last_updated": "2024-07-21",
        "deprecated": false
    },
    {
        "id": 815,
        "document_id": 228,
        "biomarkers": [
            67
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved tepotinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring alterations leading mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 335,
        "indication_id": 389,
        "last_updated": "2024-08-19",
        "deprecated": false
    },
    {
        "id": 816,
        "document_id": 228,
        "biomarkers": [
            68
        ],
        "context_id": 4,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved tepotinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring alterations leading mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.",
        "evidence": "Approval",
        "implication_id": 335,
        "indication_id": 389,
        "last_updated": "2024-08-19",
        "deprecated": false
    },
    {
        "id": 817,
        "document_id": 229,
        "biomarkers": [
            20
        ],
        "context_id": 103,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab deruxtecan (Enhertu) for reimbursement as a monotherapy treatment option for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.",
        "evidence": "Approval",
        "implication_id": 336,
        "indication_id": 390,
        "last_updated": "2024-08-19",
        "deprecated": false
    },
    {
        "id": 818,
        "document_id": 229,
        "biomarkers": [
            20
        ],
        "context_id": 104,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab deruxtecan (Enhertu) for reimbursement as a monotherapy treatment option for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.",
        "evidence": "Approval",
        "implication_id": 336,
        "indication_id": 390,
        "last_updated": "2024-08-19",
        "deprecated": false
    },
    {
        "id": 819,
        "document_id": 230,
        "biomarkers": [
            43,
            2,
            44
        ],
        "context_id": 105,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with chemotherapy for reimbursement as a treatment option for the neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, of adult patients with locally advanced or early stage triple negative breast cancer at high risk of recurrence. This cited regimen is specifically for pembrolizumab 400mg, carboplatin AUC 5, and weekly paclitaxel 80mg/m^2 followed by dose dense doxorubicin and cyclophosphamide (AC 60/600) therapy.",
        "evidence": "Approval",
        "implication_id": 337,
        "indication_id": 391,
        "last_updated": "2024-08-19",
        "deprecated": false
    },
    {
        "id": 820,
        "document_id": 231,
        "biomarkers": [
            43,
            2,
            44
        ],
        "context_id": 105,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with chemotherapy for reimbursement as a treatment option for the neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, of adult patients with locally advanced or early stage triple negative breast cancer at high risk of recurrence. This cited regimen is specifically for pembrolizumab 400mg in combination with weekly carboplatin AUC 1.5 and paclitaxel 80mg/m^2 followed by dose dense doxorubicin and cyclophosphamide (AC 60/600) therapy.",
        "evidence": "Approval",
        "implication_id": 337,
        "indication_id": 392,
        "last_updated": "2024-08-19",
        "deprecated": false
    },
    {
        "id": 821,
        "document_id": 232,
        "biomarkers": [
            18
        ],
        "context_id": 10,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved vandetanib for reimbursement as a monotherapy treatment option for the treatment of patients with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC) that is Rearranged during Transfection (RET) mutation positive.",
        "evidence": "Approval",
        "implication_id": 338,
        "indication_id": 393,
        "last_updated": "2024-09-01",
        "deprecated": false
    },
    {
        "id": 822,
        "document_id": 233,
        "biomarkers": [
            79
        ],
        "context_id": 63,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved tretinoin (ATRA) with arsenic trioxide (ATO) for reimbursement as a treatment option for the treatment of patients with newly diagnosed low to intermediate risk Acute Promyelocytic Leukaemia (APL) (defined as WCC <= 10x10^9L). This regimen contains the eligibility criteria of a clinical diagnosis of APL and subsequently confirmed to have PML::RARA rearrangements by a valid test method.",
        "evidence": "Approval",
        "implication_id": 339,
        "indication_id": 397,
        "last_updated": "2024-09-01",
        "deprecated": false
    },
    {
        "id": 823,
        "document_id": 233,
        "biomarkers": [
            79
        ],
        "context_id": 63,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved tretinoin (ATRA) with arsenic trioxide (ATO) for reimbursement as a treatment option for the treatment of adult patients with relapsed or refractory Acute Promyelocytic Leukaemia (APL) after ATRA/chemotherapy. This regimen contains the eligibility criteria of a clinical diagnosis of APL and subsequently confirmed to have PML::RARA rearrangements by a valid test method.",
        "evidence": "Approval",
        "implication_id": 339,
        "indication_id": 398,
        "last_updated": "2024-09-01",
        "deprecated": false
    },
    {
        "id": 824,
        "document_id": 234,
        "biomarkers": [
            2,
            43,
            44
        ],
        "context_id": 64,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved sacituzumab govitecan for reimbursement as a monotherapy treatment option for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease.",
        "evidence": "Approval",
        "implication_id": 340,
        "indication_id": 399,
        "last_updated": "2024-09-01",
        "deprecated": false
    },
    {
        "id": 825,
        "document_id": 234,
        "biomarkers": [
            2,
            43,
            44
        ],
        "context_id": 65,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved sacituzumab govitecan for reimbursement as a monotherapy treatment option for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease.",
        "evidence": "Approval",
        "implication_id": 340,
        "indication_id": 399,
        "last_updated": "2024-09-01",
        "deprecated": false
    },
    {
        "id": 826,
        "document_id": 235,
        "biomarkers": [
            63
        ],
        "context_id": 58,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved entrectinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with solid tumors expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, (i) who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and (ii) who have not received a prior NTRK inhibitor, and (iii) who have no satisfactory treatment options.",
        "evidence": "Approval",
        "implication_id": 195,
        "indication_id": 400,
        "last_updated": "2024-10-16",
        "deprecated": false
    },
    {
        "id": 827,
        "document_id": 235,
        "biomarkers": [
            64
        ],
        "context_id": 58,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved entrectinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with solid tumors expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, (i) who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and (ii) who have not received a prior NTRK inhibitor, and (iii) who have no satisfactory treatment options.",
        "evidence": "Approval",
        "implication_id": 195,
        "indication_id": 400,
        "last_updated": "2024-10-16",
        "deprecated": false
    },
    {
        "id": 828,
        "document_id": 235,
        "biomarkers": [
            65
        ],
        "context_id": 58,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved entrectinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with solid tumors expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, (i) who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and (ii) who have not received a prior NTRK inhibitor, and (iii) who have no satisfactory treatment options.",
        "evidence": "Approval",
        "implication_id": 195,
        "indication_id": 400,
        "last_updated": "2024-10-16",
        "deprecated": false
    }
]